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B:P 
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DIG 
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GF 
GF-R 
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G-CSF 
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HH 
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HSC 
amino acids 
biotin:protein (ratio) 
erythroid burst~forming unit 
bone marrow 
bovine serum albumin 
complementary DNA 
colony-forming unit in culture 
erythroid colony-forming unit 
granulocyte! macrophage colony~forming unit 
spleen colony-forming unit 
chronic myeloid leukemia 
DIG:protein (ratio) 
digoxigenin 
dimethyl sulfoxide 
erythropoietin 
fluorescence activated cell sorter 
fetal calf serum 
factor~dependent cell line - clone PI 
fillorescent in situ hybridization 
fluorescein isothiocyanate 
forward light scatter 
goat atiti-mouse antibodies 
goat anti-rat antibodies 
growth factor 
gro~vth factor receptor 
granulocyte! macrophage colony~stiml1lating factor 
granulocyte colony-stimulating factor 
Hoechst 33258 
Hanks' Hepes buffered salt solution 
HID serum! azide 
hemopoietic stem cell 
Abbreviations 
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lL-
IP 
LTRA 
M-CSF 
mAb 
NBS 
PB 
PBS 
PCR 
PE 
PerCP· 
PHA 
PI 
PLS 
PMUE 
PO 
PSA 
R 
RELACS 
Rhl23 
RT-PCR 
SCF 
scm 
STRA 
TBS 
TPO 
WGA 
8 
interleukin-
immunoprecipitation 
long-term repopulating ability 
macrophage colony-stimulating- factor 
monoclonal antibody 
N- hydroxy succinimide 
peripheral blood 
phosphate-buffered saline solution· 
polymerase chain reaction 
PhycoErythrin 
peridinin chlorophyll protein 
phytohemagglutinin 
propirlium iodide 
perpendicular light scatter 
pregnant mouse uterus extract 
peroxidase 
PBS; semml azide 
receptor 
Rijswijk experimental light activated cell sorter 
Rhodamine 123 
reverse transcriptase polymerase chain reaction 
stem cell factor (~KL, Kit ligand; MGF, mast cell growth factor; SF, 
Steel factor) 
severe combined immunodeficiency 
short-term repopulating ability 
Tris-buffered saline solution 
thrombopoietin 
wheat germ agglutinin 
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1.1 Hemopoiesis 
Blood cells fulfill a number of important functions, including 02 and C02 transport 
(erythrocytes), blood clotting (platelets), specific immunity and antibody production 
(lymphocytes), and nonspecific defense against pathogens (monocyte,/ macrophages and 
granulocytes). Most blood cells have a limited life span, varying from several hours to 
several months. Replacement of these cells requires a daily production of approximately 2 
x 1011 red and 1.5 x lOti white blood cells in an average human adult. Under changed 
env!ronmental conditions (e.g., low atmospheric oxygen tension), or pathologic 
cond,itions, such as blood,loss, tissue damage, or infections, this production capacity may 
be increased at least IO-fold. The process of blood cell formation, hemopoiesis, takes 
place mainly in the bone marrow (EM) in adult mammals. In'fetal hemopoiesis, liver and 
spleen also play an important role. There is residual hemopoiesis in the spleen of adult 
mice. 
All blood cells are derived from a small pool of pluripotent hemopoietic stem cells 
(HSC) IMcCulloch, 1983) IMetcalf, 1989). Most of these are kept in a quiescent state, only a 
small subset of HSC is actively proliferating at any moment [Becker et a!., 1965] [Moore, 
19911. This population is responsible for the formation of 'daughter cells, which after 
progressive cell divisions gradually lose their multipotent differentiation potential and 
acquire the characteristic phenotypiy and functional properties of the individual blood cell 
lineages (figure 1.1). These committed progenitors undergo terminal differentiation into 
mature blood cells, which are released into the circulation. 
The mechanism by which the HSC population is maintained and develops into mature 
blood cells is still incompletely understood. It is possible that blood cell formation is 
initiated by donal expansion df activated HSC with asymmetrical cell divisions, resulting 
in simultaneous formation of new HSC that maintain the stem cell pool as well as 
committed descendants that eventually differentiate into mature blood cells [Holtzer ct ai., 
19721. Alternatively, analogous to oocyte development, there might be a limited pool of 
HSC, whi~h are acti~ated successively and undergo terminal differentiation into mature 
blood cells IRosendaal et al .. 19791. According to this theory, the daughter cells are not 
identical to the parent cell, indicating that 'self renewal' of HSC does not take place. In 
agreement with such a hypothesis, a decrease in the mean telomere length during 
proliferation of immature hemopoietic cells into mote differentiated precursors has bee'n 
observed {Vaziri ct aI., 1994] [Lansdorp, 1995]. Supported by experimental data that 
demonstrated limits to the self renewal capacity of the stem cell compartment after stress 
to the hemopoietic system [Mauch et ai., 1988], this would make depletion of the HSC 
compartment conceivable. However, since the daughter cells that result from the first 
divisions of a HSC may still be pluripotent, the HSC compartment could be effectively 
replenished when part of these cells return to a quiescent state. 
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figure 1.1 . 
Schematic representation of hemopoietic stem ceH differentiation. 
General introduction 
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Several models for the mechanism that regulates differentiation of HSC into the 
different blood cell lineages have been proposed. Commitment to differentiation may be' 
the result of a stochastic process [Till ct ai., 19641 [Nakahata et aI., 1982] [Tsuji and Nakahata, 
1989]. According to this hypothesis, commitment to a specific lineage is determined by 
intrinsic properties of the cell itself and cannot be jnfluenced by external factors. 
Alternatively, cells may be directed to enter a particular lineage by specific 
microenvironmental stimuli and! Or lineage-specific hemopoietic growth factors {Curry and 
. Trentin, 1967] [Van Zant and Goldwasser, 1977]. According to this model, the direction HSC 
differentiation wiII take is determined by the relative concentration of stimulatory and 
inhibitory signals. However, although in the stochastic model HSC commitment is an 
intrinsic property of the HSC itself, whether or not these cells will proliferate or 
differentiate is still dependent on the availability in the microenvironment of the 
appropriate OFs and other stimuli to which those cells can respond. Therefore, these 
models are not necessarily mutually exclusive. 
1.2 Hemopoietic. growth factors (GFs) 
Growth factors (GFs) play an imp<?rtant role in the maintenance of viability [Iscove, 
1977] [Wagemakcr ct aL, 1919J {Tushinski et ai., 1982] {Williams and Broxmeycr, 1988] {Williams ct 
a!.. 1990J [Koury and Bondurant, 1990] [Brandt et aI., 19941 [Keller ct al.. 19951 and the stimulation 
of proliferation and differentiation of cells (reviewed by [Metcalf. 1989] [Moore. 1991]). 
Hemopoietic GFs are produced locally by stromal cells or hemopoietic cells in the 
hemopoietic organs, by mature blood cells, by endothelial cells, and by specialized cells 
in various organs, such as lungs (granulocyte/ macrophage colony stimulating factor, 
GM-CSF), brain (interleukin-3. IL-3) pancreas (IL-6), kidneys and liver (erythropoietin, 
EPO). A short summary of the cells that produce hemopoietic GFs is given in table 1.1. 
It should be noted, that some of the data on GF production were based on activities in 
various biological assays and that production has·not in all studies been confirmed by 
neutralization with OF-specific antibodies or by detection of OF RNA expression in 
homogeneous cell populations. 
Initially, GFs were purified from various natural sources, such as urine (EPO (Miyake 
ct al.. 1977j and M-CSF [Motoyoshi et al.. 1978]), murine lung cells (G-CSF {Nicola et ilL, 
1983]), or human tonsil cells (lL-2 [Robb and Smilh, 1981]). or from GF-producing cell lines 
(e.g. stimulated lurkat cells for IL-2 [Gillis el al .. 1982J, and WEHI-3 cells for IL-3 [Ihle el 
al.. 1982]). Large quantities of recombinant OFs have become available for research and 
clinical purposes since the molecular cloning of the OF genes and the production of 
complementary DNA (cDNA), and the development of techniques that enabled expression 
and large scale prodpction of recombinant OFs in bacteria, yeast, and mammalian cells. 
12 
Marg de Jong Chapler 1 General introduction 
!vIany of the hemopoietic GFs, which are all glycoproteins,' share the same basic 
architecture, a four a helix bundle. This has been demonstrated for IL-2 [Brandhuber et al.. 
1987] [Bazan. 1992], IL-3 [Fcng et aI., 1995], IL-4 {Powe.rs et al.. 1992] [Walter et al.. 1992b] 
[Powers et al.. 1993], IL-5 [Walter et al.. 1992b], IL-6 [Van Dam et al., 19?3], GM-CSF [Diederichs 
et ai., 1991] [Walter ct aI., 1992a], G-CSF [Zink et aI., 1992] [Hill ct al.. 1993] [Wcrnc~ ct a!.. 1994] 
[Zink et at., 1994], M-CSF [Pandit et at., 1992], SCF [Bazan, 199!f[Matous et at., 1996], EPO 
[Krantz, 1991], and thrombopoietin (TPO) [Gurney et al.. 1995]. Some properties of these 
GFs are discussed below. 
table 1.1.a. GF production by different cells (overview). 
produced by 
Stromaa Lymphocytes Monocytes Granulocytes Endothelium other cellsb 
IL-1 
IL-2 
IL-3 
IL-4 
IL-5 
+ 
IL-6 + 
IL:11 + 
GM-CSF + 
G-CSF + 
M-CSF 
SCF ,+ 
EPO 
TPO + 
+ 
+ 
+ 
+ 
+ 
+ + 
+ + 
+ 
+ + 
a 'stromal is used to Indicate fibroblastoid cells 
+ 
+ + 
+ 
+ + 
+ + 
+ + + 
+ 
+ 
+ 
+ 
b cells in brain (IL-3 and IL-11], pancreas (IL-6), lungs (GM-CSF and IL'll), skin (IL-11), liver 
and kidneys (EPO and TPO) 
IL-
G(M)-CSF 
SCF 
EPO 
TPO 
interleukin-
granulocyte (macrophage)-colony stimulating factor 
stem cell factor 
erythropoietin 
thrombopoietin 
literature cited: see second part of table 
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table 1.1.b. GF produclion by different cells (references). 
GF produced by 
Il·l stromal caUs 
monocytes 
andothelial cells 
Il·2 Iymphocytas 
Il·3 lymphocytes 
granulocytes 
brain cells 
Il·4 lymphocytes 
granulocytes 
Il·5 lymphocytes 
Il·B stromal cells 
lymphocytes 
monocytas 
endothelial cells 
pancreas cells 
Il·ll stromal cells 
endothelial cells 
other cells 
GM·CSF stromal cells 
lymphocytes 
monocytes 
granulocytes 
endothelial cells 
lung cells 
G·CSF stromal cells 
monocytes 
endothelial cells 
M·CSF lymphocytes 
monocyles 
endothelial cells 
SCF stromal cells 
EPO kidney cells 
liver cells 
. TPO kidney cells 
liver cells 
stromal cells 
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Interleukin-2 
IL-2 is produced by activated T lymphocytes (table 1.1). Human IL-2 cDNA 
encodes a polypeptide of 153 amino acids (AA), the N-terminal 20 AA of which are 
cleaved off in the secretion process, resulting in a mature IL-2 molecule with a molecular 
weight of 15 kD {Taniguchi et al., 1983]. The sequences of human and murine IL-2 have 
64% homology and point to stmctural differences in the -amino-terminal region of the 
molecule [Brandhuber et al., 1987]. Murine ll..--2 exerts some biological activity on human 
cells [Zurawski el al., 1986], and human IL-2 shows activity on murine cells [Rosenberg et a1., 
1984]. N-glycosylation sites (Asn-X-Ser or Asn-X-Thr) are absent from Ihe reported 
amino acid sequence of human IL-2 [Taniguchi et aI., 1983]. However, O-linked 
carbohydrates might be responsible for the molecular heterogeneity of the protein [Robb 
and Smith, 19811. One disulfide bridge is present between 2 cysteine residues and links two 
of the four (( helices of the protein [Bazan, 1992]. Different regions of the IL-2 molecule 
interact with the three subunits (see section 1.3) of the IL-2 receptor [Buzan, 1992] [Zurawski 
ct aI., 19931. 
Interleukln-3 
IL~3, also known (is multi-CSF, is produced by lymphocytes and granulocytes. and 
expression of IL-3 mRNA fn mouse brain celIs has also been demonstr'ated (table 1.1). 
Murine IL-3 is a glycosylated protein with a molecular weight of approximately 28 kD 
[Ihle et aI., 1982]. Of the I 66-AA precursor protein, 26 AA are removed to yield mature 
murine ll..--3 {Fung et aI., 1984]. Glycosylation at the 4 potential N-glycosylation sites of 
murine ll..--3 is not required for its biological activity in vitro or in vivo, since recombinant 
bacterial IL-3 as well as a chemically synthesized form of nonglycosylated IL-3 are 
biologically active [Kindler et aI., 1986] [Zilten~r ct al.. 1994]. Human IL-3 consists of 133 
AA, with 2 N-linked glycosylation sites. Two of the 4 cysteine residues that are prese'nt 
in murine IL-3 are also found in human IL-3 [Dorsscrs el ai., 1987). In both species, the 
disulfide bridge between these cysteines is required for protein folding and biological 
activity [Dorsscrs et al .• 1991]. IL-3 acts in a species-specific manner, e.g., rat IL-3 does not 
induce proliferation of murine BM cells, v.v. (Cohen et a1., 1987}. Human IL-3 is much less 
effectiv~ than rhesus monkey (Macaca mulatta) IL-3 in inducing proliferation of rheslls 
monkey cells, whereas rhesus n~onkey ll..--3 stimulates human hemopoietic cells with 
similar efficiency as rhesus monkey cells [Burger et aI., 1990]. Chimpanzee (Pan 
troglodytes).IL-3 can also stimulate human hemopoietic cells, whereas ll..--3 from tamadn 
(Sanguinus oedipus) or marmoset (Callithrix jacchus) cannot [Burger et aI., 1994al [Dorssers 
et aI., 1994]. These differences are reflected in the large heterogeneity between the 
sequences of different primate IL-3 sequences, and this suggests rapid evolutionary, 
changes of the IL-3 gene during primate evolution [Burger et ai., 1994b]. 
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Interleukln-4 
IL-4, originally termed B cell stimulatory factor-I, is produced by T lymphocytes and 
granulocytes (table 1.1). Mouse and human JL-4 have been reported to contain 140 and 
153 AA, respectively [Lee et at., 1986J [Yokota et at., 1986J. Mature human IL-4 consists of 
128 AA as a result of post-translational processing and, like murine IL-4, contains 6 
cysteine residues and multiple glycosyJation sites [Paul and Ohara, 1987] [Solari et aI., 1989] [Le 
et at., t991J. The in vitro biological activities from glycosylated and unglycosylated human 
IL-4 are similar [Solari et al:, 1989J. Two of the 3 disulfide bridges that are found in human 
IL-4 are also present in similar locations in the murine molecule, The different positions 
of the cysteine residues that are linked by the third disulfide bridge result in structural 
differences between human and murine ll.-4 molecules [Walter et a1., 1992bJ. Therefore, it 
is not surprising that ll.-4 does not cross-react between these species: 
Interleukln-5 
IL-5 is produced by T lymphocytes (table 1.1). Human IL-5 contains 115 AA. IL-5 
forms homodimers that are linked by two intermolecular disulfide bonds', The crystal 
structure reveals that the structural fold of each domain shows similarity to that of IL-2, 
IL-4, OM-CSF and M-CSF [Milbum et at., 1993J. A particular property of IL-5 is that it 
forms dimers, in which each 4-helix domain contains the C-terminal helix of one chain 
and the N-terminal 3 helices of the other chain [Milburn et al., 1993], 
Interleukin-6 
IL-6, also known under differ.ent names, which include B cell stimulatory factor-2, 
interferon-P2, 'and hybridoma/ plasmacytoma GF, is produced by'stroma cells, 
lymphocytes, and monocytes. In addition, IL-6 secretion by endothelial cells and 
pancreas cells has also been reported (lable 1.1). Human JL-6 is a 21-kD glycoprotein 
containing 184 AA with 4 cy.steine residues and 2 potential N-linkcd glycosylation sites 
[Hirano et Olio, 1986] [Gauldie et aL, 1987J. N-linked glycosylation s!tes are not fqund in murine 
and rat IL-6, which are probably only O-glycosylated. Human IL-6 stimulates both 
human and murine cells~ n1:urine IL-6 is only active on murine cells [Coulie et aI., 1989]. 
Using various chimeric IL-6 proteins, which have ·been constructed by introducing 
different domains of the murine molecule into human IL-6, it has b.een shown that the 
domain that contains the first (X helix [Bazan, 1990] does not determine species specificity of 
IL-6 [Vnn Dam et aI., 1993], 
GM-CSF 
OM-CSF is produced by stroma cells, lymphocytes, monocytes, granulocytes, 
endothelial cells, and lung cells (lab Ie 1.1). The gene that encodes OM-CSF is located 
at mouse chromosome J I or its human analog human chromosome 5, and is closely 
linked with the IL-3 gene {Barlow et aI., 1987] [Yang et aI., 1988a]. These genes might 
16 
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originate from one gene by gene duplication, especially since they are stmcturally similar, 
and share overlapping functions. Murine GM-CSF is·a protein of 23 kD [Gough ct al.. 
t984J. Human GM-CSF has a relative molecular mass of 20-23 kD and consists of 144 
AA, 17 of which are removed from the precursor protein. GM-CSF contains 2 potential 
N-Iinked glycosylation sites [Kaushansky et at" t986J and is highly glycosylated. The two 
glycosylation sites in murine GM-CSF are located at different positions from those in the 
human molecule [Walter et al" t992a). In vitro, deglycosylaled human GM-CSF showed 
increased affinity for its receptor and increased biological activity [Moonen et al.. 1987J 
[Chiba et aI., 1990J. The disulfide bridges in the 4-helix GM-CSF molecule are both located 
at the same end of the molecule [Diederichs et al.. 1991]. Human and murine GM-CSF act 
species-specific. Studies with chimeric human-murine GM-CSF or with neutralizing 
monoclonal antibodies have shown the importance of the third ex helix for biological 
activity [Kanakura et al.. 1991] [Diederichs et al.. 1991]. 
G·CSF 
G-CSF is produced by stroma cells, monoc)'tes, and endothelial cells (table 1.1). 
Murine G-CSF has a molecular weight of 24-25 kD [Nicola et al" 1983J. Human G-CSF is 
a 19-kD protein that contains 174 AA [Nomura et aI., 1986J. The O-linked glycoside that is 
present in human G-CSF is not needed for binding to the receptor [Oh-eda et aI., 1990]. The 
4 cysteine residues that are present in human G*CSF are required for biological activity 
[Lu et aI., 1992J. The 2 disulfide bonds that are formed by these residues are located at 
opposite ends of the molecule [Hill et ai., 1993]. 
M·CSF 
M-CSF is produced by lymphocytes, monocytes, and endothelial cells (table 1.1). 
Human M-CSF has a molecular \veight. of 65-70 kD [Pisloia et aI., i987]. As a result of 
alternative splicing three forms of M-CSF exist, con.sisting of 256, 438, or 554 AA [Pandit 
et aI., 1992]. The COOH*terminns,.which contains a transmembrane region, is not required 
for in vitro activity [K"awasaki and Ladner, 1990]. Soluble as well as cell*surface forms of M-
. CSF exist [Reltenmier et aI., 1987] [Stein el aI., 1990], the former of which are generated by 
proteolytic cleavage of membrane-bound glycoproteins. Biologically active soluble M-
CSF is a homodimer [Stanley et al.. 1983], consisting of two 4-helix bundles, which contain 
3 intramolecular disulfide bridges in each monomer, and one interchain disulfide bond 
(Pandit et al.. 1992]. Human M*CSF stimulates both human and murine cells [Takahashi et aI., 
1994J. 
SCF 
SCF is produ~ed by stroma cells (table 1.1). Similar to M-CSF, SCF is also found 
in ce~1 surface and soluble forms [Anderson et aI., 19901 [Flanagan and Leder, 1990]. Soluble 
SCF consists of the first 164 or 165 AA of the extracellular domain of the transmembran.e 
17 
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form, and exists in solution as a noncovalently linked homodimer [Martin et 01.. 1990). SCP 
contains N-linked as well as O-Iinked glycosylation sites, and 4 cysteine residues [Zsebo et 
al.. 1990b), which are important for the three-dimensional structure of the GP. These 
cysteines are conserved among SCP, M-CSP, and Plt3 ligand, the receptors of which 
also share structural similarities (see section 1.3). As SCP, M-CSP, and Plt3 ligand also 
have similar intronl exon structures, these GFs may be derived from a common ancestral 
gene, although their AA sequences are ~90% different ILyman et 01.. 19941. Based on its 
sequence homology with M-CSP, the positions of 4 a helices of SCP have been 
predicted [Bazpn, 1991]. Studies using human! murine chimeric eDNA constructs, 
neutralizing monoclonal antibodies, and murine SCF that had been mutated with 
corresponding residues from M-CSP point to the importance of the first, third, and fourth 
helix of SCP for its biological activity [Matou, et a1 .. 19961. SCP is partly species specific, 
as rat SCP supports growth of murine and human cells, but human SCP hardly stimulates 
murine cells [Mnrtin et aI., 1990]. 
EPO 
EPO is produced by cells from kidney and liver (table 1.1). Under conditions where 
the partial 02 pr~ssure is low, such as at high altitude, the EPO production is enhanced, 
providing a feedback mechanism for the regulation of red blood cell production. Human 
EPO is a 30-34-kD glycoprotein,of 166 AA [Miyake et al.. t9771 [Jacobs et al.. (985) [Lin et 
at .. t985J. It contains 4 cysteine residues, which are important for protein folding and 
biological activity [IVang et al.. t985aJ [Lai et al.. t986). EPO contains 3 N-Iinked and I 0-
linked glycosylation sites. Glycosylation of EPO is not necessary for its biological 
activity in vitro, but essential in vivo [Schooley and Mahlmann, 1971] {Dordat et aI., 1985] [Tsuda 
et aI., 1990] [Wasley et aI., 1991]. EPa. shows a high degree of AA conservation between 
different mammalian species. Murine EPO is active on human erythroid precursor cells 
and vice versa, and the same is true for EPO of other species, e.g:, sheep [Teppennan et aI., 
1974] [Shoemaker and Milsock, 1986] . 
TPO 
TPO is produced by cells from the kidney and the liver and by stromal cells (table 
1.1). The protein consists of a highly conserved amino-terminal domain that is related to 
EPO and a unique carboxy-terminal domain [Barlley et al., 1994] [De Sauvage et aI., 19941 [Lok 
et a1 .• t994J. The mature form of human TPO contains 332 AA: 153 AA in theN-terminal 
part and 179 AA in the C-terminal domain [Gurney e,l a1 .. 1995J. Similar to EPO, TPO 
contains 4 cysteines. Three of the 4 cysteines present in EPO are conserved in TPO, 
which suggests that the EPO homology domain may assume a 4-helix bundle 
configuration [De Sauvage et al.. 1994] [Gurney et aI., 1995]. A variant form of TPO, in w~ich 
alternative splicing results in a 4 AA deletion in the EPO homology domain of pig, 
mouse, and human TPO, is not biologically active [Gurney et at., (995). The 6 (human 
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TPO) or 7 (murine TPO) potential N-Iinked glycosylation sites are located in the C-
terminal domain of TPO [Bartley et aL, 1994] [De Sauvage et aI., 1994J [Lok et aI., 1994J. This 
domain is probably highly glycosylated, as the predicted molecular weight for TPO is 38 
kD, whereas immunoprecipitation of human TPO shows a protein of 68-85 kD [Gurney et 
aI., 1995J. In vitro culture, experiments have shown that this C-terminal domain of TPO is 
. not required for binding and activation of its receptor [De Sauvage et ai., 1994]. This region 
may act to stabilize and increase the half-life of circulating TPO, and might be cleaved off 
the full-length TPO protein to generate the 18-25 kD and 28-32 kD species of TPO 
[Bartley et ai., 19941 [De Sauvage et ai., 1994]. TPO is not strictly species specific: porcine and 
murine TPO stimulate human receptors, and human TPO is active on the murine receptor, 
although less than murine TPO [De Sauvage et aI., 19941 [Gurney et a1.. 1995]. Plasma TPO 
levels appear to be regulated primarily by TPO binding to the c-Mpl receptor on platelets 
and thereby by the platelet mass [Fietder et al" t996J. 
1 .3 HemopoietJc GF receptors 
Hemopoietic OF receptors belong in majority to two different families based on 
homologous sequences of the genes [Olsson et al.. 19921. The tyrosine kinase receptor 
family consists of cell-surface receptors that possess an intrinsic, ligand-sensitive, protein 
tyrosine kinase activity [Yardcn and Ullrich. 1988J [Ullrich and Schlessinger .. 1990}. The receptors 
of this family are classified into three subclasses. based on distinct structural 
characteristics (figure 1.2), Monomeric forms of tyrosine kinase subclass I receptors, 
which include the epidermal growth factor (EGF) receptor [Ulldch et oJ.; 1984J, contain an 
. figure 1.2 
II III 
EGF·R InsuIin·R SCF·R 
insulin·like GF1·R M·CSF·R 
F1I3! Flk-2 
PDGF·R 
Schematic representation of tyrosIne kinase receptors of different subclasses. 
Boxes represent tyrosine kinase regions (black) of the cytoplasmic domains, or cysteine-
rich regions (white) within the extracellular domains. Circles represent disulfide-bonded 
loops. 
19 
Flow cytometric analysis of growth factor receptor expression on hemopoIetic progenitors 
intracellular tyrosine kinase domain. ~nd two cysteine-rich repeat sequences in the 
extracellular domain. Similar cysteine-rich sequences and tyrosine kinase domains are 
found in the subclass 11 receptors for insulin and insulin-like growth factor I [Ebina et al.. 
1985] [Ullrich et al." 1986J. which consist of disulfide-linked heterotetrameric up structures. 
The third subclass of the tyrosine kinase receptor family is characterized by a bisected 
intracellular tyrosine kinase domain, and five immunoglobulin-like repeats in the 
extracellular domain containing 10 conserved cysteine residues and specific flanking 
sequences [Hanks et aI., 1988]. This subclass contains the receptors for SCF [Chabot et aI., 
1988] and M-CSF [Rettenmier et al.. 1985] [Rothwell and Rohrschneider, 1987J {Yeung et al.. 1987]~ 
. the receptor FIt3, also referred to as Flk-2 or STK-I {Matthews et al.. 1991] [Rosnet et aI., 
1991J [Small et aI., 1994J, and the receptor for platelet derived growth factor (PDGF) [Yarden 
et aI., 1986] [Gronwald et ai., 1988]. 
The hem(at)opoietin or cytokine receptor superfamily [Cosman et al., 1990} contains most 
other hemopoietic GF receptors, including the receptors for IL-2 [Sharon et aI., 1986] 
{Hatakeyama et aI., 1989] [Takeshita et aI., 19921. IL-3 [Itoh et aI., 1990], IL-4 [Idzerda et aI., 1990J, 
IL-5 [Takaki et aI., 19901. IL-6 [Yamasaki et aI., 19881, IL-7 [Goodwin et aI., 1990], IL-9 [Rcnauld 
et aI., 19921 [Chang ct ai., 1994], GM-CSF [Gearing et aI., 1989], G-CSF [Fukunaga et al.. 1990]. 
E~O [D'Andrea et ai., 1989] [Jones et aL, 1990], thrombopoietin (TPO) [Vigon et aI., 1992], IL-
11 [Cherei et aI., 1995J, and leukemia inhibitory factor (LIF) [Gearing et al" 1992bJ. and the 
common receptor units that are mentioned in the next paragraphs. The hemopoietin 
receptors do not contain intrinsic tyrosine kinase domains and are heterogeneous with 
respect to tile structure of the intracellular domains, which range in length fror:n 54 (GM-
CSF receptor) to 568 amino acids (IL-4 receptor). The extracellular domains of these 
receptors (figure 1.3) are identified by four highly conserved cysteine residues (except 
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IL-3·R 
GM"CSF·R 
IL·5·R 
a P 
EPO·R IL-2·R aPr 
gp130 
IL·6·R 
a 
~ 
Sch(!malic representation of examples of hemopoietin receptors. 
Boxes represent regions where conserved cysteine residues (striped) or WSXWS 
residues (shaded) are located within the extracellular domain. Note that the cytoplas,mic 
domains and some parts of the extracellular domains, represented by the rod-like 
structures, differ considerably. 
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the lL-7 receptor which has only two) and a five-residue motif of Trp-Ser-X-Trp-Ser 
(WSXWS), all located within a region of approximately 210 amino acids, which for most 
receptors is positioned just outside the membrane-spanning domain [Bazan, 1989] [Cosnlan, 
1993J. 
GF receptor subunits 
Most hemopoietic GF receptors fmiction as mul.ti-subunit complexes (figure 1.2.and 
1.3). High affinity class III tyrosine kinase receptors [Ullrich and Schlessinger, 1990J as well 
as some of the hemopoietin receptors. in particular the receptors for EPO [Ohashi et aI., 
1994J [Watowich et ai., 1994], TPO [Alexanderet al.. 1995] and G-CSF [Hiraoka et al.. 1994] [Horan 
et aI., 1996J, are homodimers of single receptor chains. For other receptors the situation is 
more complex. as high affinity ligand binding and signal transduction require the 
association of two or more differe~t receptor chains in heterodimeric or hetero-oligomeric 
complexes. Some of these receptor subunits are used by different receptor systems. For 
example. the IL-6 rec-eptor consists of a low affinity a. subunit and a signal transducing P 
subunit, gpl30 [Taga et aI., 1989J [Hibi et al" 1990J. This p subunit is also used by the 
receptors for IL-ll [Yin et al.. 1993} [Fourcin et ai., 1994] [Hilton et aI., 1994] {Nandurkar et al.. 
19961. leukemia inhibitory factor (LIF) [Gearing ct aI., 1992a], oncostatin M [Gearing et ai., 
1992al, ciliary neurotrophic factor (CNTF) (Ip et aI., 1992], and cardiotrophin-l [Pennica et 
ul., 1995). This receptor subunit plays an important role in hemopoiesis, as is 
demonstrated by the severe hemopoietic defects in mutant mouse strains that are deficient 
for gp130 [Yoshidaetal,,1996J. 
A similar situation as describe0 for these receptors exist for at least two other groups 
of cytokine receptors. Functional high-affinity receptors for IL-3, GM-CSF. and IL-5 
each contain a unique a subunit and a common p subunit, Pc, which is shared by these 
receptors JKitamura et al.. 1991) (Tavcrnier el aI., 1991) [Sakamaki et aI., 1992J [i\-liyujima el aI., 
1993}. In addition to the Pc chain, mice have a second, closely homologou's P chain, PIL-
3. which can replace Pc in the high-affinity receptor for IL-3, but not in the receptors for 
IL-5 or GM~CSF [Hara and Miyajima, 1992J. Such a second, IL-3 receptor-specifiC subunit 
has as yet not been described for other species, and does not seem to occur in primates 
sllch as humans. 
Receptors for IL-2 consist of an a chain (Tac [Leonard et al .. 1984) [Nikaido et ai., 1984}). a 
P chain {Sharon ct al., 1986] that is shared with IL-15 [Giri el ai., 1994], and a common 'Y 
chain [Takeshita el aI., 1992] that is shared with th,e receptors for IL-4 {Kondo et al.. 1993], IL-
7 {Kawahara et al.. 1994], IL-9 {Kimura et al.. ·19951, and IL-15 [Giri el ai., 1994]. Low affinity 
IL-2 receptors contain only the a chain, which is not necessary for signal transduction. 
Unlike the other subunits the fJ. chain does not belong to the hemopoietin-receptor family 
and- is not expressed constitutively on resting lymphocytes [L~i el al.. 1991]. The P and 'Y 
chains do not bind IL-2 individually, but intenilCdiate affinity receptors consist of 
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.heterodimers of p and y chains [Tak~shila et aI., 1992). A 'pseudo-high' affinity IL-2 
receptor is formed by interaction of a and ~ chains [Nakarai et ai., 19941. which can only be 
internalized when combined with.the y subunit. The trimeric high affin!ty IL-2 receptor 
has a higher association rate and a lower dissociation rate than the ap complex [Matsuoka 
et aI., (993). Heterodimerization of the p and y chain is required for signaling of IL-2 
(Nakamura el aI., 1994) [Nelson el aI., 1994) and IL-15 [Oiri el aI., 1994). The physiological 
importance of y chain is illustrated by severe immunological defects in severe combined 
immunodeficiency (SCID) patients. who .lack a functional gene for this receptor subunit 
[Matthews et aI., 1995) [Pepper et 01..1995) [Leonard, 1996]. 
The target cell specificity of Ihese GF receptors is primarily determined by the 
expression of the different a subunits. On ceHs that coexpress different 0: chains, 
responsiveness to the different ligands is influenced by competition for available p 
subunits. This is dependen't on the relative concentration of each receptor subunit, and the 
affinity of the resulting GF-receptor complex. 
1,4 Biological activities of hemopoietic GFs 
Analysis of the range of biological activities exerted by individual GFs in vitro and in ' 
vivo is essential to identify- the differentiation stages and lineages on which GFs act and to 
establish their physiological role in hemopoiesis. Clonal assays have been developed for 
analysis of the in vitro proliferation potential of BM cells' after plating in semi-solid 
medium supplemented with GFs [Bradley and Metcalf, 196~J [Guilbert and Iscove, 19761 [Iscove et 
aJ., 1980] [Kubola et 01., 1983] [Mcrchav and Wagemaker, 19841 [Eliason and Odortchenko, 1985). 
These assays can be used to examine GF actions on un fractionated BM cells as well as on 
purified HSC and progenitor populations, and <.lre, therefore, of great assistance to 
identify the differentiation stages and Ifneages on which individual GFs can act, and to 
examine interactions between different GFs on defined cell populations. 
GF actions on purified human HSC and progenitor cell populations can also be studied 
in vivo, by transplantation into immunodeficient mice .. This allows examination of the 
effects of different GFs on transplantable stem cells and their progeny in vivo. The GFs 
can be administered to the cells by regularly injecting the mice with human GFs, or by 
employing immunodeficient mice carrying human cytokine transgenes. Very few studies 
have yet been published on GF stimulation of severe combined immunodeficient (SCID) 
mice transplanted with purified human cells. SCID mice injected with or expressing 
human IL-3, GM-CSF and SCF show an improved level and duration of engraftment of 
human BM and cord blood cells [Lapidot el 01., 1992] [Bock ci aI., 1995J, but such studies 
have only been done with un fractionated BM and not with purified HSC or progenitor 
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cell populations, thus making it difficult to distinguish OF actions on HSC from actions 
on more mature progenitors. 
Effects of GF administration or GF gene overexpresslon In vivo 
Data on thy in vivo activities from (pre)~linical studies in which GFs were 
administered to laboratory animals and human patients, combined with studies using 
transgenic animals with enforced overexpression of a GF gene, have provided insight 
into the biological actions of GFs in vivo, their therapeutic usefulness in the clinic as well 
as'adverse side-effects. E.g., in vivo administration of IL-3 to rhesus monkeys resulted 
in an increase of BM progenitor cell numbers, followed by enhanced production of 
granulocytes, monocytes, erythrocytes and platelets [Mayer et aI., 1989] [Wagemaker et aI., 
1990J. Formation and activation of basophils after injection of JL-3 led to histamine release . 
and adverse reactions, in particular skin rash, urticaria, and joint swelling [Van Oils et aI., 
1993J IVan Gils ct aI., 1995J. In sublethally irradiated mice, JL-3 induced significant recovery 
of T and B cell populations [Doria et .1" t993], suggesting a role for JL-3 in Iymphop,?iesis. 
Possible applications for JL-3 have been shown in the treatment of neutropenia and 
thrombocytopenia that result from chemotherapy [Ganser et al., 1990] (Ganser, 19931. 
potentially in combination with other OFs such as OM-CSF ISlahl cl aI., t9921. However, 
recent results with O-CSF and the newly discovered OF thrombopoietin (TPO) suggest 
that a combination of these GFs will be more effective for these purposes [Neelis et al.. in 
press). 
Administration of OM-CSF as a single OF to mice or rhesus monkeys predominantly 
resulted in increased numbers of macrophages and granulocytes [Metcalf et aI., J987b} 
[Donahue et aI., 1988} [Wielenga. 19901 {Metcalf, 19911. As injection of GM-CSF has also been 
shown to enhance the number of myeloid progenitor cells in lhe peripheral blood [Siena et 
.1., 1989J, this OF can be used, to mobilize progenitor cells for transplantation purposes 
[Kessinger ct al.. 1995J. However, adverse side effects might occur if the malignant cells 
themselves are stimulated by OM-CSF [Dedhar et aI., 19881. Another possible therapeutic 
role for GM-CSF is stimulation of immune respo.nses against tumor cells by promoting 
antigen-presenting cells and antibody-dependent cell cytotoxicity by macrophages [Charak 
el al" 1993J. It has been shown that genetically modified tumor cells expressing OM-CSF 
can induce immune responses against pre-existing tumors in mice, and cure the iitnirnals " 
from their disease. Similar results have been obtained with other OFs, including IL-6, 
sugge~ting potential 'application of these GFs for immunotherapy against cancer 
(reviewed by [Gilboa, 1996]). 
IL-6 transgenic mice exhibited plasma cell abnormalities and an increased number of 
granulocyte and monocyte precursors as well as mature granulocytes and megakaryocytes 
[Hirano et al.. 1990J[Kitamura et aL, 1995]. Administration of IL-6 to nonhuman primates 
(cynomolgus monkeys (Macaca fascicularis) and marmosets (Callithrix jacchus) 
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predominantly resulted in increased peripheral bloo~ thrombocyte counts {Zeidler et"al., 
1992] [Ryffcl ct al.. 1994]. In addition, thrombocyte counts of irradiated monkeys that were 
injected with IL-6 did not drop as low as those of control monkeys, and the duration of 
thrombocytopenia was shorter {Zeidler et aL, 1992]. This selective effect on 
thrombocytopoiesis, combined with the finding that relatively high doses were well 
tolerated in marmosets [Ryffei et aI., 19941, indicates that IL-6 might be useful for the 
treatment of thrombocytopenic patients. However, the therapeutic usefulness of IL-6 the 
is limited, as it induces fever and other acute phase reactions in human patients {Weber et 
al.. 1993] [Van Gameren et aL, 1994J {D'Hondt ct aI., 1995] {Schrczcnmcier et aI., 1995]. Results of a • 
phase I trial of IL-Il, which has similar effects on thrombopoiesis [Yoncmurn et al.,. 1993], 
. showed no fever after administration of this GF to breast cancer patients-{Gordon et aL, 
1996]. This means that IL-U has less adverse effects in human patients than IL-6. 
However, the possible application of IL-II to alleviate thrombocytopenia has, at least 
conceptually, become less likely due to the availability ofTPO. 
A potential role for SCF in alleviation of thrombocytopenia was suggested by elevation 
of platelet levels after. administration of SCF to mice (Chow et aL, 1993]. In addition, 
stimulation of human erythroid colony formation by SCF promised a possible use of this 
GF to treat anemia in patients with aplastic anemia [Amana et aI., 1993]. Moreover. injection 
of SCF causes an increase of the absolute number of human or !liurine HSC [Bodine et aI., 
1993J [Tong et aI., 1993], and SCF is ~ery effective for mobilization of stem cells into 
peripheral blood, especially in combination with G-CSF [BriddelJ et al.. 1993]. However, a 
serious adverse effect of SCF administration to mice or primates is the expansion and 
activation of mast cells [Wcrshil el al.. 1992] {Galli et al.. 1993]. This also occurred in breast 
carcinoma patients receiving SCF {Costa et al.. 1996]. The acute hypersensitivity-like 
reaction that results from mast cell activation severely limits tI\e usefulness of SCF as an 
in vivo therapeutic agent. 
Severe adverse effects have ,lot been associated with the clinical uses of EPO or G-
eSF. In contrast to the pleiotropic effects of other GFs on various hemopoietic lineages, 
EPO is a specific regulator of erythropoiesis. EPO administration to hemodialysis patients 
has been shown to counteract the anemia of renal failure [Winearls et a!., 1986] {Eschbach ct 
aI., 1987), for which it is now widely used. Injection with recombinant human G-CSF 
stimulated granuloI?oiesis in normal hamsters and mice [Cohen ct al.. 1987], and promoted 
mobilization of HSC and progenitor cells from EM marrow to blood in mice following 
treatment with cytotoxic dmgs [Neben et aI., 1993} .. Patients who were treated with G-CSF 
in a phase IIII clinical trial showed an increase in circulati~g progenitor cell numbers 
{OUhrscn et aI., 19881. These in vivo effects as well as the absence of significant adverse 
rea~tions have permitted the clinical use of G-CSF to treat neutropenic patients and to 
mobilize HSC and progenitor cells into the circulation for autologous (and allogeneic) 
transplantation jn patients that suffer from malignancies [Morstyn ct a!.. 1994]. 
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Effects of GF (receptor) deficiency In vivo 
Analysis of the phenotype of mouse strains that, either naturally or through 
homologous recombination, lack functional genes for GFs or their receptors, provides 
another means to examine the physiological functions and target cell range of GFs. \VeJl-
known examples of such mouse strains are those that lack functional genes for SCF or its 
receptor, resulting of mutations of the Steel (Sl) [Copeland et aL, 1990] [Flanagan and Leder, 
1990] [Huang et ai., 19~0] [Zsebo et al., 1990a] or the white spotting (lY) locus [Chabot et a1., 
1988] [Geissler ct aI., 1988],"respectively. The reduced numbers of progenitors and mature 
blood cells in these mice demonstrate that this GF! receptor system is indispensable for 
stem cell outgrowth. However, stem cells are present in the hemopoietic organs of \l'l\V 
embryos, although at reduced nu'mbers, suggesting that Kit is less crucial for the 
production and survival of stem cens in vivo [Ikuta and Weissman. 1992]. 
Osteopetrotic (op/op) mice, which·do not synthesize biologically active M-CSF as a 
result of an inactivating mutation, exhibit a severe deficiency in \fle macrophage lineage 
[Yoshida et al.. 1990]. This defect is progressively corrected when the mice age, which 
. suggests substitution o"f M-CSF by other GFs. "Knockout" studies have shown. that 
GM-CSF is not the GF responsible for this correction [Nilsson et al.. 1995]. 
The role of IL~6 has been studied using mice in which either the gene for IL-6 or the 
gene for the signal transducing subunit of the IL-6 receptor, i.e. gp 130 (see section 1.3), 
has .been inactivated by homologous recombination [Bluethina~n ct al.. 19941 {Yoshida et a\., 
1996]. IL-6 knockout mice develop normally. These mice are very sensitive to infections, 
which has been attributed to a crucial role for IL-6 in the bactericidal function of 
m~crophages and the T-cell dependent antibody response [Kishimoto. 1994] [Kopf et a\., 
19941. Homozygous gpl30 mutant mice die before birth. Apart from heart abnormalities, 
which might be attributed to functional inactivation of cardiotrophin-l, which is one or 
the other GFs that utilize gpl30 (see section 1.3), these embryos have greatly reduced 
numbers of hemopoietic progel~itors in the liver and T cells in the thymus. and 
approximately 20% of the embryos show impaired erythropoiesis [Yoshida et al.. 1996]. 
Although it is clear that the combination of IL-6/ IL-6 receptor/ gp 130 plays an important 
role in the development of prirnitive hemopoietic progenitor cells [Sui et aI., 19951. the 
phenotypic differences between IL-6 and gp 130 knockout mice demonstrate that other 
GFs that use gp 130 for signal transduction also have important functions in hemopoiesis. 
Mice that do not express TPO or its receptor, c-Mpl, develop normally but show 
decreased platelet counts, whereas other blood cell counts are normal [Gurney et al.. 1994] 
[Alexander ct al.. '1996] [Carver-Moore et aI., 1996]. These results demonstrate that the major 
physiological role of TPO is platelet production. However, these mice also have reduced 
numbers of multipotential as well as committed progenitors of multiple lineages in BM, 
spleen. and peripheral blood [Alexander et aI., 1996] [Carver-Moore et al.. 1996]. TPO 
administration to TPO-deficient mice and control mice significantly increased ~he numl?er 
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of myeloid, erythroid, and mixed progenitors [Carver-Moore et aI., 1996]. This indicat~s a 
function for TPO and c-Mpl in the production of primitive pluripotent progenitor cells as 
well as progenitor cells committed to non-megakaryocytic lineages. 
Genetically engineered mice that lack functional genes for GM-CSF or the shared Pc 
chain of the IL-3, GM-CSF and IL-5 receptors (see section 1.3) have relatively mild 
hemopoietic defects [Dranoffand Mulligan, t994J [Robb el at" t995J. These mice exhibit lung 
pathology, prob~bly as a resl,lt of a deficiency in lung macrophages, whereas mice that 
lack the unique 1L-3 receptor P chain, which has been found only in mice (see section 
1.3), are normal [Nishinakamura et aI., 1995J [Nicola et at, 1996]. Mice that lack Pc and IL-3, 
and thus have no functionallL-3f GM-CSFf 1L-5 system, are still viable and have similar 
d,efects as the Pc knockout mice [Nishinakamura ct al., 1996]. These results demonstrate that 
IL-3, GM-CSF, and 1L-5 are not essential for normal steady state hemopoiesis in vivo. 
Although this may be true, important physiological functions of these GFs and their 
receptors in the regulation of stem cell development cannot be excluded, as hemopoietic 
cell proliferation and differentiation involves the overlapping actions of multiple 
cytokines. In view of this GF redundancy, it is not possible to obtain an accurate insight 
into the target cell range and physiological functions of GFs on the basis of the phenotype 
of knockout mice. 
Target cell specificity of hemopoietic GFs 
The in vitro and in vivo studies have demonstrated that most GFs display a wide range 
of biological effects on different cell types, including HSC, committed progenitors at 
various stages of differentiation, and mature blood cells. A summary of the target cell 
range of various GFs in hemopoiesis, as derived mainly from functional studies, is 
shown in table 1.2 . 
.In addition to hemopoietic cells, many GFs are also involved in the development and 
functional activation of nonhemopoietic cell types:These include endothelial cells [Broudy 
et aI., 1987] {Segal et aI., 19871 [Sironi et aI., 19891 [Zsebo et aI., 19881 and stromal fibroblasts 
[Lee et aI., 1987] {Ya?g et aI., J988b], which produce various GFs in response to IL-l. Other 
nonhemopoietic target cells for hemopoietic GFs include skin fibroblasts [Katz et al., 1989], 
pancreatic islet cells [Campbell et aI., 1989] and hepatocytes {Nesbitt and Fuller, 1992J (all 
responsive to IL-6), osteoblasts (stimulated by IL-6 [Kitamura el al.. 1995) and GM-CSF 
(Evans cl aI., 1989]), brain cells {Manova et aI., 1992], melanocytes [Matsui et al., 1990], germ 
cells [Manova et aI., 1993J, endometrium and placental tissues [Kauma et aI., 1996] (all 
stimulated by SCp)o 
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table 1.2.a. Target cells for GFs based on biological actions (overview). 
tL- -CSF 
SCF EPO TPO 
BlasV 
multillneage 
progenitors sIp 
Monocytic 
progenitors p 
Myelotd 
progenitors p 
2 3 4 5 
sip p 
p/d p1 
p/d p/d P 
6 11 GM G M 
sip p sip p sip p 
p P p/d p/d P p/d 
p p/d/m p/d p/d p p/d 
Erythroid 
progenitors p p p p p P s/p/d p/d 
Monocytesl 
macrophages 9 
Granulocytes: 
neutrophils 
basophils a 
eosinophils 
Lymphocytes: 
T a 
B a 
9 P (g)2 d g/(g)3 a s/p/g 
a a a 
a 
a a 
p/d p p 9 
alp d alp p m 
no influence reported 
The characters 5, p, d, a, m, and 9 are used to describe the inHuance that is exerted on 
the cells (as defined in the respective studies that are cited): 
2 
3 
s sU/vival 
p proliferation 
d differentiation 
a activation 
m maturation (final) . . 
9 stimulalion (or abrogation2,3) of growth factor production by 
monocytesl macrophages ~r lymphocytes . 
also- reported: Inhibition of macrophage colony formation by IL·4 
P Interleron synthesis is abrogated by IL-4 
macrophage inflammatory cytokine production is down-regulated by IL·11 
literature cited: see second· part of table 
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tabfe 1.2.b. Target cells for GFs based on biological actions (references). 
A. Progenitors. 
progenitors 
Blast! 
Mullilineage 
Monocyticl 
Myeloid 
Erythroid 
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GFs 
Il·l 
Il·3 
Il·4 
Il·6 
Il·ll 
GM·CSF 
G·CSF 
SCF 
TPO 
IL·l 
IL·3 
Il·4 
IL·5 
IL·6 
IL·ll 
GM·CSF 
G·CSF 
M·CSF 
SCF 
TPO 
Il·3 
IL·4 
Il·6 
IL·ll 
GM·CSF 
SCF 
EPO 
TPO 
references 
[Ikebuchi at al., 1988bJ (Lardon et aI., 1994) [Stanley et aI., 1986J 
[80t et al., 1988] {Garland and Cromplon, 1983] [Ihle et al., 1983J [Ikebuchi 
et aI., 1987J [Ikebuchi et aI., 1988a] [Leary et al., 1988J [Monette and 
Sigounas,1988aJ {Monelle and Si~ounas, 1988b] {Oltmann et aI., 1989J 
[Saeland at aI., 1988J [Spivak el aI., 1985J (Suda el aI., 1985J 
[Keller el al., 1994) [Kishi al al., 1989) (Migliaccio el aI., 1989/1990] 
[Ikebuchl et aI., 1987) [lkabuchi at aI., 1,988bJ [Koika el ar., 1988) [lardon 
et aI., 1994] {Leary al aI., 1988J 
[Du and Williams, 1997J (Hirayama et al., 1992J [Holyoake el aI., 199'6J 
[Melcalf et ai" 1980J [Melcalf et a1., 1986c] [Siefi et aI., 1985J [Slrife et 
ai., 1987J 
[Ikebuchl et aI., 1988aJ (Ikebuchi et aI., 1988bJ [Suda et aI., 1987] 
[Han, 1992J [lardon et aI., 1994] [Migliaccio et aI., 1991c] 
[Ku al aI., 1996J [Sitnicka el al., 1996] 
[Gasparetto el aI., 1989] 
[801 al aI., 1988J [Ema el al., 1990] [McNieca et al.. 1989] {Metcalf et al.. 
1987aJ {Migliaccio et aI., 1988aJ [Migliaccio el aI., 1988bJ [Migliaccio al aI., 
1991b] [Monelle and $lgounas, 1988aJ [MoneUe and Sigounas, 1985bJ 
[Oltmann et al., 1989J [Quesenberry et aI., 1985J [Sonoda at aI., 1988J 
[Jansen el aI., 1989J [Kajitani et ai" 1989J [Kishi el ar., 1989J 
[Clullerbuck and Sanderson, 1988J {Clutterbuck el ar., 1989J {Dvorak al 
al., 1989J {Ema el aI., 1990J 
[801 el aI., 1989J [Koike al aI., 1988] [Caracciolo el aI., 1989bJ [Hoang el 
ai., 1988J 
[Du and Williams, 1997] (Musashi et aI., 1991] 
[Johnson and Burgess, 1978J [Kaushansky el al., 1986J [Caracciolo et aI., 
1989b) IMcNiece el at, 1989) [Merchav and Wagemaker, 1984J [Melcalf 
and Merchav. 1982) (Metcalf et aI., 1986bJ {Melcalf el aI., 1986c) (Siatl et 
aI., 1985] (Sonoda al aI., 1988J (Strife al aI., 1987] [fomonaga at aI., 1986] 
[Venlura et aI., 1990] 
[Avalos el aI., 1990J {Begley et aI., 1988J {Caracciolo el al.: 1989aJ (Cohen 
et al., 1987J [De Haan et aI., 1994) [Deinelri and Griffin, 1991J [Ema el aI., 
1990J {Ieki at aI., 1990} [McNiece et aI., 1989J [McNiece el aI., 1991} 
[Metcalf and Nicola, 1983J [Migliaccio et aI., 1989J [Strife al,al., 1987] 
[Suda el aI., 1987J [famura et aI., 1987] 
[Bicknell et aI., 1988J {Bot et al., 1989J [Guilbert and Stanley, 1980] 
[De Haan et al., 1994J [Uesvald el aI., 1995J [McNiece el aI., 1991] 
[Migliaccio et al., 1991e] 
[Alexander et aI., 1996] [CalVar-Moore el aI., 1996] 
[Bol el aI., 1988] [McNieca et aI., 1991] (Migliaccio el al., 1988a] 
[Migliaccio et al., 1988bJ [Monette and Sigounas, 1988aJ [MoneUe and 
Sigounas, 1988bJ [Ottmann ~t al., 1989J [Saeland at a!., 1988J [Sonoda el 
aI., 1988J [Wrighl Goodman at aI., 1985J 
(Kishi el al., 1989) {Paschel al aI., 1987] 
(Ulich et aI., 1991) 
[Du and Williams, 1997J [Quesniaux el ai., 1992} 
[Donahue et al., 1985] (Kaushansky et ai" 1986J [McNiece at at., 1991) 
(Metcalf el aI., 19801-[MetcaU at aI., 1986a] (Metcalf el ai" 1986c] 
[Migliaccio et aI., 1988a] [Ottmann ~t aI., 1989J (Sieff at aI., 1985) [Sonoda 
et at., 1988J [Strife el aI., 1987) 
[Dai el aI., 1991J [De Haan et aI., 1994J {McNiece at ai" 1991] (Sui al at, 
1996J (Migliaccio el aI., 1991c] 
(Iscove, 1977) {De Haan at aI., 1994J (Goldwasser el ar.. 1974] & (Gregory, 
1976] & [Haga and Falkangar, 1979J & {Iscove, 1977J (McNieca et al., 
1991] (Migliaccio at al., 1988aJ (Migliaccio el aI" 1988bJ {Stephenson el 
aI., 19711 [Tepperman et aI., 1974J [Ventura at aI., 1990J [Wagamakar al 
al., 1977J [Wagemaker et aI., 1979] 
[Alexander el aI., 1996] [CalVer·Moore el aI., 1996] 
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B. More mature cells. 
cells GFs references 
Monocyles! IL-l 
Macrophages IL·2 
[Ruppert and Peters, 1991] {Tosalo and Jones, 1990] 
[Numerof el aI., 1988] 
Granulocytes 
Lymphocytes 
IL· 
G(M)·CSF 
SCF 
EPO 
TPO 
IL·3 
IL·4 
IL·6 
IL·ll 
GM·CSF 
M·CSF 
IL·l 
IL·3 
IL·4 
IL·S 
GM·CSF 
G·CSF 
IL·l 
IL·2 
IL·3 
IL·4 
IL·S 
IL·6 
IL·ll 
[Chen and Clark, 1986J {Whelton et al., 1986J 
[Nickolaus and Zawatzky, 1994J (Novak et aI., 19901 [Ogawa el aI., 1991) 
[Sampson et ar., 1991] [Zloinik el aI., 1987] 
- • [Ruppert and Pelers, 1991J 
[Trepicchio eral., 1996] 
[Dranoff and Mulligan, 1994J [Hamifton el aI., 1980J [Handman and 
Burgess,1979] {Johnson and Burgess, 19781 (Wang et at., 19B5b] 
[Becker et aI., 19B7] [Chen and Clark, 1986] [Guilbert and Stanley, 19BO) 
[Hamilton et aI., 1980] [Stanley et aI., 1983] {Tushlnski and Stanley, 1983J 
(Tushinski et aI., 1982] [Tushinski and Stanley, 1985J {Warren and Ralph; 
1986J {Whelto~ el aI., 1986J 
(Subramanian and Bray, 1987J 
(Brunner el al., 1993J {MacDonald et aI., 19891 [Mayer et aI., 1989J (Valent 
et aI., 1989) 
[Bober et ar., 1995J 
(Clulterbuck and Sanderson, 1988J [Enokihara et aI., 1988J 
[Kaufman et aI., 1989J [Dranoff and Mulligan, 1994J [Lopez el aI., 1983] 
{Mayer el al., 1987J (Melcalf et aI., 1986a] [Schaafsma et at, 1989] 
{Stanley and Burgess, 1983] 
[Avalos el at, 1990J (Begley et at, 1988J (Burgess and Metcalf, 1980J 
{Demelri and Griffin, 1991] (Lopez et aI., 1983J [Nicola and Metcalf, 1985J 
[Emilie et aI., 1988J (FalkoH et aI., 19S3] [Lipsky et aI., 19S3J (Maizel et ar., 
1 9S1 J {T osa\o et aI., 1990J 
{Croft and Swain, 1991] [Farrar et at, 19801 {Gi1l!s and Watson, 1980] 
[Gillis et al., 1980] {LaWme el aI., 1983] [Mochizuki at al., 1.980b1 
[Mochizuki et aI., 1980a] [Mooke~ee et al., 1989]" {Tigges el aI., 1989] 
[Weiss, 1989J 
{Djeu et aI., 1983] [Hapel el a!., 1981] [Ihle et aI., 1981) (Laltime et aI., 
1983] [radmQri el al.,·1989] 
(Croll and Swain, 1991] [Defrance et aI., 19891 (Elenstrom and Sevarinson, 
1989] [Fernandez-Bolran et aL, 1986J [Fernandez·Bolran el aI., 1989J 
(Lee et ar., 1986] [O'Garra at aI., 1986J [Ohara and Paul, 1987) [Smeland 
et aL. 1989J (Yokota et aI., 1986] 
[Harada el aI., 1987] [Migila et aI., 1990) 
[Croft and Swain. 19911, {Emilie el at, 1988J (Helle et aI., 1989} [Hirano el 
aI., 1986] [T osato el al.. 1990} 
[Anderson et aI., 1992] 
interleukin-
granulocyte (macrophage)-colony stimulating factor 
stem cell factor 
erythropoietin 
Ihrombopoietin 
Hemopoietic effects of GFs can be the result of direct stimulation of HSC and 
progenitors, but al,so of indirect mechanisms, e.g., through stimulating the release of 
secondary cytokines from the hemopoietic cells themselves and from no'nhemopoietic 
sources [Broudy et aI., 1987] [Hagiwara et aI., 1987J {Fibbc et aI., 1988] {Numerof et aI., 1988] IHellc 
et aI., 1989] {HUhner et aI., 1989} [Schaafsma et aI., 1989] {Sironi et aI., 1989] [Splcland ct·a!.,' 1989] 
{Bot ct aI., 1990} {Tosato and Jones, 1990] [Migliaccio et aI., 1991b], or by transmodulnting cell 
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surface receptors for other OFs [Von Hoegen et aI., 1989] [Salo et al.. 1993] [Hanazono et ai., 
'1995]. This aspecl of OF aClions makes iJ difficult to identify Ihe larget cells of an 
individual OF on the basis of its biological actions alone, in particular when 
heterogeneous cell populations such as unfractionated BM are used. Studies of OF target 
cell specificity are less obscured by indirect actions via mature cells ~r nonhemopoietic 
cells when purified prQgenitors are used. However, the production of differentiated blood 
cells usually requires the actions of muliiple OFs, and may involve Ihe activity of 
inhibitory cytokines as well as direct interactions between different cells. Various OFs 
may act simultaneously on the same cell type and provide synergi~tic, additive or 
antagonistic stimuli [Ikebuchi et aI., 1987J [Ikebuchi et aI., 1988b] [McNiece et aI., 1988] [Migliaccio 
et aI., 1988b] [Warren and Moore, 1988] [Bot et aI., 1989] [McNiece et aI.. 1991] [Okada et a!.. 1992] 
fOe Haan et aI., 1994] [Lardon et al., 1994], or they may act sequentially on cells in successive 
differentiation stages. Therefore, as the endpoints of most biological assays involve the 
proliferation of Ihe larget cells and the produclion of malure blood cells, iJ is not possible 
'10 distinguish between OF actions on the purified largel cells Ihemselves and Oil Iheir 
progeny Ihal is produced in culiure. 
To understand at what differentiation stages an individual GF acts, how it stimulates 
Ihe survival and! or oulgrowlh of the cells, and how differenl OFs interact on HSC and 
on more di~ferentiated cells of various hemopoietic lineages it is necessary to identify the 
cell types that can be directly stimulated by these OFs. Analysis of OF receptor 
expression on HSC and of changes in GF receptor expression during differentiation of 
different blood cell lineages provides the most straightforward means to examine the 
target cell range and thus the possible spectrum of biological activities of GF within the 
hemopoietic system. 
1.5 Examination of GF receptor expression on hemopoietic cells 
Different techniques can be used to examine GF receptor expression. The structure of 
receptor proteins is usually examined by immunoprecipitation of antibodyl receptor- or 
OF! receptor-complexes. Similar approaches have been used to sludy phosphorylalion of 
the receptor after GF stimulation, and to identify interactions with intracellular signaling 
molecules [Pawson and Gish, 1992] [Budel et .1 .. 1995] [Ihle, 1995]. 
Receptor RNA expression call be detected using various techniques, including reverse 
transcription polymerase chain reaction (RT-PCR) (reviewed by [Bell, 1989]) and RNA 
blotting combined with receptor-specific probes. To gather information about gene 
expression in a specific subset of hemopoietic cells, -it is important that·a pure, 
homogeneous cell population is used, as this technique is sensitive enough to pick up a 
signal from very low numbers of cells" which may include contaminating cells unrelated 
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to the cells studied. In addition, this approach does not provide a decisive answer about 
the cell surface expression of receptor proteins, because of the possibility·of discrepancies 
between RNA levels and protein expression [Migliaccio et aI., 1991a] [Ham and Miyajima, 
t994}. 
Quantitative binding experiments, using radioactively labeled GFs, provide 
information about the average number of receptors per cell, receptor binding kinetics and 
affinit~ for the OF. These techniques can also be used to study modulation of receptor 
levels as a result of GF binding [Fukamachi et aL, 1987] [Elbaz et nl.. 1991a] [Elbaz et aL. 1991b] 
and to examine competition between different GFs [Lopez et al.. 1989] {Budel et aI., 1990] 
{Lopez et aL. 1991], and have been essential for the identification of receptor subunits that 
are shared between different GFs. However, such binding studies are not suitable to 
examine heterogeneous cell pop~lations, as the resulting data represent an average for the 
whole population. Purified cell populations can be used, but only if sufficient cell 
numbers can be isolated. The requirement for large cell numbers precludes the use of 
quantitative binding studies to analyze receptor expression on rare subsets of immature 
hemopoietic cells. Although it is possible to deduce information about subsets of rare 
cells by comparing receptor numbers on unfractionated cell populations with those. of a 
cell fraction from which the immature cells have been depleted [Testa et aI., 1993J. it is 
doubtful whether the data obtained by such an indirect approach are meaningful, if 
accurate. 
Radioactively labeled OFs are also used for in situ autoradiography, to analyze 
receptor distribution on cells that can be recognized morphologically. Since multipotent 
cells comprise a low percentage of the total population of hemopoietic celis, and probably 
show little morphological heterogeneity, this technique is less suitable for analysis of 
receptor expression on HSC and immature progenitors. Autoradiography can provide 
additional information about receptor localization on the membrane or inside the cell, 
especially when it is combined with electron microscopy {Carpentier et aI., 1981]. Electron 
microscopic analysis of receptor localization can also be perfonned after cell staining with 
ferritin- or gold-labeled OF. molecules [Haigler et al., 1979} [McKanna et aI., 1979] [Boonstra et 
at .. t985}. 
Binding of f1uorescently labeled GFs or anti-receptor antibodies to cells can be 
examined by fluorescence microscopy {Dunn et a!.. 19861 (Carpentier et al.. 19871. A more 
refined technique, employing confocal scanning laser microscopy (CSLM), might 
provide additional information about the location of the receptors on or inside the cells. 
Simil~r to in situ autoradiography or· electron microscopy, fluorescence microscopy has 
. the disadvantage that it is most suitable to examine homogeneous cell populations. 
Heterogeneous cell populations can be identified by flow cytometry. Since HSC and 
progenitors make up only approximately I % of the nucleated BM cells,and the frequency 
of HSC in BM has been estimated to be in the range of 1-2 per IxlO5 [Harrison et at., 1988) 
31 
Flow cytometric analysis of growth factor receptor expression on hemopoietic progenitors 
[Van der Loo et al., 1994). cell samples for flow cytometry are often pre-enriched on basis of 
differences in physical properties, such as size or density. between immature and more 
mature cells [Visser and Van Bekkum, 1990). In the flow cytometer, different subsets of blood 
or BM c~n be analyzed after staining with antibodies against various cell surface markers. 
Additional c"riteria such as cell size and structure, which are revealed by flow cytometry as 
Ihe lighl scalier properlies of Ihe cells, can be employed to differenliale between BM 
subsets [Visser ct aI., 1980J. Moreover, affinity for· the Jectin wheat germ agglutinin (WGA) 
or retention of Rhodamine-l 23 (Rh J 23) [Bertoncello et aI., 1985] [Ploemacher and Brons, 1988] 
are often used to purify immature hemopoietic cellos [Visser and Bol, 1982] [Plocmacher el ai., 
1987J [Bauman ct aI., 1988J. The DNA slain Hoechst 33342 can also be employed to 
dislinguish different subsets ofBM cells [Baines and Visser, 1983J. Antigens such as CD34, 
which is specific for immature cells, are widely used to,identify, isolate and characterize 
primitive hemopoietic cells from human, monkey, or, more recently, murine origin [Civin 
et aI., 1984J [Krause et ai., 1994]. Other examples of antigens that are freqtlently used for 0 
positive selection of multipotent cells are Sca-l, which is expressed on iminature 
hemopoietic cell from mice of the Ly6A/E haplotype [Spangrude et aI., 1988J, or Thy-I, 
which is expressed on immature murine, rat, and'human BM cells [Mtiller-Sicburg et ai., 
1986] [McCarthy et aI., 1987] [Craig et at, 1993]. Negative selection after staining with 
anlibodies that bind specifically to activated or committed cells is also possible. Examples 
of these antigens are B220 and CD 19, which are present on B lymphocytes [MUller-Sieburg 
et aI., 1986J [Loken et aI., 1987aJ, CD33, which is most slrongly expressed on 
myelomonocytic cells [Andrews ct ai., 1989], CD38, which is expressed on cells that are 
committed to the erythroid, myeloid, and lymphoid lineages fTerstappcn ctoal., 1991], the 
transferrin receptor CD71, whicl~ is highly expressed on activated and erythroid cells 
[Loken et aI., 1987b], and the class II histocompatibility antigen HLA-DR [Sutherland et aL, 
1989]. Combination of positive selection for immature ceolls and negative selection of 
mature cells allows identification and isolation of different hemopoietic cell subsets that 
differ in their degree of differentiation and commitment to different lineages. By 
combining antibodies to these different cell surface markers with anti-receptor antibodies 
or labeled GFs, it is possible to identify receptor expressiOJ~ on different hemopoietic 
subsets and to monitor changes in receptor expression patterns during cOlpmitment and 
lineage-specific differentiation. Using this approach it is also possible to isolate (different 
subsets of) receptor expressing cells for morphological analysis, in vitro culture, or 
transplantation purposes, and thus to functionally characterize different hemopoietic' cell 
subsets separated on the basis of their rec~ptor phellotype. 
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1 .6 Objectives and outline of this thesis 
The purpose of this study was the development and application of methodology to 
examine receptor expression on hemopoietic cells by flow cytometry. This method was to 
be used to detect OF receptors on HSC, and to examine OF receptor expression patterns 
during lineage commitment and differentiation of various blood cell precursors from HSC 
to mature blood cells. One of the main objectives was to examine receptor expression in 
relation to other phenotypic parameter~, and to isolate viable cells on the basis of receptqr 
phenotype for morphological and functional analysis. As outlined in section 1.5, flow 
cytometry using either receptor-specific antibodies or labeled OF molecules is the niethod 
of choice to achieve these purposes, as this enables identification of receptor-expressing 
cells within heterogeneous cell populations (such as unfractionated BM) and identification 
of qualitative differences in receptor density on different cells within these populations as 
well as isolation of receptor-expressing cells by FACS. 
We focused on methodology to detect GF receptor expression on the basis of the 
ability of receptor-positive cells to bind ligand, since cell staining baseq on binding of 
ligand is a better predictor for the ability of cells to bind and respond to GFs than methods 
, that employ receptor-specific antibodies. Binding of iigand is indicative Of expression of 
functional high affinity receptors, a'od specificity of binding can be checked in 
competition experiments using a combination of labeled and non-labeled ligand. In 
contrast, anti-receptor antibodies recognize individual subunits of multi-subunit OF 
receptor complexes and may also bind to nonfunctional receptor isoforms, Moreover, 
antibodies often show variable levels of binding to. nOlH'eceptor proteins such as Fc 
receptors, which is difficult to eliminate or distinguish from specific binding to the 
receptors. 
As OF labeling reagent we chose· biotin, which has a high affinity for the egg white 
protein avidin or its bacterial equivalent streptavidin (Kd;:::: 10-15 M) [Guesdon et ai., 1979} 
[Hnatowicli et a\., 1987] [Wilchek and Bayer, 1988], The feasibility of preparing and using 
biotin-labeled GFs to assess receptor expression by flow cytometry was examined in the 
studies described in chapter 2. For these studies, the I'ecombinant hemopoietic OFs IL-
2, IL-3, IL-6, GM-CSF, and SCF were biotinylated with retention of their biological 
activity. We demonstrated that these biotinylated OFs can be used to stain receptor-
positive cell lines, peripheral blood lymphocytes, and BM cells when combined with 
fluorescently labeled (strc:pt)avidin. After amplification of the fluorescence signal, it was 
possible to detect cells with receptor levels as low as 100 molecules per cell. 
In chapter 3, we compared various methods and biotinylation reagents to label OFs 
with biotin for flow cytometric analysis of receptor expression. Using IL-2 as a model for 
hemopoietic GFs, the most suitable biotin derivatives were selected. Optimal biotin-to-
protein ratios and reaction conditions were established to prepare biologically qctive 
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biotinylated 9Fs and achieve maximal specific staining and highest fluorescence intensity 
on receptor-expressirig target cells. 
In the study described in chapter 4, murine BM hemopoietic cells were isolated on 
the basis of Kit expression, using flow cytometry after cell staining with anti-Kit 
antibodies or biotinylated SCF. A higher percentage of BM cells reacted with anti-Kit 
than with biotin-SCF, suggesting differences in target cell specificity between SCF and 
anti-Kit. Fun~tional characteristics of Kit-expressing hemopoietic cells were examined, 
and the presence of short- and long-term repopulating cells in the Kit+ BM fraction was 
demonstrated using a quantitative mouse transplantation model. 
The experiments described in chapter 5 were designed to examine the differential 
staining between biotin-SCF and anti-Kit antibodies that was found on BM cells in the 
study described in chapter 4. Results of these two staining methods for Kit+ cells were 
compared on an SCF growing subline and an IL-3 growing subline of the murine cell line 
FDC-P I. In an attempt to elucidate the "molecular basis for observed differences between 
ligand binding and antibody reactivity of the two sublines, Kit molecules were isolated 
using immunoprecipitation, and RNA expression of differen~ functional domahis of the c-
kit gene was studied using RT-PCR. 
Staining with biotinylated GFs can be combined with analysis of other cell surface 
markers. Biotinylated human SCF and antibodies against CD34 were used in chapter 6 
, 
for immuilophenotyping, isolation, and functional analysis 'Of different subsets of Kit-
expressing hemopoietic cells in rhesus monkey BM. After cell sorting based on 
expression of CD34 and Kit, we showed that myeloid and erythroid progenitors can be 
distinguished and isolated on the basis of differences in Kit 1?xpression levels. 
The feasibility to simultaneously stain functional receptors for different GFs was 
examined in the study described in chapter 7. For this purpose, we combined biotin-
SCF with digoxigenin (DIG) labeled preparations of EPO, IL-!i, and GM-CSF, and with 
antibodies against other cell surface markers. This technique was applied to analyze 
patterns of coexpression of Kit and the receptors for these GFs on immature progenitors 
and differentiating erythroid and myelomonocytic precursors. 
In chapter 8, the differential expression of the receptors for IL-3, IL-6, GM-CSF, 
and SCF on subsets of BM cells is reviewed. 
In the final chapter; chapter 9, the results of our study are summarized and 
discussed. Limitations and possibilities of the methodology are reviewed, and possible' 
approaches for further research are outlined, aimed at examination of the presence and 
functional significance of low level receptor expression on HSC and immature 
progenitors. 
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2.1 ABSTRACT 
In this study, the feasibility of biotin-labeled growth factors (OFs) to analyze the 
expression' of GF receptors on hemopoietic celis was examined. The recombinant 
hemopoietic OFs interleukin-2 (IL-2), IL-3, IL-6, granulocyte! macrophage-colony 
stimulating factor (OM-CSF), and stem cell factor (SCF) were biotinylated. 
Examination of the ability of the labeled OFs to stimulate proliferation of OF-dependent 
cell lines showed that the biotin-OFs remained biologically active. Cells were stained 
with biotinylated OFs and (strept)avidin-FITC. The fluorescence signal was amplified 
with alternate layers of biotinylated anti-(strept)avidin and (strept)avidin-FITC, and tIie 
samples Were analyzed using a flow cytometer. With this highly sensitive method, cells 
with 100 cell surface receptor molecules were detectable. 
2.2 INTRODUCTION 
Hemopoietic stem and progenitor cells have low numbers of growth factor (OF) 
receptors on their surface. After binding to these receptors, hemopoietic. GFs regulate 
the survival, proliferation and differentiation of the primitive hemopoietic cells. The 
exact relationship between the expression of certain GF receptors and the ability of the 
cells to differentiate is still not clear. To study this, cells must be sorted based on the 
presence of GF receptors, and then cultured. 
Most receptor studies are performed using either radiolabeled GFs [Foxwell et aI., 
1988b1 [Nicola et aI., 19881 [Park et al., 1989] or antibodies against the receptor [Weil Hillman et 
at., 19901. With radiolabeled OFs, only functionally intact receptors are labeled. 
However, 125I-Iabeled GFs cannot be llsed to sort cells for culture experiments. Celis, 
stained with antibodies against the receptors, can be double-stained for other markers 
and sorted in a fluorescence activated cell sorter (FACS). However, use. of anti-receptor 
antibodies can cause. problems if the stained and sorted cells are used for in vivo assays. 
Antibody stained cells may be eliminated by phagocytosis induced by the Fc parts of 
the antibodies or by complement-mediated lysis, resulting in selective removal of the 
receptor expressing cells by the immune system of the recipient animals [Bauman et ai., 
19851· 
In this paper we describe a universally applicable technique for cell staining 
involving biotinylated OFs, combining the advantages of radio labeled OFs and 
antibodies. The recombinant murine hemopoietic OFs interleukin 2 (IL-2), IL-3, IL-6, 
granulocyte! macrophage-colony stimulating factor (OM-CSF), and stem cell factor 
(SCF) were biotinylated. These biotin-OFs retained the capacity to induce proliferation 
of OF-dependent cells. Several studies on the use of biotin-OFs to detect receptor-
expressing cells have been published. In these studies cells with high receptor densities 
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(10 4-105 receptors per cell) were used [Foxwell et aI., 1988a) [YMlasaki et aI., 1988} [Newman 
et aI., 1989) [Peters and Norback, 1990). The fluorescence signal of cells with low receptor 
numbers has to be amplified for analysis in a flow cytometer [Wognum et aI., 1992). We 
incubated the cells with biotin-GFs and f1uorescentIy labeled (strept)avidin. After 
amplification of the fluorescence signal with alternate layers of biotinylated anti-
(strept)avidin and fluorescentIy labeled (strept)avidin, it was possible to analyze cells 
with 100 cell surface r~ceptors in a flow cytometer. 
2.3 MATERIALS AND METHODS 
Biotinylation of growth factors 
Murine recombinant IL-3 (rIL-3) and rGM-CSF (gifts of Behringwerke 
Aktiengesellschaft, Marburg, Germany), human rIL-2 (Biogen, Geneva, Switzerland), 
human rIL-6 and rat rSCF (both from Amgen, Cambridge, UK) were biotinylated using 
biotin-N-hydroxy succinimide ester (Pierce, Rockford IL, USA). Different amounts of 
NHS-biotin in dimethyl sulfoxide (OMSO) were added to solutions of GFs in 0.2 M 
carbonate-bicarbonate buffer pH 8.5, to obtain various mo'Jar biotin:protein (B:P) ratios 
between 4 and 100 during the reaction. As controls, samples were mock-biotinylated (at 
B:P 0) by just adding DMSO without biotin. After 3 h of incubation on ice, the samples 
were dialyzed overnight against PBS to remove the remaining free biotin molecules 
from the samples. 
The protein concentration after biotinylation was determined using the BCA Micro 
Protein Assay (Pierce). The presence of biotinyhited GF was checked by spotting 1 III 
of stepwise dilutions of the samples directly on a nitrocellulose membrane, followed by 
immuno-enzymatic staining of the membrane with streptavidin-alkaline phosphatase 
and 4-Nitl'o Blue Tetrazoliumchloride 5-Bromo-4-Chloro-3-Indolyl Phosphate (NBT 
BCIP) development. 
The biotinylated GFs were stored at 4'C in the presence of 0.02% (wt/vol) sodium 
azide. 
eel/lines and biological activity assay 
Before adding sodium azide, the biological activity of the biotinylated GFs was 
determined using GF-dependent cell lines (CTLL-2 for IL-2, Tll65 for IL-6, DA-I, 
32D, or FOC-PI for IL-3, and FOC-PI forGM-CSF and SCp)o Cells were grown in 
RPM! 1640 supplemented' with 10% (voUvol) heat inactivated fetal calf serum, 0.1 mM 
~-mercapto ethanol, 2 mM L-glutamine, and the appropriate GF. Cultures were 
maintained at 37'C in a humidified atmosphere of 5% C02 in air. 
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To determine the ability of the biotinylated GFs to stimulate cell proliferation, lO4 
cells per well were cultured for I day in 96 well microtiter plates in 200 J-li RPM! 
medium containing different amounts of either biotinylated GFs or unmodified GFs. 
[3Hjthymidine (0.25 J-lCi per well) was added after 24 h. After 16-18 h of thymidine 
incorporation the cells were harvested, the radioactivity was ineasured in a liquid 
scintillation counter, and expressed as counts per min (cpm). 
Immunocytochemical staining and flow cytometry 
Cells were stained in 50 J-li PBS! Semml Azide (PSA): PBS containing 5% (vol/vol) 
fetal or newborn calf serum and 0.02% (wt!vol) sodium azide. First, 106 cells per 
sample were incubated in 50 ~tl PSA with biotin-OF (1-100 nM) for 60 min on ice or at 
room temperature (resulting in similar levels of fluorescence). Next, the samples were 
stained for 15-30 min on ice, depending on the,desired fluorescence wavelength either 
with avidin-FITC (1:300 vol/vol; Vector Laboratories, Burlingame CA, USA) or 
streptavidin-BODIPY (1:100 vol/vol; Molecnlar Probes, Eugene OR, USA), or with 
streptavidin-PhycoErythrin (1:5 vol/vol; Becton Dickinson, San Jose CA, USA; or 
1:200-1:1000; Molecular Probes). After each incubation the samples were washed in 
PSA. The fluores<;ence sign~l was mnplified by incubating the cells for 15 min on ice 
with alternate layers of biotinylated goat-anti-avidin or goat-anti-streptavidin (both 
I: 100 vol/vol; Vector) and f1uorescently labeled (strept)avidin. Specificity of binding of 
the biotin-GF samples was determined by incubating the cells with biotin-GF in the 
, presence of a lOO-fold molar excess of unbiotinylated Gr. As a negative control, only 
PSA was used in the first incubation. 
Samples were analyzed using a RELACS (Rijswijk Experimental Light Activated 
Cell Sorter, TNO, Rijswijk, The Netherlands) flow cytometer. Cells were illuminated 
witl~ the 488-nm line of an argon ion laser. Greefl FITe or BODIPY fluorescence was 
measured through a 530-nml 30-nm bandpass filter, orange PE fluorescence ,was 
measured through a 575-nml lO-nm bandpass filter. 
2.4 RESULTS AND DISCUSSION 
Biological activity 
In staining experiments it is important that the biotinylated GFs bind to the receptors. 
To determine this, we compared the abilities of biotin-GFs and mitive GFs to stimulate 
proliferation of OF-dependent cell lines. On DA-I cells, IL-3 was shown to have 
retained full growth promoting activity after biotinylation at B:P ratios of 20 (figure 2.1 
A) or less. After biotinylation at B:P 50, approximately 50% of the.growth promoting 
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ability was recovered, whereas at B:P 100 biotin-IL-3 lost almost all biological activity 
(not shown). 
Biotin-IL-6 also retained most of its growth promoting activity at B:P 20 (figure 2.1 
B). Similar resuits were obtained on CTLL-2 cells with biotin-IL-2 (see chapter 3), and 
on FDC-P I cells with biotinylated SCF (see chapter 5) or OM-CSF (not shown). 
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figure 2.1 
Biological activity of (A) biotin-IL-3 and (8) biotin-IL-6. 
Incorporation of [3Hjlhymidine into DNA of GF-dependent celis (A DA-1 celis, 8 T1165 
cells) is shown as a function of the concentration of native GF (open circles) and blotln-
GF (B:P 20, closed circles). 
Fluorescence amplification 
Cells were incubated with biotin-OF and flttorescently labeled avidin or streptavidin, 
and the effect of fluorescence amplification with alternate layers of biotinylated anti-
(strept)avidin and fluorescently tabeled (strept)avidin (depicted schematically in figure 
2.2) was studied using a flow cytometer. As shown for avidin-FITC in figure 2.3, with 
figure 2.2 
Schematic drawing of cell staining 
'with biotinylated GFs (1) and 
fluorescently labeled (strept)avldin. 
(2), and subsequent amplification 
with biotlnylated anti-(strept)avidin 
(3) and fluorescently labeled 
(strept)avidin (4). 
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figure 2.3 
IL-3 receptor expression on DA·1 cells. 
, Fluorescence histograms are shown of DA-1 cells, Incubated with biotinylated IL·3 (bold 
solid lines). Cells were stained with avidin-FITC, and fluorescence signals were 1x (A), 2x 
(8), or 3x (C) amplified with blotlnylated anti-avidin and avidin-FITC. Control celis were 
incubated without blotlnylated IL-3 (broken lines). Thin solid lines indicate unstained cells. 
Markers were set on the basis of fluorescence of control cells to indicate the percentages 
of IL-3 receptor-posiiive cells. 
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each amplification step the difference in fluorescence intensity between negative and 
positive cells was larger, even if t,here was an increase in noise (background signal) 
along with the increase in signal. When a threshold was set for cell sorting experiments 
at the maximal background fluorescence,. about 1 % of DA-I cells were positive without 
fluorescence amplification. The respective percentages of true positive cells after I, 2 or 
3 amplifications were 7, 31 and 51, as indicated in figure 2.3 A, B, and C, respectively. 
These results show that alternate layers of biotinylated anti-avidin and avidin-FITC can 
be used to achieve a better separation between positive and negative cells after staining 
with biotin-GF and avidin-FITC. 
The sensitivity of the staining method was studied on FDC-P I cells. These cells have 
approximately 100 GM-CSF receptors per cell,as shown by equilibrium binding with 
t2SI-GM-CSF and Scatchard analysis (L. Budel, personal communication). Cells were 
stained with biotinylated GM-CSF and avidin-FITC, and the fluorescence signal was 
amplifi~d twice. A very weak fluorescence signal was obtained (figure 2.4). The 
specificity of the staining was studied by incubation with biotin-GF in the presence of a 
100-fold molar excess of the unbiotinylated GF. This resulted in a fluorescence signal 
that was approximately equal to the background signal of cells without biotin-GF, as 
shown in figure 2.4, which demonstrated that the staining of FDC-P I cells. with biotin-
GM-CSF was specific. Therefore, these results show that cells with 100 cell surface 
receptors can be stained for analysis using a flow cytometer. However, these- results 
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figure 2.4 
GM-CSF receptor expression on FDC-Pl cells. 
Cells were stained with biotin-GM-CSF and avidin-FITC, 2x amplified with biotinylated 
anti-avidin and avidin-FITC (bold solid line). Control cells were stained without biotln-GM-
CSF (thin solid line), or with biotin-GM-CSF In the presence of a 100-fold molar excess of 
native GM-CSF (broken line). 
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were obtained using homogeneous cell suspensions; cells with low receptor numbers 
may remain undetected in heterogeneous cell suspensions, sllch as BM, especially when 
,these cells are present at low frequencies. 
Since the start of this study several papers on the preparation and use of biotin-OF 
for detection of receptor-expressing cells have been published [Foxwell et aI., 1988a] 
[Yamasaki et aI., 1988) [Newman et aI., 1989). In these studies use was made of cells with high 
receptor densities (lOL 105 per cell). With our method it is possible to analyze cells 
with 100 or more cell surface receptors, Other applications of biotin-OF include the 
study of receptors with different affinities for a OF, like the IL-2 receptor [Weil Hillman et 
al" 19901. and binding to the same receptor by different GFs such as IL-3 and GM-CSF. 
For example, competition bet,veen biotinylated IL-3 and unbiotinylated GM-CSF vice 
versa can be used in the study of the receptor or subunit that can bind both IL-3. and 
OM-CSF [Park et al., 1989) [Kitamura et aI., 1991}. Additionally, since occupied OF receptors 
are rapidly internalized into the cells [Nicola et ai., 19881, it may be possible to target 
streptavidin-conjugated immunotoxins in.to the cells, using biotin-OF instead of 
biotinylated antibodies [1'!eyer et al., 19911. 
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3.1 ABSTRACT 
The main prerequisites for the use of biotinylated ligands to study the expression of 
growth factor receptors on heterogeneous cell populations, such as peripheral blood or 
bone marrow, by flow cytometric methods, are that the biotinylated ligand retains its 
binding ability and that binding of the biotinylated ligand to the receptor does not 
inhibit the subsequent interaction of biotin with f1uorescently tagged avidin or 
streptavidin. Using Interleukin-2 (IL-2), we compared the usefulness of various 
biotinylation reagents, NHS-Biotin, S-NHS-Biotin, S-NHS-LC-Biotin, DBB and 
Photobiotin, and developed optimal biotinylation conditions for the preparation of 
biologically active biotin-labeled IL-2 and the detection of IL-2 receptor expressing 
cells by flow cytometry. As determined by spot blot analysis, biotinylation of IL-2 was 
most efficient at (he highest biotin-to-protein (B:P) ratio used. At a B:P ratio of lOa, 
most of the biological activity of IL-2 was retained when S-NHS-LC-Biotin was used. 
In contrast, most of the biological activity ofIL-2 samples that were labeled with NHS-
Biotin or Photobiotin was lost under these conditions. Biotin-labeled IL-2 preparations. 
were tested in order to detect IL-2 receptors on IL-2 dependent CTLL-2 cells by flow 
cytometry after sequential staining with the biotinylated IL-2 and fluorescence tagged 
streptavidin. A high B:P ratio generally resulted in a high specific fluorescence intensity 
of the cells, particularly when S-NHS-LC-Biotin was used as the biotinylation reagent. 
Biotin-IL-2 could also be used to detect IL-2 receptors eXpressed by lymphocytes in 
peripheral blood and bone marrow. Comparison of staining of lymphocytes with 
biotinylated IL-2 and an antibody against the IL-2 receptor a chain demonstrated that 
only a subset of the cells that showed a strong fluorescence signal after staining with 
biotinylated IL-2 expressed high numbers' of the IL-2 receptor a chain. This is in 
agreement with the expression of functional IL-2 receptors on resting T cells and NK 
cells which do not express the a chain. After stimulation with PHA, virtually all 
lymphocytes expressed the a chain, whereas only part of these cells showed a strong 
fluorescence signal after staining. with biotin-IL-21 while the rest of the cells had very 
low numbers of IL-2 binding sites. Our results demonstrate that, in addition to staining 
individual receptor subunits with antibodies, staining with biotinylated IL-2 is a useful 
indicator of functional IL-2 receptor expression. 
3.2 INTRODUCTION 
Growth factors control the growth, differentiation and maturation of hemopoietic 
cells as well as, in many cases, the functional activity of mature end cells, by binding to 
specific cell surface receptors. To examine the target cell specificity ·of growth factors 
(GF) and the presence of GF receptors, in vit,o culture systems are used to study 
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biological responses [Sonoda et aI., 1988] [Warren et aI., 1989] [Ishida et aI., 1991J, as well as 
direct methods to study receptor expression. Direct receptor labeling studies can be 
performed using radiolabeled GF [Foxwell et aI., 19880] [Nicola et al.. f988) [Park et al.. 1989] 
with the advantage that only functionally intact OF receptors are labeled. However, 
because 125I-labeled OF are usually quantified as'mean number of receptors per ceil, 
these studies are of limited use for heterogeneous cell populations. Receptor expression 
on subsets of cells in heterogeneous populations can be studied using a fluorescence 
activated cell sorter (FACS) when cells 'are labeled with antibodies against the receptors 
[Wei I-Hillman et aI., 1990], and double-stained for other markers. However, many receptors 
consist of several different subunits, and the expression of more than one subunit is 
often required to generate functional, high affinity receptors [Takeshita et al.. 1992b] [Ishii et 
31., 19941 [Nakamura et a1., 1994] [Nelson et aI., 1994]. In addition, some receptors share 
subunits, e.g. the high affinity receptors for human IL-3, OM-CSF and IL-5 [Kitamura et 
at" 199tl [Tavernier et at" 1991], and the high affinity receptors for IL-2, IL-4 and IL-7 
[Kondo et aI., 1993J [Noguchi ct aI., 1993] [Russell et al.. 1993] [Kawahara et aI., 1994]. Since 
antibodies usually recognize only one of the constituents of a receptor complex, 
antibody binding may not always be indicative of expression of functional receptors. 
Instead of antibodies or radiolabeled OF. biotinylated OF may be used lFoxwcll ct aI., 
1988b] [Yamasaki et al.. 1988J [Newman et al.. 19891 [Peters and Norback, 1990] [Wognum et aI., 1990] 
to combine the advantages of both other methods, Biotin is a small molecule of 244 
Daltons, which can easily be coupled to proteins such as OF. The strong interaction 
between biotin and the' egg white protein avidin, or the bacterial protein :streptavidin, 
can be used to detect binding of bidtinylated OF to target cells [Wilchek and Bayer, 1988J. 
By such a method. functionally intact receptors are labeled and the cells can be 
analyzed by flow cytometry and sorted using a FACS. The efficiency of this approach 
depends on the efficiency of the biotinylation reaction and on its effect on the binding 
affinity and, thus, on the biological activity. 
Many different kinds of biotinyl derivatives are availabJe. For biotinylation of 
proteins, the N-hydroxy succinimide ester of biotin (NHS'Biotin) or its water soluble 
analog N-hydroxysulfo-succinimide biotin (S-NHS-Biotin), both of which bind 
primarily to lysine residues under alkaline conditions, are possibly the most often used 
[Newman ct al.. 19891 [Pieri and Barritault, 1991]. Variants with an extended spacer arm (S-
NHS-Long Chain-, S-NHS-LC-Biotin) can be used to reduce the effect of sterie 
hindrance [Hnatowichet a!., 1987]. If a sufficient number of lysine residues is not available, 
or when labeling of lysine causes changes of the biological activity of the protein, other 
classes of reactive biotin derivatives can be used to biotinylate other functional groups. 
Tyrosines or histidines can be labeled with I"Diazobenzoyl Biocytin (DBB) [Wilcheket 
at., t9861. Sulfhydryls can be biotinylated with N-iadaacetyl-N'-biotinyl-hexanediamine, 
or with N- [6-(biotinamido)hexyIJ-3-(2-pyridyldithio) propionamide (Iadaacetyl-Biotin 
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and Biolin-HPDP, respectively). An advanlage of Biotin-HPDP is, Ihal the S-S bridge 
which is formed by the biotinylation reaction can be cleaved to remove the biotin 
[Shimkus et aI., 1985], which may be useful to recover biotinylated proteins from av.idin 
affinity columns. Cleaving off biotins from proteins is also possible when sugar 
residues on glycoproteins are biotinylated using biotin hydrazide [O'Shannessy et a1., 19841 
[Wognum et aI., 1990]. Another biotinylation method uses Photobiotin, a photo-activatible 
analog of biotin [Forster et al" 1985J [Lacey and Grant, 1981J which forms stable (presumably 
covalent) linkages when illuminated. 
In this study, we have compared the effect of conjugation with different biotin 
derivatives on the biological activity as weB as on the receptor binding ability and 
resulting labeling intensity of IL-2 and examined the application of biotinylatedIL-2 to 
detect receptor expression on subsets of p~ripheral blood and bone marrow cells. 
3,3 MATERIALS AND METHODS 
Blollnyl.llon 
E. Coli derived human recombinant IL-2 (specific activity 2.8 x 106 U1mg; Biogen, 
Geneva, Switzerland) was biotinylated using different biotin derivatives (figure 3,1). 
NHS-Biotin, the water soluble S-NHS-Biotin and its extended spacer arm analog S-
NHS-LC-Biotin (all from Pierce, Rockford IL, USA) were dissolved in dimethyl 
sulfoxide (DMSO) or in 0.1 M carbonate-bicarbonate buffer pH 8.5. DBB precursor 
(Calbiochem, San Diego CA, USA) was dissolved in DMSO, and prepared according to 
the manufacturer's instructions. IL-2 was diluted in 0.1 M carbonate-bicarbonate buffer 
pH 8.5 (for the different NHS-Biotins) or in 0.05 M borate or carbonate buffer pH 9.0 
(for DBB). Biotin was added to the GF solution to obtain a molar biotin:protein (B:P) 
ratio of 100,20, or 4 during the reaction. As controls, samples were mock-biotinyJated 
(at B:P 0) by just adding DMSO or buffer without biotin. The biotinyJation reactions 
were allowed to take place for 1.5 h (DBB) or 3 h (NHS-Biotin) at room temperature, or 
for 3 h on ice (S-NHS-Biotins). Photoactivatible biotin (Photobiotin, stock solution of I 
mg/ml; Vector Laboratories, Burlingame- CA, USA) was used, according to the 
manufacturer's instructions at B:P reaction ratios of 10:1, 1:1 and 1:10 (wt/wt; 
corresponding to molar B:P ratios of approximately 250, 25 and 2.5, respectively). 
figure 3.1. 
Structure of the different biollnyl derivatives that were used in this study . 
. (A) NHS·Blolln, (B) S·NHS·Blolin, (C) S·NHS·LC·Blolin, (D) DBB and (E) Pholoblolin. 
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. These reaction mixtures and a control without Photobiotin were illuminated with UV 
light for 30 min on ice using a mercury arc lamp. The reaction was stopped by adding 
an equal volume of 0.1 M Tris pH 9.0. The remaining free biotin molecules in the 
samples were removed either by size exclusion chromatography. using a PD-: I 0 column 
containing Sephadex G-25 (Pharmacia, Uppsala, Sweden), or by extensive dialysis at 
4°C. More protein material was lost during size exclusion chromatography than during 
dialysis (up to 50% and 15%, respectively). Dialysis of small volumes was achieved by 
floating a low-protein-binding filter unit with the sample (10,000 NMWL filter unit, 
Cat. No. UFC3 LGLOO, Millipore, Bedford MA, USA) on PBS containing 0.04% 
Tween-20 and 0.02% (wtlvol) sodium azide. The biotinylated GF were stored at 4'C in 
the presence of 0.02% (wt/vol) sodium azide. The protein concentration after 
biotinylation was determined with the BCA Micro Protein Assay (Pierce). The presence 
of biotinylated IL-2 was determined by spotting I III of stepwise dilutions (112) of the 
samples directly on a nitrocellulose membrane, followed by immuno~enzymatic 
staining of the membrane with streptavidin-alkaline phosphatase and 4-Nitro Blue 
Tetrazoliumchloride 5-Bromo-4-Chloro-3-Indolyl Phosphate (NBT BCIP) 
development. 
Gel/line and biological activity assays 
Cells from the IL-2 dependent mouse cytotoxic T cell line CTLL-2 were grown in 
RPMI 1640 supplemented with 10% (vol/vol) heat inactivated fetal calf serum, 0.1 mM 
p-mercaptoethanol, 2 mM L-glutamine, and 20 Ulml of IL-2. Cultures were maintained 
at 3TC in a humidified atmosphere of 5% C02 in air. To determine the biological 
activity of the biotinylated GF, 104 cells per well of 96 well microtiter plates were 
cultured in 200 It I RPMI medium containing serial dilutions of either biotin-IL-2 or 
unmodified IL-2. After 24 h, 0.25 IlCi 3H-thymidine was added to each well. The cells 
were harvested after 16-18 h of thymidine incorporation, and the radioactivity was 
measured in a liquid scintillation counter. Alternatively, in a non-radioactive assay the 
number of nucleated cells per well' was determined by staining the nuclei with 
propidium iodide (PI) and measuring the f1ubrescence intensity. For this purpose, the 
cells were cultured for 40-48 h, after which 0.5% (vol/vol) Triton X- 100 and 0.002% 
(wt/vol) PI were added to the wells. After approximately 15 min the microtiter plates 
were read in a Leitz Diavert inverted microfluorometer using green excitation by a 
halogen lamp. 
Mouse bone marrow cel/s 
Bone marrow from 7 week old BCBA (C57BLlLiARij x CBAlBrARij)FI mice was 
harvested by flushing femora and tibiae with I ml of ice-cold Hanks' Balanced Salt 
Solution (Laboratoires Eurobio, Paris, France) buffered at pH 6.9 with 10 mM Hepes, 
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(Merck) (HH, osmolarity 300-305 mOsm/kg). A single cell suspension was obtained by 
filtration through a six-layer nylon sieve. 
Human peripheral blood cells 
Peripheral blood cells from normal human volunteers were cultured in a humidified 
atmosphere of 5% C02 in air at 37'C in RPMI 1640 supplemented with 10% (vol/vol) 
heat inactivated fetal calf serum, 0.1 mM ~-mercaptoethanol, 2 mM L-glutamine and 90 
Ilg/ml phytohemagglutinin (PHA, I % of stock solution, Wellcome Foundation Ltd., 
Dartford, England). 
Immunocytochemical staining and flow cytometry 
Cells were stained in 50 III PBSISerumlAzide (PSA, human cells) or 
HHiSerum/Azide (HSA, mouse cells): PBS or HH, containing 5% (vol/vol) fetal or 
newborn calf serum and 0.02% (wtlvol) sodium azide. Cells (106 per sample) were 
incubated with biotin-IL-2 (14-140 nM) in a volume of 50 III for 60 min at room 
temperature. Similar results were obtained by incubation on ice. The samples were then 
stained for 15-30 min on ice, using either avidin-FITC (I :300 vollvol, Vector 
Laboratories, Burlingame CA, USA), streptavidin-BODIPY (I: 100 vollvol, Molecular 
Probes), or streptavidin-PhycoErythrin (streptavidin-PE, 1:5 vollvol, Becton Dickinson, 
San Jose CA, USA; or 1:200 vollvol, Molecular Probes, Eugene OR, USA). After each 
incubation the samples were washed in PSA or HSA. Low intensity fluorescence 
signals were amplified by incubating the cells for 15-30 min on ice with alternate layers 
of biotinylated goat anti-(strept)avidin (both I: 100 vollvol, Vector) and fluorescence 
labeled (strept)avidin. Control cells were incubated only with the fluorescence labeled 
(strept)avidin and the amplifying layers of biotinylated anti-(strept)avidin and 
fluorescence labeled (strept)avidin. Specificity of binding of the different biotin-IL-2 
samples was determh~ed by incubating the cells with biotin-IL-2 in the presence of a 
100x molar excess of unbiotinylated IL-2. 
For staining with anti-IL-2 receptor fJ. chain antibody, mouse cells were incubated 
with the antibody 5A2 [Moreau c' aI., 1987) (undiluted culture supernatant of hybridoma 
cells, kindly provided by Dr. Theze, Departement d'Immuno[ogie, Institut Pasteur, 
Paris, France) for 30 min on ice. Human cells were incubated with the rat-anti-TAC 
antibody 36AI.2 [Olive e' aI., t986), followed by. staining with FITC-conjugated goat anti-
nit antibodies (GARa-FITC; 1:100 vollvol, TAGO, Burlingame CA, USA). In double-
staining experiments, these antibodies were added during amplification of the 
streptavidin-PE signal: the anti-TAC antibody was added to the cells together with 
biotinylated goat anti-streptavidin, followed by incubation with GARa-FITC and 
streptavidin-PE. In some experiments a combination of streptavidin-BODIPY and 
GARa-PE (/:200 vollvol, TAGO) lVas used. 
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To analyze the expression of IL-2 receptors on subsets of human peripheral blood 
lymphocytes, cells were double-stained with mouse-anti-CD4 antibodies (1:20 vol/vol, 
Becton Dickinson) and either anti-TAC or biotin-IL-2, combined with PE-conjugated 
goat anti-mouse antibodies (GAM-PE; I :100 vol/vol, Sigma Chemical Company, St. 
LouisMO, USA) and either GARa-FITC or streptavidin-BODIPY. 
Samples were analyzed using a flow cytometer (RELACS: Rijswijk Experimental 
Light Activated Cell Sorter, ITRI-TNO, Rijswijk, The Netherlands). Cells were 
illuminated with the 488-nm line of an argon ion laser. Green FlTC or BODIPY 
fluorescence was measured through a 530-nml 30-nm bandpass filter (Becton 
Dickinson, Mountain View CA, USA). Orange PE fluorescence was measured through 
a 577-nml lO-nm bandpass filter. 
3.4 RESULTS 
Blol/nylatlon of IL-2 
IL-2 was biotinylated using either NHS-Biotin, S-NHS-Biotin, S-NHS-LC-Biotin, 
DBB or Photobiotin (figure 3.1). The degree of biotinylation of the different samples 
was studied by spotting I III of stepwise dilutions of'biotin-IL-2 on a nitrocellulose 
filter and comparing the intensity of the spots following incubation with streptavidin-
alkaline phosphatase and NBT BCIP development. The various biotin-IL-2 samples 
table 3.1 
Spot-blot analysis of the different biotin-IL-2 samples. 
minimal detectable- amount (ng) of blotin-IL-2 per J.1I a 
NHS S·NHS S·NHS·LC DBB Photo 
DMSO DMSO buffer DMSO buffer 
B:P bO >100 >100 >100 >100 >100 >100 B:PO >100 
B:P4 5 20 50 10 10 90 B:P2.5 >100 
B:P20 5 10 10 B:P25 40 
B:P 100 <1 <1 <1 <1 <1 <1 B:P250 <1 
a The minimal detectable amount (ng) of blotin·IL·2 per ~I was determined by spotting 1 ~I 
of stepwise dilutions of the blotin-IL-2 samples on nitrocellulose, followed by immuno-
enzymatic staining with streptavldin-alkaline phosphatase and NBT BCIP development. 
b B:P = biotin:proteln ratio. 
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contained different amounts of biotin, as shown by the amounts minimally needed to 
give a visible slain on Ihe nilrocellulose membrane (table 3.1). As expecled, Ihe highest 
degree of biotinylation was achieved at the highest B:P reaction ratios, whereas the B:P 
o controls were not visible on the membranes. The water-soluble S-NHS-LC-Biotin 
appeared to label with similar efficiency after dissolving in DMSO or in buffer. S-NHS-
Biotin labeled slightly more efficiently after dissolving in DMSO than in buffer. Nl;IS-
Biotin and S-NHS-LC-Biotin gave the best biotinylation efficiency, followed by S-
NHS-Biotin and DBB, which were 4-10 fold less efficient. The lowest degree of 
biotinylation occurred when IL-2 was labeled with the Photobiotin reagent (table 3.1). 
Biological activity of blotlnylBted IL-2 preparations 
Using the IL-2 dependent mouse cytotoxic T cell line CTLL-2, the B:P ratio was 
found to affect the biological activity of biotin-IL-2 (table 3.2). At the lowest B:P ratio 
used in the biotinylation reaction, biological activity was not lost as a result of 
biotinylation. Higher B:P ratios had a marked negative effect on the biological activity 
of some biotinyl derivatives (table 3.2). Loss of biological activity w?s highest when 
IL-2 was biotinylated with NHS-Biotin or Photobiotin. When used at B:P 100, 
biotinylation with DBB also led to a large loss of biological activity. The use of the 
water-soluble NHS-Biotins dissolved in DMSO resulted in twofold larger losses of 
biological activity than when these reagents were dissolved in buffer. The highest 
recovery of biological activity (? 70-80% at B:P 100) was achieved with S-NHS-LC-
Biotin and S-NHS-Biotin (table 3.2). 
table 3.2 
Biological activity of the different blotin-IL-2 samples. 
recovery of biological activity a 
NHS S-NHS S-NHS-LC DBB Photo 
DMSO DMSO buffer DMSO buffer 
B:p'bO 100 100 100 100 100 100 B:P 0 100 
B:P4 100 100 100 100 100 100 B:P 2.5 100 
B:P20 33 90 85 90 100 80 B:P 25 33 
B:P 100 5 33 72 40 80 20 B:P 250 7 
a IL-2 dependent CTLL-2 cells were grown In the presence of different amounts of biotin-IL-
2. The amount of blotin-IL-2 needed per well for 50% maximal stimulation of the cells was 
calculated for the different samples. Results are expressed as % biological activity, as 
compared to unbiolinylated IL·2 (100%). 
b 8:P = biotln:protein ratio. 
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Cell staining 
Immunocytochemical staining properties of the different biotin-IL-2 samples were 
compared using flow cytometry. figure 3.2 shows an example of the f1tlOrescence 
histograms, resulting from the incubation of CTLL-2 cells with biotin-lL-2 made by 
biotinylation with S-NHS-LC-Biotin at different B:P ratios. The mean fluorescence 
intensities of cells, labeled with the different biotin-IL-2 preparations are presented in 
table 3.3. IL-2 labeled with the NHS-Biotins gave the highest fluorescence intensities: 
with the extra long spacer arm between the protein and the acq.131 biotin molecule (S-
NHS-LC-Biotin) the fluorescence signal was even higher than with the normal spacer 
arm (NHS-Biotin and S-NHS-Biotin). Dissolving the water soluble S-NHS-Biotin or S-
NHS-LC-Biotin in DMSO before biotinylating the IL-2 resulted in higher fllIorescence 
intensities of stained cells than dissolving in buffer. In comparison with the various 
NHS-Biotins, biotinylation with DBB resulted in a lower fluorescence signal. The 
fluorescence signal resulting from Photobiotin-IL-2 was almost indistinguishabl~ from 
the backgrollnd fllIorescence of the cells (table 3,3). For most biotinyl derivatives, the 
preparations with the highest B:P ratios resulted in the highest fluorescence intensities. 
Only with .the standard NHS-Biotin waS an impaired staining of the B:P 100 sample 
(relative to the B:P 20) consistently observed (table 3,3). For all biotin-IL-2 samples, 
the fluorescence signal of cells incubated in the presence of a lOOx molar excess 
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blotin-IL-2 
Fluorescence histograms of CTLL-2 cells, Incubated with different biotin-IL-2 samples 
and Streptavidin-PE. The fluorescence Signal was amplified by two cycles of sequential 
incubations with biotinylated anti-Slreplavidln antibodies and Streplavidin-PE. The cells 
were labeled with biotln·IL·2, blotlnylated with S-NHS·LC-Blotln that was dissolved in 
DMSO; from right to left are B:P 100, B:P 20 and B:P 4, and the B:P 0 control. 
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of unbiotinylated IL-2 was similar to that of control cells incubated without biotin-IL-2, 
which indicated specific binding of biotin-IL-2 to the cells. This is illustrated in figure 
3.3 for CTLL-2 cells. incubated with biotin-IL-2 prepared with NHS-Biotin. 
tabte 3.3 
Fluorescence intensity?f CTLL·2 c.ells, stained wilh the different biotin-IL-2 samples. 
mean fluorescence Intensity (arbilrary units) a 
NHS S·NHS S·NHS·LC 088 Photo 
DMSO DMSO buffer DMSO buffer 
8:P bO 7 7 8 7 8 7 8:PO 
8:P4 41 20 9 73 ·28 13 8:P2.5 
8:P20 157 48 32 164 116 59 8:P 25 
8:P 100 100 164 122 316 288 99 8:P 250 
a CTLL·2 cells were incubated with the different biotin-IL-2 samples and slreplavidin-PE, 
amplified with biotin-anti-streptavidin and streptavidin-PE. 
b B:P = biotin:protein ratio. 
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. Fluorescence histograms of CTLL·2 cells. incubated with biotin·IL-2 (thick sotid line). in 
the presence of a 100x molar excess of unbiotinylated IL-2 (broken line), and 
flUorescence labeled streptavidin, or stained only with fluorescence labeled streptavidin , 
without biotin-IL-2 (thin solid line). The fluorescence signal was amplified using 
biotinylaled anti·slreptavidin antibodies and a second Incubation with fluorescence 
labeled streptavidin. 
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When IL-2 receptors on lymphocytes from peripheral blood or bone marrow were 
stained, a difference was found between incubation with biotin-IL-2 and with antibodies 
against the a. chain of the IL-2 receptor. The majority of unstimulated lymphocytes 
from mouse bone marrow as well as human peripheral blood were biotin-IL-2 positive 
(figure 3.4 A and C, respectively), whereas a much smaller fraction expressed the IL-2 
receptor a. chain at a level above background fiuorescence (figure 3.4 Band D). 
Double-staining experiments revealed that the a. chain positive cells were aU biotin-IL-2 
positive (data not shown). After stimulation of human peripheral blood 
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figure 3.4 
Fluorescence histograms of mouse bone marrow lymphocytes (A and B) and human 
peripheral blood lymphocytes (e and 0), stained with biotin-IL-2 and streptavidin·PE, and 
amplified (A and C), or stained with rat-anti-lL-2 receptor (J. chain antibodies and FITe 
conjugated goat anti-rat antibodies (B and D). Thick lines represent stained cells, thin 
lines unstained control cells. 
lymphocytes (PBL) with PHA virtually all cells became a. chain-positive (figure 3.5 B), 
whereas a much smaller fraction of the cells stained strongly With biotin-IL-2 (figure 
3.5 A). Most of the cells that showed a strong fluorescence signal after staining with 
biotin-IL-2 or anti-TAC were CD4 positive. The proportion of CD4 negative cells that 
expressed high levels of IL-2 receptor was much lower. The remaining cells were either 
IL-2 receptor negative or expressed IL-2 receptors at low levels (figure 3.5). 
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figure 3.5 
Dot plots of human peripheral blood lymphocytes that were stimulated with PHA for 3 
days, and stained with mouse-anti-CD4 antibodies in the first step, in combination with 
either biotin-IL-2 (A) or rat-anti·IL-2 receptor ex chain antibodies (8). In Ihe second step, 
cells were stained with PE-conJugated goat anti-mouse antibodies in combination with 
either Streptavidin-80DIPY (A) or FITC-conjugated goat anti-rat antibodies (8). 
Quadrants were set on the basis of background flUorescence of unstained cells to 
discriminate between brighlly stained cells and cells with low or no fluorescence signal. 
3.5 DISCUSSION 
This study has evaluated the biotinylation of IL-2 using five different biotin 
deriva.tives. The data presented extends previous observations concerning the use of OF 
labeled with (mostly NHS-) biotin [Foxwell et aI., 1988b] [Yamasaki et aI., 19881 [Taki ct aI., 
1989] [Peters and Norback. 1990) [Pieri and Barritault, 1991) [De Jong e( al.. 1992) [Wognum et al.. 
19931, by comparing Ihe results of labeling with NHS-Biotin, S-NHS-Biotin, S-NHS-
LC-Biolin, DBB and Photobiotin. The highest biotinylation efficiency, retention of 
biological activity and the highest specific slaining of JL-2 receptor expressing cells was 
achieved using S-NHS-LC-Biolin. The results with S-NHS-LC-Biotin could be 
explained by a more efficient biotinylation, because the extended spacer arm permits 
the protein to reach the lysine groups, or by a more efficient interaction of the 
biotinylated IL-2 with the streptavidin conjugates. 
Most biotin-IL-2 samples showed reduced activity in stimulating the growth of the 
IL-2 dependent cell line CTLL-2 when high B:P ratios were used. We cannot exclude 
the possibility that part of the biological activity of the biotin-IL-2 samples is due to 
residual unmodified IL-2 molecules. Attempts to separate biotin-JL-2 from IL-2 on an 
avidin-agarose column were not successful because IL-2 bound nonspecifically to the 
column. The decreased biological activity of samples with a high B:P ratio is probably 
the resull of impaired receptor binding, caused by conformational changes of the bioi in -
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IL-2 or by steric hindrance when the biotin molecules are close to the receptor binding 
site(s) of JL-2. It is also possible that these biotinylated IL-2 molecules can bind to the 
cells but fail to stimulate cell proliferation. The IL-2 receptor consists of different 
subunits [Takeshita et at, 1992aJ, with different IL-2 binding characteristics [Low~nthal and 
Greene, 19871. A low affinity IL-2 receptor contains only the 55-kD a chain' [Leonard et al.. 
1984] [Nikaido et al., 1984). A heterodimeric IL-2 receptor with intennediate affinity for IL-
2 consists of the 70- to 75-kD P chain [Sharon et al .. 1986} [Bawrrini ~t aI., 1989} and the 64-
kD Y chain [Takeshita et al .. 1992a} [Takeshita et al .. 1992b}. A "pseudo-high" affinity IL-2 
receptor is. formed by interaction of a and P chains [Nakarai et aL, 1994], which can only 
be internalized when combined with the ,¥subunit [Takeshita et aI., 1992aJ, thereby forming 
the trimeric high affinity IL-2 receptor which has a higher association rate and a lower 
dissociation rate than the ap complex [Matsuoka et aI., 1993]. Heterodimerization of thep 
and,¥ chain is required for signaling [Nakamura et aI., 1994] {Nelson et al., 1994]. The 
decreased biological activity of samples with a high B:P ratio might thus be caused by 
steric hindrance, which impedes receptor binding and/ or the formation of receptor 
complexes that are required for cell signaling or internalization. 
Despite Ihe partial loss of biological activity, the biotinylated JL-2 samples prepared 
at higher B:P ratios generally yielded better fluorescence signals. It is possible that at 
higher B:P ratios, a higher proportion of biotinylated IL-2 molecules have sufficient 
numbers of biotin molecules facing away from the receptor binding sites to permit 
binding of (strept)avidin molecules to receptor bound biotin-IL-2. Only the samples 
with high B:P ratios that lost almost all biological activity (NHS-Biotin and 
Photobiotin) showed low fluorescence intensities. 
The weak performance of DBB compared to the different NHS-Biotins may be 
explained from the amino acid composition of IL-2: NHS~Biotins mainly react with 
lysine residues, of which there are II in IL-2, while there are only 3 histidines and 4 
tyrosines (Taniguchi et aI., 1983] which are necessary for DBB binding. Direct 
measurement of the number of biotin molecules present on the IL-2j e.g. with 2-(f-
hydroxy-phenylazo)benzoic acid (HAEA) [Baxte<, 1964} , was not attempted, because the' 
procedure requires a large amount of biotinylated protein. 
Our experiments show that biotinylated IL-2 cim be used for cell staining 
experiments. When IL-2 receptors .on unstimulated lymphocytes from mouse bone 
marrow or human peripheral blood were labeled, only part of the biotin-IL-2 positive 
cells expressed high levels of the IL-2 receptor CJ. chain (figure 3,4). This is in 
agreement with the finding that only intermediate affinity lL-2 receptors are present on 
the surface of resting T cells and NK cells [Dukovieh et aI., 19871, while the 'IL-2 receptor 
a chain is induced only after activation of the cells [Hamblin, 1985] (Lai et ai., 1991). After 
stimulati9n of PBL with PHA, virtually all cells stained brightly with anti-TAC, 
particularly in the CD4 positive subset. (figure 3,5 B). However, only about two thirds 
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of these cells showed a high fluorescence signal after incubation with biotin-IL-2 
(figure 3.5 A). The cells with a low binding capacity for biotin-IL-2 may have a 
limiting number of IL-2 receptor p andlor ychains to form high affinity receptors with 
the (J. chains. Biotin-IL-2 binding thus appears to be a better marker for the expression 
of functional JL-2 receptor complexes than binding of anti-TACo A possible advantage 
of staining with biotinylated GF for in vivo studies with isolated recep~or expressing 
cells is that avidin-tagged cells are not selectively removed by the immune system of 
the recipient animals. In contrast, antibody stained cells may be eliminated by 
phagocytosis induced by the Fc parts of the antibodies or by complement-mediated lysis 
[Bauman et aI., 1985]. As shown in previous studies for other cytokines [Wognum et aI., 1990] 
{De long et ai., 1992} [Wognum et at. 1993], flow cytometric analysis 'of receptor expression 
using biotinylated GF is very sensitive: cells expressing as few as 100 cell surface 
receptors can be detected. Therefore, biotinylated OF provide a useful tool for 
investigating the distribution of functional GF receptors, e.g. on subsets of early 
. . 
hemopoietic cells in bone marrow. 
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4.1 ABSTRACT 
To characterize Kit expressing mouse bone marrow (BM) cells, and to determine' 
their contribution to short- 'and long-term repopulation of the hemopoietic system of 
irradiated recipients, we have purified Kit+ BM cells by flow cytometry. A high level of 
Kit expression was detectable on 1-2% of BM cells after staining with biotinylated 
stem cell factor (SCF) or with anti-Kit antibodies (ACK-2). Compared to unfractionated 
BM, the Kit+ fractions were enriched for immature hemopoietic cells, as shown by 
morphological differentiation, in vitro culture, and spleen colony formation. I:3nrichment 
of colony-forming cells was higher in biotin-SCF+ than ACK-2+ fractions. Colony-
forming cells were not found in the Kit- subsets.'To study the hemopoietic repopulation 
capacity of the Kit+ and ~it- cells, serial dilutions of the sorted fractions were 
transplanted into irradiated mice, and peripheral blood of these recipients was 
monitored regularly for the presence of donor-derived cells during a 1 year period. 
Nucleated blood cell repopulation by male donor cells in female recipients was assessed 
using a Y-chromosome specific DNA probe; erythroid repopulation by normal 'donor 
cells in W I\Vv recipients was examined flow cytometrically by measuring the forward 
light scatter of donor- and host-type erythrocytes. A 25- to IOO-fold enrichment of long-
term repopulating ability in the sorted Kit+ fractions showed that Kit+ cells are capable 
of reconstitution of circulating erythrocytes and nucleated blood cells after BM 
transplantation. Transient repopulation of the red blood cell lineage was observed after 
transplantation of Kit- cells. Detection of donor-derived nucleated cells 1 year after 
transplantation showed that Kit + cells contributed to donor-type repopulation of BM, 
spleen, and thymus. Our data demonstrate that isolation of BM cells on the basis of Kit 
expression is a useful addition to the methods that are commonly applied in stem cell 
enrichment protocols. 
4.2 INTRODUCTION 
The transmembrane tyrosine kinase receptor Kit (COl 17) [Chabol,lat" 1988J and its 
ligand, stem cell factor (SCF), also known as Kit ligand, mast cell growth factor, or 
Steel factor [Anderson et aI., 1990) [Huang et aL. 1990] [Martin et al.. 1990) [Zsebo et aI., 1990a] 
{Zsebo et al., 1990b] are essential for normal hemopoietic cell development in vivo. This is 
demonstrated ,by severe her'nopoietic defects which result from mutations at the 
dominant white ~pottillg (lY) locus, which encodes for Kit [Chabot et al., 1988] [Geissler et 
al" 1988J, and at the Steel (SI) locus, which encodes for SCF [Copeland el al" 1990J [Flanagan 
and Leder. 1990] [Huang et aI., 1990J [Zsebo et aL, 1990a]. The important role of Kit and SCF in 
supporting early hemopoiesis is also demonstrated by the disappearance of almost all 
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hemopoietic progenitor cells from the bone marrow (BM) of mice' injected with 
neutralizing anti-Kit antibodies [Ogawaet aI., 1991]. 
Soluble SCF, consisting of the N-terminal extracellular domain of the protein, 
synergizes with other hemopoietic growth factors to:stimulate in vitro proliferation and 
differentiation of immature hemopoietic cells as well as monomyeloid, erythroid, and 
lymphoid progenitors [Broxmeyer et aL, 1991] [De Vries et aI., 1991] (MeNiece et aI., 1991a1 
[MeNieee et aI., 1991bJ [Metcalf and Nicola, 1991J (Migliaccio et al.. 19911 [Tsuji et al.. 1991] 
[Williams et aI., 1992] [Morrissey et ai., 1994]. In vivo administration-of soluble SCF causes an 
expansion of both immature and differentiated hemopoietic progenitor cells in BM 
[Tong el al .. 19931. Following injection of SCF, mobilized progenitors appear in the 
circulation {Andrews et aI., 1992] [Bodine ct al.. 19931, and there is an increase in the number 
of mature cells of multiple lineages [Molineux et ai., 1991] [Ulich ct al.. 1991] [Chow et a1.. 
19931· 
Kit expression was shown on less than to%: of adult BM cells in primates and 
rodents using anti-Kit antibodies. Results of transplantation studies of different BM 
fractions showed, that Kit+ cells were able to repopulate recipient mice [[~kada et al.. 
1991] lIkuta and Weissman. 1992] [Okada et al.. 1992] [Orlic et al.. 1993}. In these experiments, 
only a small proportion of the Kit+ cells was selected as a result of the cell isolation 
procedures, which included counterflow elutriation, depletion of cells that express 
lineage markers. and purification of WGA + or Sca-l + cells. Little information is 
av~ilable on the quantitative and qualitative contribution of the Kit+ population to 
short- and long-term hemopoietic repopulation of irradiated recipients. It is also not 
known. if, and to what extent, repopulating cells are present in the Kit- fraction. 
Therefore, in the present study, mouse BM ceBs were sortcd solely on the basis of Kit 
expression. To ensure labeling of funclional receptors, biotinylated SCF was used for 
cell staining in parallel with anti-Kit antibodies. To obtain an accurate estimate of the 
enrichment of immature hemopoietic cells in the Kit+ BM subset as compared to 
unfractionated and Kit- BM cells, the purified Kit+ ceBs were assayed for their ability 
·to reconstitute multilineage hemopoiesis after transplantafion into irradiated recipients. 
4.3 MATERIALS AND METHODS 
Mice and 8M cell preparation 
Mice. were bred under specific pathogen-free condition (TNO, Rijswijk, The 
Netherlands). BM donor mice were 7 weeks old 'male BCBA (C57BLlLiARij x 
CBAlBrARij)FI or 27-29 weeks old male BD2-+/+ (C57BL-W/+ x DBA-2-Wv/+)FI 
mice. BM was obtained by flushing excised femora and tibiae with Hepes-buffered (10 
mM, pH 6.8-7.1) Hanks' balanced salt solution (without phenol red; Gibco BRL, 
\ . 
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Paisley, UK') with an osmolarity of 300-305 mOsmJkg (Hanks' Hepes, abbreviated as 
HH). Single cell suspensions were obtained by filtratio~ through a six-layer nylon sieve 
and kept on melting ice until use. 
Recipients were 12-20 weeks old BCBA or 21-57 weeks old BD2-W/w v mice, 
irradiated by use of a 137Cs gamma-cell-20-small-animal irradiator (Atomic Energy of 
Canada, Ottawa, Canada). Lethally irradiated male BCBA recipients (8.5 Gy total body 
irradiation) were used for spleen colony assays (CFU-S day 8 and <jay 12). Lethally or 
snblethally irradiated female BCBA or W /WV recipients (8.5 Gy or 7 Gy total body 
irradiation for BCBA, or 3 Gy total body irradiation for W/wV) were used for long-term 
repopulating ability (LTRA) assays. In the first weeks after BM transplantation, the. 
mice were maintained in laminar flow housing. 
Blotinyl.tlon of SCF 
E. coli-expressed recombinant rat stem cell factor (SCF, kindly provided by 
AMGEN Ltd., Cambridge, UK) was biotinylated using·biotin-N·hydroxy succinimide 
ester (NHS-Biotin, Pierce, Rockford IL, USA) as described previously for IL-2 [De long 
et al" 19921. Briefly, NHS-Biotin dissolved in dimethyl sulfoxide (DMSO) was added to 
aliquots of SCF in 0.1 M carbonate-bicarbonate buffer pH 8.5 at molar biotin:protein 
(B:P) reaction ratios of 10: I, 30: I, and 100: I. A control sample was mock-biotinylated 
by adding DMSO only. After 3 h incubation at room temperature in the dark, ,biotin-
SCF molecules were separated from the remaining free biotin molecules 'by extensive 
. dialysis against PBS containing 0.04% Tween-20 and 0.02% (wtlv.ol) sodium azide, at 
4"C (10 000 NMWL filter unit, Cat. No. UFC3 LGLOO, Millipore, Bedford MA, USA). 
Biotin-SCF was stored ar~20"C. 
The ability of biotin-SCF to stimulate cell proliferation was assayed using a subclone 
of the factor-dependent cell line FDC-P I that responded to SCF. The biotin-SCF sample 
prepared at a B:P r.atio of 30: 1 retained its biological activity and this preparation was 
~sed in further experiments. 
Immunocytochemical staln;ng 
Mouse BM cells were incubated in 50 III HH, containing 5% (vol/vol) fetal calf 
serum and 0.02% (IvI/vol) sodium azide (HHISerumiAzide, abbreviated as HSA) .. 
lncubation with the anti-Kit antibody ACK-2 INishikawa ct ai., 1991J (provided by Dr. K. 
Rajewski, Genetics Institute, Cologne, Germany) (final concentration 38 nM) was 
performed for 30 min on ice. The samples were then stained with PhycoErythrin- or 
FITC-conjugated goat anti-rat' antibodies (GARa-PE 1:300, GARa-FITC I: I 00 vol/vol, 
both from TAGO, Burlingame CA, USA) for 30 min on ice. After each incubation the 
samples were washed in HSA. As a negative control, only HSA was used in the first 
incubation step. 
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Alternatively, cells were incubated with biotin-SCF(lO nM) for 60 min at room 
temperature or on ice. The cells were th~n stained with PE- or BODIPY - conjugated 
. streptavidin (Str-PE or Str-BODIPY, both 3.3 Jlg/ml final concentration; Molecular 
Probes, Eugene OR, USA) for 30 min on ice. Specificity of binding of the biotin-SCF 
samples was determined by incubating the cells with biotin-SCF in the presence of a 
100-fold molar excess of unbiotinylated SCF or in the presence of ACK-2, which 
blocks SCF binding to Kit. As a negative control, only HSA was used in the first 
incubation step. 
To distinguish between living and dead cells Hoechst 33258 (2-(20-(4-
hydroxyphenyl)-6-benzimidazole)-6-(I-methyl-4-piperazyl) benzimidazole) (H58, final 
concentration I Jlg/ml; Molecular Probes) was added to the samples. In some of the 
experiments. cells sorted on the basis of Kit expression were stained with Rhodamine 
123 (Rh 123, Eastman Kodak, Rochester.NY, USA) as described [Bertoncello et aI., 1985J. 
Flow cytometry 
Stained cells were analyzed and sorted using the two-laserRELACS II flow 
cytometer (Rijswijk experimental light activated cell sorter, TNO, Rijswijk, The 
Netherlandsj. Cells were illuminated with the 488-nm line of an argon ion laser 
(Coherent lnnova 90, Palo Alto CA, USA) and UV light (351/364 nm) from an argon 
ion laser (Spectra Physics, Series 2000, Mountain View CA, USA) at 100 mW laser 
power. Orange PE fluorescence was measured through a 577-nm longpass filter (Becton 
Dickinson, Mountain View CA, USA). Green FITC, BODIPY, or Rhl23 fluorescence 
was measured through a 530/30-nm bandpass filter (Becton Dickinson). H58 
fluorescence was measured through a KV408 cut-off filter plus ~ 450-nm short pass 
filter. Dead cells stained with H58 were gated out by the FACS at the time of cell 
sorting. Pulse width (time.of flight) of the triggering signal (forward light scatter) was 
routinely measured to support exclusion of cell clumps. 
In vitro colony assay 
S<;>rted populations were assayed for their content of in· vitro colony-forming units 
(CFU-C) by colony formation in agar. Semisolid agar culture medium consisted of 
0.3% (wt/vol) agar (Bacto agar, Difco Laboratories) in supplemented Dulbecco's 
Modified Eagle Medium (Gibco 042 250IH), containing 3 mM L-glutamine, and 20% 
(vol/vol) of a mixture of 2 volumes of horse serum and 1 volume of fetal calf serum 
(FCS). Aliquots of I ml containing 2;"104 unfractionated BM cells or Kit- cells, or 250-
1000 Kit+ cells, were plated in 35-mm petri dishes (Falcon 1008) in triplo. Cultures 
were. stimulated with recombinant murine IL-3 (1000 Units/ml; Behringwerke AG,· 
Marburg, Germany), recombinant murine GM-CSF (100 U/ml; Behringwerke AG), 
recombinant'rat SCF (100 ng/ml; AMGEN Ltd.), and pregnant mouse utems extract 
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(PMUE; 12 Ililml) [Bradley ct aI., 1971), The cultures were maintained in a humidified 
atmosphere of 10% C02 in air for 7 days, after which the colonies were counted. 
Spleen colony assay 
Unseparated BM cells or Kit- cells (2xI04), or Kit+ cells (250-1000) were injected 
into each of 7 to 10 lethally irradiated mice per experimental group via the tail vein. The 
spleens were removed on days 8 or 12 after transplantation and fixed in 
Telleyesniczky's solution (70% ethanol : acetic acid : formalin; 20: I: I). 
Macroscopically visible spleen colonies were counted. 
Repopulation capacity assays 
Serial dilutions of cells from male donor mice were injected into lethally or 
sublethally irradiated female mice. Three recipients were used per experimental group. 
Between 3 weeks and 1 year arter BM transplantation, tail vein blood samples were 
collected every 2-4 weeks and monitored for the presence of donor-type cells. 
Red blood cell chimerism of BD2 recipients was examined by measuring the 
differential forward light scatter of small, normal, +1+ red blood cells and large, 
macrocytic, W IWv red blood cells, using a FACScan flow cytometer (Becton 
Dickinson, San Jose CA, USA), similar to the method described previously [Van"den Bos 
et aI., 1992). Blood cells were suspended in a hypotonic saline solution (0.75% wtlvol 
NaCI). Percentages of donor-type red blood cells were determined by setting a marker 
based on control cells from +1+ and W/Wv mice. 
Blood smears were made on microscope slides to study nucleat.ed blood cell 
chimerism. Slides were air dried overnight, fixed in a mixture of :3 .volumes 100% 
ethanol and I volume acetic acid, and washed in ethanol. After baking at 70'C for 3 h, 
the slides were storeQ at _20°C under nitrogen gas until analysis for presence of 
nucleated donor cells by fluorescent in situ hybridization (FISH). 
One year after transplantation, mice w~re sacrificed and femoral spleen and thymus' 
were removed. Cell suspensions were. made in a 0.9% (wI/vol) NaCI solution, fixed 
. with a mixture of methanol and acetic acid (3: I), resuspended in a small volume 
(approximately 100 Ill) of methanol-acetic acid, and dropped onto microscope slides. 
The slides were air dried and stored at -20'C under nitrogen gas until FISH was 
perfonned. 
FlUorescent In situ hybridization (FISH) 
The mouse Y-chromosome specific DNA probe p17-M3412 [Singh et ,1.,1994) (Dr. L. 
Singh, Center for Cellular and Molecular Biology, Hyderabad, India) was labeled with 
biotin-16-dUTP (Sigma Chemical Co.,S!. Louis Mo, USA) by nick translation .. FISH 
was performed similar to the method described previously [Van Dekken ct al.. 1989]. Cells 
were permeabilized in 0.1 M HCI containing 0.05% (vol/vol) Triton X-IOO (7.5 min, 
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3TC) and fixed in a phosphate-buffered saline solulion (PBS) containing I % (vol/vol) 
formalin (15 min, room temperature). The slides were dehydrated in an ethanol series 
(70%, 83%," 96%) a~d air dried. ChrojTIosomes were denatured in 70.% (vol/vol) 
deionized formam ide (Merck, Darmstadt, Germany) in 2xSSC for S min. at 70"C 
(IxSSC is 0.15 M NaCl, O.OIS M sodium citrate). The slides were dehydrated in an 
ethanol series and air dried. The probe (2.S Ilg/ml) was denatured for S min. at 70'C in 
the hybridizalion mixture, which contained O.S mg/ml herring sperm DNA, 0.1 % 
(vol/vol) Tween-20, 10% (wt/vol) dextran sulfate, and SO% deio~ized formamide in 
2xSSC, pH 7. Under glass coverslips, hybridization was allowed to take place overnight 
at 3TC in a humidified atmosphere. Subsequently, the slides were washed three times 
for 3 min in SO% formamide /2xSSC followed by two limes for S min in 2xSSC, both 
at 4S'C (or at room temperature), and immersed in 4xSSC / 0..1% (vol/vol) Triton X-
10.0. at room temperature. The slides were incubated for 20. min at 3TC with 
fluorescein-labeled avidin DCS (2 Ilg/ml; avidin-FITC, Vector Laboratories, 
Burlingame CA, USA) in 4xSSC containing S% non-fat dry milk (Prolifar, Nutricia, 
Zoetermeer, The Netherlands) and 0..0.2% NaN3. After washing the slides twice in 
4xSSC / 0..1% (vol/vol) Triton X-lOa, the fluorescence intensity was amplified using 
subsequent layers of biolinylated goat anti-avidin antibodies (S Ilg/ml, Vector 
Laboratories) and avidin-FITC )pinkel et al .. t986]. For microscopic observation the cells 
were stained for total DNA with propidium iodide (o,.S Ilg/ml) and DAPI (0..1 Ilg/ml) in 
an antifade solution (50. g/I 1,4-diazobicyclo-[2.2.2] octane (B) in a solution of 90.:10 
(vol/vol) glycerol/ 0..1 M Tris-HCI, pH 8). A random sample of at least 100. complete 
nuclei per slide were counted and scored for probe-related FITC fluorescence, and the 
percentage of Y chromosome positive cells was determined. 
Statistics 
Data of in vitro and in vivo colony assays are expressed as average number of 
. colonies per 104 cells plated or injected. Standard errors were obtained by taking the 
square root of the absolute number of colonie~ counted, assuming that colony counts are 
Poisson distributed [Blackett, 1974) [Iscove, 1977}, 
Differences between colony data of different BM fractions were analyzed using the 
Mann-Whitney test. 
4.4 RESULTS 
Kit expression on mouse BM cells 
The expression of Kit on the cell surface of BM cells was determined using either 
biotin-SCF or anti-Kit anlibodies (ACK-2), A distinct cluster of Kit+ cells was found 
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after staining with biotin-SCF and fluorescentlylabeled streptavidin (figure 4.1 A). 
Staining with biotin-SCF was specific, as. showl) by incubation of cells with biotin-SCF 
in the presence of either a I DO-fold molar excess of unlabeled SCF or the blocking anti-
Kit antibody ACK-2 (figure 4.1 B). The fluorescence. signal of these control cells was 
similar to that of cells incubated without biotin-SCF. 
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figure 4.1 
Kit expressIon on mouse 8M cells . 
. Cells were stained with biotin·SCF and streptavidin·PE (A), or with ACK·2 and FITC· 
conjugated goat anti·rat antibodies (GARa'FITC) (e). Control samples were incubated 
with biotin·SCF in the presence of ACK·2 before staining with streptavidin·PE (B), or only 
with GARa·FITC (0). Indicated are the windows that were used to sort Kit+ and Kit- cells. 
Green FITe fluorescence and autofluorescence was measured through a 530/30-nm 
bandpass filter, orange PE fluorescence and .autofluorescence through a 577-nm 
longpass filler. . 
Staining of BM cells with ACK-2 and fluorescence·tagged second layer antihodies 
resulted in a different fluorescence distribution than staini!1g with biotin-SCF (figure 
4.1 C). As at so shown by others [O~ada et al.. 1991) [Odic et at" t994), ACK-2 staining 
resulted· in a weak fluorescence signal on a large proportion of the ceUs, and a bright 
signat on a small subset of BM cells. This ACK-2+ subset contained a similar 
percentage of ,cells (1-2%) as was found in the ciuster ofbiotin·SCF+ cells. 
As indicated in figure 4.1, the Kit- fractions as well as the brightest Kit+ cells were 
sorted in the flow cytometer. The Kit+ cells were negative or low positive for lineage 
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markers specific for granulocytes, monocytes, macrophages, erythroid and lymphoid 
cells (15-1.1, 10-2.2 [De Vries, 1988], 45D8 [Bauman e. a1 .. 1988l, B220, and GM1.2 [Bau,nan 
et aI., 1986]) (not shown). The majority of the Kit+ cells showed a light scatter pattern of 
large blast cells. Additionally, part of the ACK-2+ cells displayed a lymphocyte-like 
scatter pattern (not shown). Cells with this phenotype were not found in the biotin-
scF+ fraction. These results indicat~d that the Kit+ populations identified with biotin-
SCF or anti-Kit are qualitatively different. Unfortunately, double-staining of BM cells 
wilh biotin-SCF and ACK-2 to directly compare their target cell specificity was not 
possible because ACK-2 interfered with binding of biotin-SCF to the cells (as shown in 
figure 4.1 B). 
A B 
• 
•• 
figure 4.2 . 
Morphology of mouse bone marrow cells purified on basis of Kit expression. 
May-Grunwald Giemsa stained cytospin preparations of isolated Kit+ (A) and Kit- (8) 8M 
cells. These cells are representative of the fractions obtained by flow cytometry after 
staining with either biotin-SCF or ACK-2. The .Kit+ subsets contained many blasts, and 
small cells that resemble lymphocytes. The percentage of mature granulocytes and 
monocytes in the Kit- fractions was lO-fold higher than in the Kit+ subsets. (Original 
magnification 1 OOx objective.) 
Morphological differentiation of Kit positive and negative subpopulatlons of 8M 
Purified Kit+ and Kit-'- cells differed in morphology (figure 4.2). Differential counts 
of all nucleated cells showed a striking difference in the monomyeloid compartment 
between Kit+ and Kh- cells. ACK-2+ as well as biotin-SCF+ fraction.s contained a 3- to 
5-fold more immature inyeloid and monocytic cells than unfractionated BM (13-19% 
and 4%, respectively). In agreement with previous reports [Orlic et aL, 1994], many of the 
cells in the Kit+ fractions (especially the ACK-2+ fracHon) morphologically resembled 
lymphocytes. This lymphocyte-like subset may also contain very immature, 
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undifferentiated progenitors and erythroid _cells, which are difficult- to distinguish 
morphologically from lymphocytes. This implies that the actual percentage of immature 
Kit+ cells may be higher than the 13-19% that were scored as immature monomyeloid 
cells. 
Mature myeloid"and monocytic cells were rare in the Kit+ fractions (3-4%), but 
comprised 30-40% of the cells in the Kit- subsets and in unfractionated BM, which is 
within nom1al ranges [Hoang et aI., 1983] {Berloncello et al., 1986] [Ploemacher et aI., 1993]. 
In vitro and Iii vivo colony forming potential of Kit positive 8M cells 
In vitro culture showed that the sorted Kit+ cells were 20- to 70-fold enriched for 
colony forming units in culture (CFU-C) as compared to U1~fractionated BM (table 4.1). 
One in every 5-6 biotin-SCF+ celis, or I in every 13-18 ACK-2+ cells formed a colony 
in vitro. Therefore, Kit+ fractions that were sorted after cell staining with biotin-SCF 
contained CFU-C at significantly (2'-3-fold) higher frequencies than cells that were 
sorted after staining with ACK-~ (9 independent sorting experiments). 
table 4.1 
Distribution of in vitro and spleen colony forming potential on the basis of Kit expression. 
CFU.C b CFU-Sda c CFU-S d12 c 
Population %a 
Incidence Enrichment Incidence Enrichment Incidence Enrichmenl 
per 104 cells Faclor per 104 cells Faclor per 104 cells Faclor 
control BM 100% 27.5 ± 6.4 4.2±0.1 5.1±1.4 
AC~-2+ 0.91 ± 0.30% 672.2 ± 109.2 24.5 11O.4± 15.4' 26.3 136.5±33.1 • 26.8 
biotin·SCF+ 0.97 ±O.36% 1838.9 ± 152.6' 67.0 224.5 ± 27.2 • 68.5 209.0 ± 25.6' 41.0 
ACK-2- 83.51 ± 2.74% 1.5±0.1 0.05 M)d M) 
biolin-SCr- 95.95 ± 3.56% 2.9± 0.3 0.11 M) M) 
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a Mean (± S.E.M.) of 3 different experiments are shown. 
b Colony-forming units in cullure. /n each experiment, the sorted cells were cultured in 
three replicate dishes. 
c The sorted cells were injected into groups of 7-10 lethally Irradiated (8.5 Gy) recipients 
per fraction in each experiment. The spleens were removed on days 8 or 12 after 
transplantation and fixed in Telleyesniczky's solution. Data were corrected for the number 
of endogenous colonies observed in the control irradiated groups. 
d NO, not determined. In one experiment, CFU-S were determined using the biotin-SCF- . 
fraction, which resulted in 0.0 CFU-S dS and 0.3 ± O.S CFU-S d12 per 104 cells injected. 
Differences between biotin-SCF+ and ACK-2+ subsets were significant (P < 0.001, Mann-
Whitney test). 
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To examine the spleen colony forming potential of the sorted fractions, the cells were 
injected into lethally irradiated mice. and CFU-S were counted at day 8 or 12 after 
transplantation. As shown in table 4.1. the Kit+ sorted fractions were approximately 25-
to 60-fold enriched for CFU-S compared to unfractionated BM. The subsets that were 
sorted using biotin-SCF contained 1.5- to 2-fold as many spleen colony forming cells as 
the ACK-2+ fractions. 
These differences in colony formation between the Kit+ and Kit- subsets were not 
due to stimulation of the cells by biotin-SCF or inhibition by ACK-2. since differences 
between colony numbers obtained from unfractionated BM after incubation with buffer, 
biotin-SCF or ACK-2 were not significant (not shown). When forward light scatter' 
criteria were used to separate ACK-2+ cells on the basis of size, the majority of the 
CFU-S were recovered in the fraction of large blast-like cells, and similar results were 
obtained fO,f in vitro colony-forming cells (not shown). Recovery of colony-forming 
ceHs ranged from 15-40% for ACK-2+ subsets. and from 22-96% foe biotin-SCF+ 
fractions. 
Repopulating capacity of Kit positive and negative BM cells 
To assess the short- and long-term repopulating ability (STRA and LTRA. 
respectively) of Kit+ and Kit- BM cells. sorted cells of male donor mice were 
. . 
transplanted into female recipients. In addition to normal mice, transplantation 
experiments were performed using W/wv mice that received sorted fr'actions' of +1+ 
BM cells. The presence of donor cells in the peripheral blood (PB) of the recipients was 
monitored regularly during a one year period. Red blood cell chimerism was determined 
by measuring the percentage of normal-sized erythrocytes in the PB of the WfWv 
recipients, which originally suffered from macrocytic anemia (figure 4.3). Nucleated 
blood cell chimerism was assessed using fluorescent in situ hybridization (FISH) to 
determine the percentage of Y -chromosome-positive nucleated PB cells in the female 
recipients. As shown in figure 4.4. stable chimeras with high percentages of donor-type 
erythrocytes and nucleated blood cells were found in the mice that had been 
transplanted with 1 x 1 0 5 unfractionated BM cells. This is consistent with the estimated 
frequency of at least 1-2 stem cells per IxlOS BM cells [Harrison et al .. 19881 [Van der Loo ct 
al .. 1994J. Transplantation of 103 Kit+ (biotin-SCF+ or ACK-2+) cells resulted in high 
percentages of donor-type PB cells in 6 out of 7 recipients in. this experiment. 
Repopulation by ACK-2+ cells (not shown) was similar to that ofbiotin-SCF+ cells. In 
general. repopulation of erythrocytes occurred faster than that of nucleated blood cells. 
and higher percentages of donor-type erythrocytes than nucleated blood cells were 
found. Transplantation of 105 Kir- cells resulted in short-term repopulation of red blood 
cells. returning to the macrocytic host-type after 10-15 weeks in all mice. Little or no 
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nucleated blood cell chimerism was observed in these mice during the period that the 
PB was monitored, which was between 3 weeks and 1 year after transplantation. 
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figure 4.3 
Frequency distributions of forward light scatter of erythrocytes of W/wV, +/+, and chimeric 
mice. 
Forward light scatier characteristics of PB erythrocytes of macrocytic wrwv (top 
histogram) or normal +1+ (bottom histogram) control mice are shown as a measure of cell 
size. To illustrate various degrees of chimerism, histograms of 4 WN-/v recIpIents, 3-4 
weeks after transplantation of different sorted fractions df +1+ BM cells are shown. The 
broken line indicates the marker that is set on basis of forward light scatter characterisllcs 
of cells from control mice, to discriminate between norm~1 and macrocytic erythrocytes 
and to calculate the percentages of normal-sized erythroc}'tes (shown on the left of the 
histograms). Because the histograms of WIWv ("host") .and +1+ ("donor") erythrocytes 
overlap, chim~rism percentages range between 20 and 80%. 
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figure 4.4 
Time course of erythrocyte and nucJeated blood cell chimerism in female WN,Jv recipients 
after transplantation with sorted fractions of male +1+ donor 8M, 
LInes represent data of Individual mice, For each recipient, erythrocyte (left panels) as 
well as nucleated (right panels) blood cell chimerism Is shown, Transplanted cells were 
(A and B) 100,000 BM cells, (C and 0) 1,000 Kit+ cells stained with biolin-SCF,(E and F) 
1.000 Kit+ cells stained with ACK-2, (G and II) 100,000 Kit- cells stained with biolin-SCF, 
and (I and K) 100,000 Klt- cells stained with ACK:2. Pooled data from 2 independent 
sorting experiments are shown, Percentages of donor-type P8 cells were determined 
using both FISH (left panels) and flow cytometry (right panels). Broken lines In the left 
panels Indicate the 20-80% range of red blood cell, chimerism as described In the legend 
to figure 4.3. 
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To determine the enrichment of LTRA in the Kit+ fractions compared to Kit- and 
uilfractionated BM, serial dilutions of sorted cells were transplanted. The results of one 
of these experiments are depicted in figure 4.5 and show the percentages of donor-type 
nucleated blood cells one year after transplantation. Similar results were obtained at 
earlier time points. To estimate the enrichment of immature cells in the sorted fractions 
as compared to unfractionated BM, we calculated the cell numbers of the different 
fractions that were needed to reach 50% donor-derived nucleated blood cells. FISH data 
from 4 different sorting experiments showed stable chimeras containing 50% donor-
type nucleated PB cells after transplantation of 50,000-100,000 unfractionated BM 
cells or 500-2,000 Kit+ eells (figure 4,5 and table 4.2). This corresponds to a 25-100- . 
fold enrichment for LTRA in the Kit+ fraction. Repopulation by biotin-SCF+ fractions 
was ~imilar to that of ACK-2+ cel1s. Enrichment factors based ,Of! erythrocyte 
repopulation could not be calculated, since. the majority of mice tra~lsplanted with 
l1nfractioI~ated or Kit+ BM cells became stable chimeras with high percentages of 
donor-type red blood cells, even when low cell numbers were used (table 4.2). Similar 
to the nucleated blood cells, the red blood cells of mice transplanted with Kit- BM cells 
remained mostly of host-type (table 4.2 and figure 4.5), which demonstrated that the 
Kit- fractions were depleted ofLTRA cells. Hemopoietic repopulation in mice that had 
received total BM, sorted after staining with biotin-SCF or ACK-2, was similar to that 
after transplantation of unstained BM (not shown). This indicated that the staining 
procedures did not infiuence the repopulation capacity. 
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figure 4.5 
Nucleated bloqd cell chimerism in PB of female recipients, one year after transplanlallon 
with different numbers of sorted 8M cells of male donor mice. 
BCBA mice were transplanted with unfractionated 8M cells (closed circles), or with sorted 
Kit+ after incubation with biolin·SCF (open circles) or ACK·2 (triangles). Very few mice 
transplanted with biolln·SCF- and ACK·2- fractlons were alive after 1 year, therefore 
data from surviving mice were pooled (open squares). Percentage of donor· type 
nucleated ceUs was determined by FISH. Each dot represents the mean percentage of 2 
or 3 recipients; error bars indicate the SD. 
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table 4.2 
Repopulation of nucleated and red blood cells after transplantation of serial dilutions of sorted 
8M cells. 
# cells # cells 
injected biotin-SCF+ injected unfractlonated biotin-SCF-
x103 BIv1 x 103 BIv1 BIv1 
nucleated cells a 0.25 0 I SC 12.5 2 I 8 c 0 I 5 c 
0.5 2 I 5 25 2 I 7 0 I 2 
1 S I 8 SO 3 I 6 0 I 1 
2 4 I 8 100 5 I 7 0 I 3 
4 5 I 6 >200 d 6 I 6 3 I 4 
8 6 I 7 
red cells b 0.25 1 I 2 12.S S I 5 0 I 5 
0.5 2 I 2 25 3 I 4 1 I 2 
1 4 I 5 50 3 I 3 0 I 1 
2 5 I 6 100 4 I 4 0 I 3 
4 3 I 3 >200 d 4 I 4 4 I 4 
8 4 I 4 
a nucleated blood cell repopulation ability of the indicated fractions was assayed by FISH 
with a V-chromosome specific DNA probe, 5 months after transplantation of male donor 
cells into female recipients. 
b n3d blood cell repopulation ability was assayed by FACS analysis. of PB samples 5 
months after transplantation of +1+ donor cells into WN/v recipients. 
C number of mice with more than 50% Y -positive nucleated PB cells, or more than 50% 
. donor-type erythrocytes, respectively, per number of mice assessed. Data from 3 
independent experiments were pooled. Similar results were obtained at other Ilmepolnts, 
up. to one year postlransplantation. 
d 200,000-800,000 cells per mouse 
Comparison of the long-term repopulation of PB, BM, spleen, and thymus 
To investigate the effect of transplantation of the sorted fractions on the nucleated 
blood cell chimerism in the major hemopoietic organs, the recipients were sacrificed 
one year after transplantation, and the percentages ofY-chromosome positive nucleated 
cells in BM, spleen and thymus were determined. The results of one of these 
experiments are shown in table 4.3. A large variation was observed for the percentages 
of donor-type nucleated cells in PB, EM, spleen and thymus of individual mice, which 
is in agreement with previously reported differences in the contribution of transplanted 
cells to various lineages ILemischka et aI., 1986] {Jordan and Lemischka, 1990}. Despite this 
variation, these results show that Kit+ cells contributed to donor-type repopulation in 
each of these hemopoietic organs. Pooled data of sorted Kit+ and unfractionated BM 
cells from 3 different experiments (figure 4.6) showed a high correlation between 
donor-type . nucleated cell numbers in PB and BM (r ~ 0.88). As may have been 
expected, the correlation with spleen and thymus donor-type cells and those in BM is 
progressively lower, respectively (r ~ 0.69 and 0.50). 
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figure 4.6 
Correlation between nucleated blood cell chimerism in 8M and PB (A), spleen (8) and 
thymus (C) one year after transpla.ntaUon of different BM subsets. 
Male donor 8M cells were injected Into female recipient mice. Percentage of donor-type 
nucleated cells was determined using FISH. Each dot represents data of one mouse. 
Transplanted cells were unfractionated 8M (closed circles; n=32), piolin-SCF+ (open 
circles; n=23), and ACK-2+ (triangles; n=21) celis. Pooled data are shown from 4 
Independent experiments, half of which Involved BCBA donors and recipients, the other 
half B02-+I+ donors and B02-WN/v recipients. Regression line is indicated,ih (A). 
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table 4.3 
Percentages cif donor-type nucleated cells In peripheral blood and hemopoietic organs of 22 
individual chimeric mice, 12 months after transplantation. 
Population a # cells PB BM spleen Ihymus 
injected a 
xl03 
blolin·SCF+ 0.5 6 1 16 6 
0.5 35 63 54 15 
1 7 0 10 2 
1 23 3 23 93 
1 42 23 30 22 
2 24 31 28 6 
2 74 83 77 64 
unfract. 8M 25 5 1 2 0 
25 3 0 6 6 
50 25 1 27 14 
50 73 76 78 92 
100 76 64 74 87 
100 87 90 90 100 
. 200 55 16 67 37 
200 88 80 81 88 
200 74 91 66 100 
a Per mouse, the indicated number of unfra.ctionated 8M cells or biotin-SCF+ cells was 
transplanted. One year after transplantation, the percentages of Y-chromosome-positive 
cells in the different organs wefe determined usin·g FISH. 
4.5 . DISCUSSION 
The aim "of this study was to characterize mouse BM cells that were selected solely 
on the basis of Kit expression, and to determine their contribution to short- and long-
time repopulation of the hemopoietic system of irradiated recipients. In order to purify 
cells that express functional receplors, we slained Ihe cells with biotinylaled SCF and 
compared this method with ceJl staining using the anti-Kit antibody ACK-2 [Nishikawaet 
al..19911. 
Sorted Kit+ populations were enriched for immature myeloid and erythroid cells, as 
shown by morphology, CFU-C, and CFU-S day 8 and 12. Compared to unfractionated 
BM, the Kit+ fractions were 20-70-fold enriched for clonogenic cells. This enrichment 
was achieved by using a single selection parameter: Similar enrichment values for CFU-
S have been obtained after sorting of Kit+ cells that were negative for a cocktail of 
markers with specificity for granulocytes, monocytes, macrophages, erythroid and 
lymphoid cells [Okada ct aI., 1991}. These markers, which are commonly employed in 
stem cell purification protocols, are not expressed on Kit+ cells. Therefore, cell staining 
based on Kit expression is a useful alternative for the selection of lineage-negative' cells 
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to obtain BM fractions that are enriched for immature cells. Since the Kit+ .fractions in 
the different experiments comprised 1-2% of the nucleated BM cells, 50- to 100-fold 
enrichment is the maximal value that can. be obtained with Kit expression as a si:ng1e 
sorting parameter. 
Since data on the kinetics of hemopoietic "repopulation after transplantation of Kit+ 
cells were not available, the present study included periodical monitoring of erythrocyte 
and nucleated blood cell repopulation of recipient mice during a 1 year period. 
Nucleated blood cell chimerism was measured by countil)g Y-chromosome-positive 
cells. Although this method involv~s manual counting of the cells, it has the advantage 
that actual ratios of donor- and host-type cells are measured. These values are more 
accurate than other parameters for repopulation capacity, such as the percentage of cells 
with donor-type Ly5 antigen, which is not expressed on erythroid cells [Okada" et aL, 
1991], or the relative quantity of donor and recipient hemoglobin types [Orlie et aI., 1993], 
which only provides a relative measure for chimerism and is not single-celr'based. In 
addition, our study is the first in which serial dilutions of Kit+, Kit-, and unfractionated 
BM cells were transplanted to estimate the enrichment of immatur.e ceJls in the sorted 
fractions. 
Results of the transplantation experiments demonstrated that the. Kit+ fractions were 
25- to 100-fold enriched for long-term repopulating cells as compared to unfractionated 
BM. In addition, the Kit expressing subsets contained short-term repopulating cells, 
since lethally irradiated recipients th.at were transplanted with Kit+ cells survived the 
initial cytopenic phase, and showed high percentages of donor-type P.I;J cells within a 
few weeks after transplantation. In the Kit- subsets we only found high percentages of 
short-term repopulating cells for the red blood cell lineage. However, it is possible that 
we missed the short-term repopulation of white blood cells, which have a much shorter 
life span than red blood cells, and. are likely to have disappeared before the first 
timepoillt examined. 
Repopulation with donor-type red blood cells reached stable levels sooner than 
nucleated blood cell repopulation. After transplantation with the appropriate cell 
numbers, stable chimeras in which the red cell lineage was completely repopulated by 
donor-derived erythrocytes were formed within 10 weeks. The percentage of donor-type 
nucleated blood cells of these same mice ranged from 20 to.1 00%, depending on the 
number of cells that were transplanted, and reached stable levels at variable time points, 
ranging from JO to 30 weeks after transplantation. Higher and more rapid repopulation 
by donor-type red blood cells as compared to non erythroid cells is a common finding in 
transplantation experiments in mice with defects in erythropoiesis, and indicates a 
selective advantage of the production of normal over defective erythrocytes [Barker ct al.. 
19881 [Nakano et aI., 1989] {Barker et al.. 1991J [Van den Bos el a1., 19931 [Van den Bos el aI., 1994] 
[Van der Loo et al., 1994]. 
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Similar to what we have recently shown for human SCF on rhesus monkey BM {De 
long et a1.. 1995]. incubation of mouse BM cells with biotinylated SCF results in staining 
of immature hemopoietic cells as well as differentiating progenitors. Selection of Kit+ 
cells after incubation with biotin-SCF yielded fractions with significantly (2- to 3-fold) 
higher frequencies of c1onogenic cells than obtained after staining with ACK-2. It is not 
certain whether this dissimilarity also occurs at the level of LTRA cells, as a factor 2-3 
difference is too small to result in distinctly deviating S-curves showing donor-type 
nucleated blood cell repopulation (figure 4.5). Since no effect of cell staining with 
biotin-SCF or ACK-2 on colony formation or repopulation capacity was found, the 
difference betwe<;:n the fractions may be caused by a different composition of the biotin-
SCFi' and the ACK-2+ populations. This might be reflected in the distinct staining 
patterns of biotin-SCF and ACK-2 on BM (figure 4.1), and the different light scatter 
[Bertoneetlo et at., 1985] and Rhl23 retention properties of the biotin-SCF+ and ACK-2+ 
fractions [Visser eJ aI., t993]. Moreover, it is possible that part of the ACK-2+ cells 
represent a Kit- fraction with ACK-2 bound to Fe receptors. Additionally,. the 
percentage of cells that were scored as lymphoid based on morphological criteria was 
significantly higher in the ACK-2+ than in the biotin-SCF+ fraction (not shown). 
Similar to previous reports [Okada et al.. 1991) we have not detected high frequencies of 
cells expressing lymphocyte markers in the ACK-2+ BM subset. It is possible that the 
markers used were not directed against the lymphocyte subset that binds ACK-2.· An 
alternative possibility is that ACK-2 binds to a subset of immature lymphocyte 
precursors that do not yet express these markers, as has been reported for anti-Kit 
antibodies on murine and hUinan cells fMalsuzaki et a\., 1993J [deCaslro et ai., 1994]. If this is 
the case. it \vould be interesting to determine whether these cells express an isoform of 
Kit that is recognized by ACK-2, but does not bind SCF. 
In primate BM .immature and more differentiated progenitors have been shown to 
differ in their level of Kit expression [De long et aI., 1995]. It has also been suggested that 
the KitloW fraction contains the most primitive. dormant progenitors [Katayama et ai., 1993] 
{Ogawa et aI., 1994]. For this reason it will be of interest further to dissect BM subsets on 
the basis of Kit expression' levels, combined with additional parameters such as 
expression of Sca-l [lkuta and Weissman, 1992] [Okada et aI., 1992J. CD34 [Krause et aI., 1994J, 
or Flk-2 [Visser et a!., 1993} [Orlie et al.. 1994], and differences in staining levels of Hoechst 
33342 [Baines and Visser, 1983], wheat germ agglutinin (WGA) [Plocmacher et aL, 1993], or 
Rhl23 [Ploemachcr and Brons, 1988] [Plocmacher and Brons, 1989] to separate long-term 
repopulating cells from those responsible for shorHenn reconstitution of individual cell 
lineages. 
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CHAPTER 5 
FDC-P1 cells as a model to examine 
differential binding of stem cell factor (SCF) and 
anti-Kit antibodies to hemopoietic cells 
Marg O. de Jong, Yvonne \Vesterman, Marti F.A. Bierhuizen, Henk Rozemuller. 
Jan W.M. Visser, Gerard Wagemaker, and Albertus W. Wognum 
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5.1 ABSTRACT 
Murine bone marrow c~lls show differential staining with the anti-Kit antibody ACK-2 
and with biotinylated stem cell factor (SCF): a higher percentage of the cells reacts with 
ACK-2 than with biotin-SeF. To examine this,difference, Kit expression was studied on 
two sublines of the murine FDC-PI cell line, which respond to interleukin-3 (IL-3) and 
SCF, respectively. Although ACK-2 bound to cells from the IL-3 responsive FDC-
PI(IL-3) subline, which demonstrated that Kit was expressed, SCF did not induce 
detectable proliferation of these cells. Moreover, no or very low fluorescence signals 
were found using FACS analysis after incubation of FDC-PI (IL-3) cells with biotin-
SCF. In contrast, FDC-PI(SCF) cells showed specific staining with ACK-2 as well as 
biotin-SCF, resulting in fluorescence signals that were approximately 3-fold (for ACK-2) 
or 40-fold (for biotin-SCF) higher than those of the FDC-PI(lL-3) cells. Since the 
differential binding of biotin-SCF and anti-Kit could be caused by differences in receptor 
structure, we studied c-kit RNA expression in FDC-PJ(IL-3) and FDC-PI(SCF) cells by 
reverse transcriptase polymerase chain reaction (RT-PCR). \Ve examined expression of 
the regions of the c-kit gene that encode for t~e SCF binding-site, the putative 
dimerization site of Kit monomers, and the KitA isoform that is the result of alternative 
splicing. Qualitative differences were not found between the sublines, but the FDC-
PJ(SCF) expressed 5-9-fold more c-kit RNA than the FDC-PJ(lL-3) cells. Further 
examination of Kit proteins by immunoprecipitation resulted in detection of cell surface 
expression of the 125-135 kD as well as the 160-165 kD form of Kit on both FDC-PI 
sublines. Similar to tHe c-kit RN,A expression, a higher expression of Kit proteins was 
found on the FDC-PI (SCF) than the FDC-PI (IL-3) cells. Taken together, our RT-PCR 
and immunoprecipitation results show only quantitative differences between FDC-Pl(IL-
3) and FDC-PI(SCF) cells. The discrepancy between staining with anti-Kit antibodies 
and biotin-SCF may be caused by the requirement for a minimum number of Kit 
monomers present on the cell surfftce to enable efficient dimerfzation of Kit molecules to 
form high affinity SCF receptors. 
5.2 INTRODUCTION 
Stem cell factor (SCF), also known as Kit ligand, mast cell growth factor, or Steel 
factor. is a growth factor that acts on immature hemopoietic cells [Anderson et al., 1990] 
(Huang ct al.. 1990] [Martin et al.. 1990] [Zsebo et aI., 1990a] lZscbo ct al.. 1990b]. SCF exists in 
transmembrane and soluble forms [Anderson et a1., 1990]. The receptor for SCF, Kit 
(CD 117), is encoded by the c-kit gene. Kit is a transmembrane glycoprotein, a member of 
the tyrosine kinase receptor family {Yarden and Ullrich, 1988] that includes the receptors for 
macrophage-colony stimulating factor (M-CSF) and platelet derived growth factor [Chabot 
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et ai., 1988]: These receptors have five extracellular immunoglobulin-like domains and a 
bisected intracellular tyrosine kinase domain [Hanks et ai., 1988J [Majumde~ et ai., 1988J. 
Expression of Kit has been found on 1--4% of bone marrow (BM) cells [Lerner et a1., 
1991J [Papayannopoulou et ai., 1991] [De long et ai., 1995] [De long et aI., 1996J (chapter 4 and 
chapter 6). A nonfunctional c-kit gene product, caused by a mutation at the W 
(dominant white spottiJlg).locus, which encodes for Kit [Chabot et ai., 1988] [Geissler et ai., 
1988], results in defective hemopoiesis in mice [Hayashi et al.. 1991J. Transplantation studies 
showed that the ,most immature BM cells express Kit, as Kit+ cells were able to 
repopulate 'recipient mice, whereas Kit- cells were not [Okada et ai., 1991] [lkuta and 
Weissman, 1992] [Okada et, ai., 1992] [Odic et ai., 1993] [De Jong et aI., 19961 (chapter 4) . 
. Moreover, following injection of mice with neutralizing anti-Kit antibodies, almost all 
progenitor cells disappeared from the BM {Ogawa et ai., 19911. These results, combined 
with thC? in vivo and in vitro effects of SCF on hemopoietic progenitor cells [Broxmeyer et 
ai., 1991] [McNicce et a!., 1991] [1 ... Ietcalf and Nicola, 1991J [Andrews et ai., 1992J [Bodine et aI., 1993J, 
demonstrate the important roles of Kit and SCF in th~ development of hemopoietic cells. 
In previous studies we observed qualitative and quantitative differences between Kit+ 
mouse BM cells stained wilh biolin-SCF, and Kit+ cells stained wilh the anti-Kit anlibody 
ACK-2 [Visser el al., 1993] [De long et aI., 1996] (chapter 4). A larger fraction of BM cells 
stained with ACK-2 than with biotin-SCF. Similar staining differences between biotin-
SCF and anti-Kit antibodies were found for human BM cells [Wognum et aI., 1996J. These 
differences do not appear to be caused by a'higher sensitivity of anti-Kit th~U1 biotin-SCF 
staining, as the fluorescence signals of cells stained with biotin-SCF were comparable to 
those of cells stained with anti-Kit. 
Because of the low frequency of Kit+ cells in BM·, it is difficult to isolate sufficient 
numbers of Kit+ cells to exainine the differential bind!ng of anti-Kit and biotin-SCF. In 
this study we examined this difference using the murine early myeloid f~ctor-dependent 
cell line FDC-P 1 [Dexter et ai., .1980J [Welham and Schrader, 1991], FDC-Pl cells are dependent 
on IL-3 or GM-CSF for growlh [Hapel et aI., 1984], and although SCF synergizes with 
these growth factors to induce proliferation of the cells, FDC-P 1 cells that are maintained 
with IL-3· or GM-CSF do not respond 10 soluble ·SCF alone [Caruana et aI., t993]. 
However, as shown by others [Caruana et aI., 1993] as well as in this report, the cells can be 
adapted to grow in SCPo Here we present results that show differences between Kit 
expression on Ihe original FDC-PI(IL-3) cell line and ali SCF responsive subline, FDC-
PI (SCF). Examinalion of Ihe cell surface expression of Kil on Ihese cells demonslrated 
Ihat, although the cells of both sublines showed similar reaclivity with ani i-Kit antibodies, 
there were large differences with respect to the ability to bind biotinylated SCF. To 
further examine this phenomenon, we compared expression of c-kit RNA and Kit 
proteins in both sublines. 
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5.3 MATERIALS AND METHODS 
Bone marrow cell preparation and WGA staining 
Mouse BM was obtained by flushing excised femora and tibiae from 7 weeks old 
BCBA.(C57BLlLiARij x CBAlBrARij)FI mice (TNO. Rijswijk. The.Netherlands) with 
Hepes-buffered (10 mM, pH 6.8-7.1) Hanks Balanced Salt Solution (without phenol 
red; Gibco BRL, Paisley, Scotland) with an osmolarity of 300-305 mOsmlkg (Hanks' 
Hepes). Single cell suspensions were obtained by filtration through a six-layer nylon 
sieve and kept on melting ice until use. 
Cells were incubated for 10-40 min on ice in Hanks Hepes containing 0.5 Ilg wheat 
germ agglutinin labeled \yith fluorescein isothiocyanate (WGA-FITC; Polysciences, 
Warrington PA, USA) per 60x 106 cells. The cells were then washed in Hanks Hepes. 
Cell line 
Cells from the interleukin-3 (IL-3) dependent FDC-PI cell line, FDC-PI (IL-3) cells, 
were grown in RPMI 1640 supplemented with 10% (vollvol) heat inactivated fetal calf 
serum, 0.1 mM Il-mercaptoethanol, 2 mM L-glutamine, and 10% (vollvol) conditioned 
medium of the IL-3 producing WEHI-3B cell line. Cultures were maintained at 37'C in a 
hlimidified atmosphere of 5% C02 in air. A subline was established by adding SCF (final 
concentration 10 nglml of E. coli-expressed recombinant rat SCF, kindly provided by 
AMGEN Ltd., Cambridge, UK) to the culture medium, and gradually decreasing the 
amount of WEHI·conditioned medium with each passage, Ulltil no WEHI·conditioned 
medium was present. Cells from this subline, referred to as FDC·Pl(SCF), were then. 
cultured in medium containing 10 nglml rat SCF (AMGEN) or Chinese hamster ovary 
(CHO) murine SCF (kindly provided by Genetics Institute, Cambridge MA, USA). 
Biological activity assay 
To determine the'ability of IL-3 and SCF to stimulate proliferation of FDC-PI(IL-3) 
and FDC-PI(SCF) cells, 104 cells per well of 96-well microtiter plates (Falcon 3072; 
Becton Dickinson Labware, Lincoln Park NJ, USA) were cultured in 200 ~tl culture 
.medium containing serial dilutions of growth factor. Cells were cultured for 3 days, after 
. which the cell content of each well was determined by staining the nu"lei with propidium 
iodide (PI) and measuring the fluorescence intensity. For this purpose, 0.5% (vollvol) 
Triton X-IOO and 0.002% (wtlvol) PI were added to the wells. The microtiter plates were 
read in a Leitz Diavert inverted microfluorometer using green excitation by a halogen 
lamp. Alternatively, a commercial proliferation kit (CellTiter 96 AQueous non-radioactive 
cell proliferation assay, Promega, Madison \VI, USA) was used to determine the viablt;! 
cell content of each well similar to the colorimetric assay described by Mosmann 
[Mosmann, 1983J, but yielding a soluble reaction produc!. A mixture of 3-(4,5-
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dimelhyllhiazol-2-yl)-5-(3-carboxymelhoxyphenyl)-2-(4-sulphophenyl)-2H-lelrazolium 
(MTS) and phenazine melhosulphate (PMS) was added to Ihe wells according to the 
manufacturer's instructions. After 4-18 hours the quantity of formazan, formed by 
conversion of MTS by dehydrogenase enzymes in metabolically active cells, was 
measured as the amount of 450 nm absorbance in a Bio-Rad modelA50 microplate reader 
(Bio-Rad, Hercules CA, USA). 
labeling of SCF with biotin 
SCF was biotinyl.led using biotin-N-hydroxy succinimide ester (NHS-Biotin, Pierce, 
Rockford IL, USA; or Sigma, st. Louis MO, USA) as described previously (chapter 4 
[De Jong et aI., 1996]). The protein concentration after biotinylation was determined using I 
the BCA Micro Protein Assay (Pierce). The presence of biotinylated SCF was checked by 
spotting 1 111 of stepwise dilutions of the samples directly on a nitrocellulose membrane, 
followed by immuno-enzymatic staining of the membrane with streptavidin-alkaline 
phosphatase and 4-Nitro Blue Tetrazoliumchloride 5-Bromo-4-Chloro-3-Indolyl 
Phosphate (NBT BCIP) development. The ability of biotin-SCF to stimulate proliferation 
of FDC-PI(SCF) cells was examined. Moreover, to test the efficiency of the 
biotinylation, biotin-SCF was adsorbed onto streptavidin-agarose beads (Sigma), and the 
amount of biological activity that remained in the supernatant ,was determined. Biotin-
SCF was stored at -20'C or -80'C in the presence of 0.02% (wt/vol) sodium azide. 
Immunocytochemical staInIng and flow cytometry 
Cells (106 per sample) were stained with anti-Kit antibodies or.with biotin-SCF in 50 
III Hanks Hepes, containing 5% (vol/vol) fetal or newborn calf serum and 0.02% 
(wt/vol) sodium azide (Hanks' Hepes/Serum/Azide, abbreviated as HSA). Incubation 
with the anti-Kit antibody ACK-2 [Nishikawa et aI., 199tJ (final concentration 5.7 Ilg/ml) 
(kindly provided by Dr. K. Rajewski, Genetics Institute, Cologne, Germany) was 
performed fQr 30 min on ice. The samples were then stained with PhycoErythrin- or 
FITC~conjugated goat anti-rat mAb (GARa-PE 1:200,(vollvol), GARa-FITC 1:100 
(vol/vol), both from TAGO, Burlingame CA, USA) for 30 min on ice. After each 
incubation the samples were washed in HSA. As a negative control, only HSA was used 
in the first incubation. 
Alternatively, cells were incubated with biotin-SCF (10 nM) for 60 min at room 
temperature. Similar results were obtained by overnight incubation on ice. Subsequently, 
the cells were stained with PE- or BODIPY- conjugated streptavidin (Str-PE or Str-
BODIPY, both 3.3 Ilg/ml final concentration; Molecul.ar Probes, Eugene OR, USA) for 
15-30 min on ice. After each incubation the samples were washed in HSA. Specificity of 
binding ofthe biotin-SCF samples was delermined by incubating the cells with biotin-
SCF in the presence of a 100-fold molar excess of unbiotinylated SCF or in the presence 
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of ACK-2, which is a blocking antibody [Nishikawa et a1., 1991]. As a negative control, 
only HSA was 'used in the first incubation. 
Samples were analyzed using a FACScan (Becton Dickinson, San Jose CA, VSA) or 
RELACS (Rijswijk Experimental Light Activated Cell Sorter, TNO, Rijswijk, The 
Netherlands) flow cytometer .. Cells were illuminated with the 488-nm line of an argon ion 
laser. Green FITC or BODIPY fluorescence was measured through a 530-nml 30-nm 
bandpass mter,'orange PE fluorescence was measured through a 57S-nml26-nm or a 
585-nml42-nm bandpass filter. 
RNA Isolat/on 
RNA was isolated by extraction with an acid guanidinium thiocyanate-phenol-
chloroform mixture [Chomczyns~i nnd Sacchi, 1987J. Briefly, 4x I 06 cells were lysed by 
adding 2.5 ml RNA lysis buffer (4 M guanidium thiocyanate, 25 mM sodium citrate, pH 
7.0, 10 mM Il-mercaptoethanol, 0.5% sodium lauroylsarcosinate) and 12.5 ).!g 5S 
ribosomal RNA from E. coli (Boehringer Mannheim, Mannheim, Germany) as carrier, 
and mixing vigorously. A control sample without cells was treated the same. After 5 min 
incubation at room temperature, 125 ill 2 M sodium acetate pH 4, 2.5 ml of water-
saturated phenol, and 500 ).!I chloroform were added and mixed sequentially. Samples 
were incubated for 10 min on ice, then spinned for 5 min at 5000 rpm at 4°C. The water 
phase (top layer) was transferred to another tube, and 2 volumes of 100% ethanol were 
added. Samples were aliquotted and stored at _80°C, 
Reverse transcriptase polymerase chain. reaction (RT-peR) 
RNA was precipitated with ethanol, and samples containing RNA from 0.S-2.0x106 
cells were dissolved in 'diethyl pyrocarbonate (DEPC) treated water (15 Ill). RNA was 
pretreated for 7 min at 95'C, and chilled on ice. cDNA was synthesized from RNA in 100 
III PCR buffer (50 mM KCI, 1.5 mM MgCI2, 10 mM Tris-HCI, pH 9.0) containing (final 
concentrations) I mM dNTPs (Pharmacia Biotech, Vppsala, Sweden), 5 ).!M random 
hexamers (Promega, Madison WI, VSA), 2 V/).!I ribonuclease inhibitor (RNasin, 
Promega) and 10 Vlml Moloney Murine Leukemia Vims reverse transcriptase (ML V -RT, 
Promega) for 1 hour at 3TC.RT reaction was stopped and RNA/cDNA hybrids were 
denatured by heating the samples for 10 min at 95'C and quickly chilling on ice. RT 
samples were kept at -20'C. 
Custom synthesized c-kil DNA primers were made by Pharmacia Biotech 
(Roosendaal, the Netherlands) (table 5.1). The location of the primers was selected in 
such a way that the PCR product of the primersets spanned introns. Primerset A was 
designed to yield PCR products that include exons 3, 4, and 5, which encode for the 
second and third extracellular immunoglobulin-like protein domains [Gokkel et aI., 1992J. 
The PCR product of primerset B included exons 6-9 which encode for the fourth and 
fifth protein domains {Gokkel et aI., 1992J. Using the same sense primer as in primerset B 
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and an antisense primer that is specific for KitA [Hayashi et aI., 1991], we checked the 
presence of this splice-variant of Kit (primerset C). As a control we used primers for 
human p-actin {Ponte et ai., 1984J that also react with mouse p-actin (primerset D). The 
primers were purified on a Sep·Pak CIS column (Millipore, Bedford MA, USA) 
according to the manufacturer's instructions, and freeze dried. The primersets were 
dissolved in water to a final concentration of to JlM. 
table 5.1 
DNA Primers that were used in the polymerase chain reaction 
primer set a hcaUon b strand sequence (5'-3') 
EUR·MJOl A 409 - 430 sense CAAAGAAGACAGCGACGCGCTG 
EUR·MJ02 A 837 - 859 antisense GCGTCTCCTGGCGTTCATAATTG 
EUR·MJ03 B/C 1064 - 1085 sense CCCGAGCACCAGCAGTGGATAT 
EUR·MJ05 B 1580 - 1601 antisense GCAGCGGCGTGAACAGAGTGTG 
EUR·MJ04 C 1566 - 1578 c antisense GCCTGGATTTGCTctttgttgttac 
EUR·MB6 D 741-760 sense CTGGACTTCGAGCAAGAGAT 
EUR·MB7 D 1152 - 1171 antisense TCGTCATACTCCTGCTTGCT 
a primersets A, B, and C are specific for c-kil, primerset 0 for mouse p-aclin. 
b nucleotide numbers according to Qiu et al. (Qiu "et aI., 1988] for c-kit and Tokunaga et al. 
[Tokunaga et aI., 1986) for mouse p-aclin. 
C this primer includes the 12 additional bases, Indicated with small letters, that are present in 
the KitA [Reith et aI., 1991J [Gokkel et aI., 1992) and not in the Kit isolorm. 
Non-radioactive peR was carried out in a total reaction volume of 100 JlI (containing 5 
~I RT sample) in PCR buffer containing primers at 0.5 ~M, dNTPs at 100 ~M, and 2.5 
U Taq polymerase (Pharmacia Biotech). Starting with I min at 94°C, PCR was carried 
out for 30 cycles in a Perkin Elmer DNA Thermal Cycler (Perkin Elmer Cetus, 
Uberlingen. Germany). Each cycle consisted of denaturation at 94°C for 1 min, annealing 
at 62°C for I min, and extension for 2 min at 72°C. Amplified DNA was detected in 1.5-
2% (wtlvol) agarose gels using ethidium bromide (0.5 ~g/ml). 
Radioactive PCR was carried out similarly, with 2 ~Ci (74 kBq) [CX·32p]ATP 
(Amersham, Buckinghamshire, England) per sample, but using the RT samples I: 10 
diluted compared to the non·radioactive PCR. Amplified DNA was then electrophoresed 
in 5% (wtlvol) acrylamide/ urea gels. Gels were dried under vacuum at SO°C for 60 mili 
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in a gel dryer (Bio-Rad Laboratories, Hercules CA, USA), and exposed to a blue 
sensitive CEA Medical X-ray screen (Cea Corp., Strangn.s, Sweden) for 4 h at room 
temperature. Additionally, the amount of radioac~ivity in the different bands was 
measured in a PI.lOsphorimager llsing ImageQuant software (Molecular Dynamics, 
Sunnyvale CA, USA). Titration of the number of PCR cycles showed that amplification 
was still within the linear range after 20 cycles, so this number of cycles was used for 
semi-quantitative analysis of PCR products. 
Blotlnylatlon of cell surface proteins and Immunopreclpltallon 
Cells were biotinylated with biotin-N-hydroxy succinimide ester (NHS-Biotin, Sigma) 
similar to the method as described by Cole et al. ICoie er aI., 1987J. Briefly, cells were 
washed 3x wilh ice-cold PBS and once with 50 mM borate buffer pH S.3 (the osmoJarity 
of the buffers was kept at 300 mOsmll to prevent cell lysis). A suspension of biotin was 
added to the cells (150 ~g biotin to 20xlO6 cells), and biotinylationwas allowed to take 
place for 30 min at room temperature in the dark. The cells were then washed twice with 
50 mM Tris, pH S.3, 150 mM NaCI to remove and inactivate the remaining NHS-Biotin. 
After waslling twice with ice-cold PBS, the cells were resuspended in 0.2 ml icc-cold 
PBS in eppendorf tubes, to which O.S ml of ice-cold lysis buffer was added. Lysis buffer 
consisted of PBS containing 0.625% (vol/vol) NP-40 (ICN Biomedicals, Aurora OH, 
U'1A), and the protease inhibitors aprotinin (20 ~g/ml), leupeptin (20 ~g/ml), and 
Pefabloc (I mM) (all from Boehringer Mannheim). Under occasional vortexing the 
sampfes were incubated on ice for 45 min. Extracts were cleared by centrifugation in an 
Eppendorf centrifuge for JO min at 4°C at maximum speed. Supernatant was collected 
and ~tored at -SO'C. 
After preclearing of the Iysates with pre-washed protein G beads (Gamma bind G 
Sepharose beads, Pharmacia Bio'tech; or ImmunoPure Immobilized Protein G, Pierce, 
Rockford IL, USA), Kit was immunoprecipitated by incubation for 2 hours or overnight 
at 4'C, under rocking, with protein G beads to which.ACK-2 had been bound. Samples 
were centrif~ged in the microfuge and pellets were washed three times in 1 ml PBS 
containing 0.5% (vol/vol) NP-40, I mg/ml bovine serum albumin (BSA), and protease 
inhibitors as described above. Pellets were then washed once in I mt of this buffer 
without BSA, and resuspended in 2x sample buffer for SDS-PAGE (Ix sample buffer 
consists of 10 mM Tris-HCI pH 6.S, 10% glycerol, 2% SDS, I mM EDTA, 5% p-
mercaptoethanol and 0.001% bromophenol blue). Bound proteins were eluted from the 
bends by boiling for 5 min, and beads were removed by centrifugation of the samples in 
the Eppendorf centrifuge at maximum speed and 4'C for 2 min through 0.45 ~m filters 
(Millipore). 
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SDS-PAGE and Western blot analysis 
Samples were electrophoresed by SDS-PAGE.(stacking geI4%;.separating gel 7.5% 
containing 5 III NP-40 per 80 ml) in the mini-PROTEAN II system (Bio-Rad 
Laboraiories). Proteins were blotted onto nitrocellulose filters (Schleicher and Schuell, 
Dassel, Germany) in 2 hours using an electrical field in a Trans~Blot cell (Bio-Rad 
Laboratories). Blots were rinsed in Tris-buffered saline solution (TBS; containing 10 mM 
Tris, 150 mM NaCI, pH 7.4), and blocked overnight in TBS containing 0.05% (vol/vol) 
Tween-20. Incubation with streptavidin-peroxidase (Str-PO conjugate, Boehringer 
Mannheim) was performed in TBS containing 0.02% (vol/vol) Tween-20 for I h, after 
which the blots were washed 4 times in TBS-Tween and twice in TBS. The membranes 
were incubated with chemiluminescence reagent (Dupont NEN Resea'rch Products, 
Boston MA, USA; or Boehringer Mannheim) for I min at room temperature, carefully 
dried with a tissue, put under an overhead sheet in a film cassette, and exposed to 
REFLECTION'" autoradiography film (Dnpont NEN) for 1-120 min. 
5.4 RESULTS 
Kit expression on murine 8M cells 
Staining of mouse BM cells with the anti-Kit an'tibody ACK-2 or with biotin-SCF 
showea a di,fference between the percentage of ACK-2+ cells and biotin-SCF+ cells, as is 
also described in chapter 4 [De Jong et aI., 1996]. This discrepancy is clearly shown in the 
WGA+ fraction (figure 5.1), which consisted of one third of the BM cells and 
contained all Kit+ cells. Whereas 1.21 ± 0.29% (average ± SD of 7 different 
experiments) of nucleated mouse BM cells stained specifically with biotin-SCF, the 
percentage of ACK-2+ cells (2.10 ± 0.49%) was significantly higher (paired t-test; p < 
0.01). These differences were not caused by a higher sensitivity of anti-Kit than biotin-
SCF staining, as the fluorescence signals of cells stained with biotin-SCF were 
comparable to those of cells stained with anti-Kit. After incubation of BM cells with 
biotin-SCF in the presence of an excess of unbiotinylated SCF the fluorescence signal of 
the cells \Va's comparable to that of unstained control ceils, which demonstrated that 
staining with biotin-SCF was specific (not shown). Moreover, as has also been reported 
previously for SCF binding [Nishikawa ct aI., 1991], binding of biotin-SCF to the cells was 
blocked by ACK-2 (not shown), which demonstrated that biotin-SCF bound to the same 
receptors as ACK-2. 
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figure 5.1 
fluorescence intensity (a.u.) 
Kit (PE) 
Kit expression on WGA-positive mouse bone marrow 'cells. 
Cells were double-stained with WGA-FITC and either ACK-2 and PE-conjugated anti-rat 
antibodies, or blotln-SCF and PE-conjugated str,eptavidin. Kit expression was analyzed 
Inside a window based on WGA·FlrC fluorescence (Indicated in A). Histograms represent 
PE fluorescence (In arbilrary unils) 01 WGA·posilive cells, incubated with AGK-2 (8) or 
blot!n·SCF (C). Vertical markers indicate the threshold above which the cells were 
designated Kit-positive. 
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figure 5.2 
Biological activity of IL-3 and SCF on different sublines of the FOC-P1 cell line. 
Gells were incubated with serial dilutions of IL-3 (A) or SGF (8) for 3 days in 96-well 
microliter plates, after which the propidium iodide (PI) fluorescence of the nuclei was 
measured as an Indication of the cell content of each well. Open circles represent FOC-
P1 (IL-3) cells, closed circles are FDC-P1 (SCF) celts. Each circle represents the mean PI 
fluorescence (in arbitrary units) of 4 di.fferenl wells. Standard deviations are indicated. 
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Induction of FOC-PI cell proliferation by SCF 
To furiher examine Kit expression, we used an SCF responsive subline from the IL-3 
dependent cell line FDC-P I (IL-3), which was raised by gradual weaning of FDC-PI (IL-
3) cells from IL-3 to SCF containing medium. The ability of IL-3 to stimulate 
proliferation of this FDC-P I (SCF) subline was comparable to. the effect of IL-3 on the 
original cell line (figure 5.2 A). Whereas the FDC-PI(IL-3) cells did not show 
detectable proliferation in the pre.sence of SCF (up to 156 ng/m!), SCF induced 
proliferation of the FDC-P I (SCF) subline in a dose-dependent manner at concentrations 
higher than I nglml (figure 5.2 B). 
Cell surface expression of Kit on FOC-PI cells 
An explanation for the apparent lack of SCF responsiveness of the FD.C-P I (IL-3) cells 
might be absence of Kit on the cell surface of the majority of these cells. Alterqatively, it 
is possible that the FDC-PI(IL-3) cells express an SCF receptor with an impaired ligand 
binding or activation capacity. To distinguish between these possibilities, FDC-PI (IL-3) 
and FDC-PI(SCF) cells were stained with ACK-2 or biotin-SCF. ACK-2 bound to FDC-
Pl(IL-3) as well as FDC-Pl(SCF) cells (figure 5.3). The average Kit expression on 
FDC-PI(SCF) cells was approximately 3-fold higher than on FDC-PI(IL-3) cells as 
deduced from the differences in fluorescence intensities (table 5.2). Biotin-SCF was 
barely detectable on FDC-PI(IL-3) cells, but showed strong binding to FDC-PI(SCF) 
cells, resulting in a fluorescence interisity of FDC-P I (SCF) cells that was approximately 
40-fold stronger than that of the FDC-PI(lL-3) cells (figure 5.3 and table 5.2). 
table 5.2 
Kit expression on the FDC-P1 sublines. 
mean fluor. intensity mean fluor. intensily 
fluor. fluor. 
subline ACK-2 a control b index C b-SCFa control b index C 
FDC-P1 (tL-3) 47.8 10.5 3.6 9.4 7.1 0.3 
FDC-P1 (SCF) 86.8 6.8 11.8 73.0 5.4 12.4 
a Cells were incubated with ACK-2 and GARa-FITC or with biotin-SCF and StroPE. 
b Control cells were incubated only with GARa-FITC or StroPE. 
Data represent results of one of 20 experiments giving similar results. 
C flUorescence index is calculated by the following formula: 
mean flUorescence test sample - mean flUorescence control 
flUorescence index = 
mean fluorescence control 
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Biotin-SCF binding to the cells was not limited by low concentrations of the labeled 
ligand, as cell staining was performed at 10 nM biotin-SCF, resulting in presentation of 
approximately 6xlO5 ligand molecules per cell. The discrepancy between ACK-2 and 
biotin-SCF staining was not caused by impaired binding of biotinylated SCF molecules to 
Kit, since the biological activity of biotin-SCF was similar to that of unbiotinylated SCF 
in proliferation assays using FDC-Pl(SCF) cells (not shown). Staining with biotin-SCF 
was specific and due to binding to Kit, as shown by incubation with biotin-SCF in the 
presence· of an excess of unlabeled SCF (figure 5.3) or in the presence of ACK-2. 
These results indicate that, although Kit protein is apparently expressed on both sublines, . 
the majority of the FDC-Pl(IL-3) cells binds SCF very weakly or not at all. 
ACK·2 biotin-SCF 
A B 
FDC-Pl (IL-3) 
10' 10~ 
C 
FDC-Pl (SCF) 
10' 10' 102 
fluorescence intensity (a.u.) 
figure 5.3 
Kit expression on different sublines of the FDC-P1 cell line. 
FOC·P1(IL·3) (A and B) and FOC·P1(SCF) (C and 0) cells were stained with anti-Kit 
antibodies 9r blotlnylated SCF. Fluorescence histograms of cells, incubated with anti-Kit 
antibodies (bold lines) are shown In the left panels, histograms of blotin-SCF stained cells 
(bold lines) In the right panels. Controls Include cells that were only stained with 
fluorescence conjugated second layer antibodies Or streptavldin (thin solid lines), and 
cells that were incubated with biotin-SCF In the presence of a 1 DO-fold molar excess of 
unblotlnylated SCF (broken lines). 
RNA .expresslon of a-kit 
To examine whether the differential binding of biotin-SCF and anti-Kit could be 
caused by variations in structure of the c-kit gen'e product, e.g. as a result of alternative 
splicing, we studied c-kit RNA expression in FDC-PI(IL-3) and FDC-Pl(SCF) cells. 
Using RT -PCR and specific primers (table 5.1), expression of different domains in the 
extracellular part of Kit was examined, as shown schematically in figure 5,4 A. We 
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figure 5.4 . 
PCR analysis of c-M/ RNA expression in different sublines of the FDC-P1 eel[ line. 
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Total RNA was isolated from each subline, reverse transcribed and PCR-amplified using 
specific primers for different parts of c-kit (primersets A, B and C) or b actin (pr/merset D). 
A shows a schematic representation of the extracellular domain of Kil in which the five 
immunoglobulin-like domains [Gokkel et al., 1992] are Indicated by Roman numerals. Bold 
lines represent the parts of the protein of which RNA expression is studied using the 
different primersets as indicated. The position of the four additional amino acids of the 
KitA splice variant Is indicated with *. . 
Band C show the results of analysIs of the non-radioactive and radioactive RT -PCR-
products on 1.5% agarose gel and 5% acrylamide/urea gel, respectively. As indicated In 
table 5. t, primerset A-D yield fragment sizes of 451,537.515 and 431 bp, respeclively. 
Lanes 1.4.7.1.0 PCR controls; lanes 2,5,8,11 FDC·P1(IL·3); lanes 3,6.9.12 
FDC·P1 (SCF). M = size markers (bp). 
checked for deviations in RNA expression of Kit protein domains that are essential for 
binding of SCF (using primerset A) and for dimerization of Kit molecules (primerset B) 
(Gokkel et al .. 1992J (Blechman et al .. 1995J. In both sublines ofFDC·PI a specific PCR 
product of the appropriate size was detected with each of these primersets, using non-
radioactive as well as radioactive PCR methods (figure 5.4 Band C,.respectively) .. 
In the region that was amplified using the primerset for,the dimerization site also lies 
the 12 bp sequence that is characteristic for KitA, an isoform o~ Kit that contains 4 extra 
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amino acids within the extracellular domain as a result of alternative splicing [Hayashi et al.. 
1991] [Reith et aI., 1991). We used aKitA-specific primer'(primerset C) to examine if 
expression of this splice variant of the receptor might playa role in the difference between 
the sublines. In addition to the standard non-radioactive PCR procedure (figure 5.4 B), 
radioactive PCR followed by analysis of the PCR products on acrylamide/ urea gels 
(figure 5.4 C) was used to distinguish between the Kit and KitA bands that result from 
PCR with primerset B. Using these methods, we found that Kit as well as KitA isoforms 
of the receptor were present in both sub lines. 
Although the level of expression of fl-actin RNA (primerset D) was similar in the 
FDC-PI(IL-3) and FDC-PI(SCF) sublines, results of RT-PCR with the c-kit primersets 
indicated that c-kit RNA expression was higher in the FDC-PI (SCF) than in the FDC-
Pl(IL-3) subline. The amounts of radioactivity in the different bands after radioactive 
PCR (figure 5.4 C) were quantitated using a Phosphorimagec Comparison of the 
different bands showed that the expression of c-kit RNA in FDC-P 1 (SCF) cells was 5-9-
fold higher than in FDC-Pl(IL-3) cells (table 5.3). Similar Kit:KitA ratios were found 
in the FDC-Pl(1L-3) as in the FDC-Pl(SCF) subline (table 5.4). 
table 5.3 
Dillerences between amounts 01 PCR producl in FDC-P1(IL-3) and FDC-P1(SCF) cells. 
relative amount of radioactivity (%) a 
primerset FDC-P1(IL-3) FDC-P1 (SCF) -fold difference b 
exp.1 A 4.2 29.8 7.1 
B 6.1 49.1 8.0 
C 1.7 9.6 5.6 
exp.2 A 5_6 . 41.8 7.5 
B 5.7 50.0 8.8 
C 2.0 12.4 6.2 
a Data represent relative amount of radioactivily (see figure 5.4 C) measured in a . 
Phosphorimager, after radioactive PCR using different primersets. Amount of radioactivity 
of PCR products of primersets A, B 'and C is expressed relative to the internal control 
(primersel D), which was set at 100%. Results from two different expe.riments are shown. 
b Differences between the FDC-P1 subHnes weJe calculated by dividing radioactivity of 
PCHproducts Irom FDC-P1(SCF) cells by those Irom FDC-P1(IL-3) cells. 
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tabte 5.4 
Kit:KitA ratios of FDC·P1 (IL·3) and FDC·P1 (SCF) cells. 
exp.1 
expo 2 
cells 
FDC·P1 (IL·3) 
FDC·P1 (SCF) 
FDC·P1(IL·3) 
FDC·P1(SCF) 
relative amount of radioactivity (%) a 
Kit 
4.1 
34.2 
3.8 
38.2 
KitA 
2.3 
15.3 
2.1 
13.8 
Kit:KitA 
ratio 
1.8 
2.2 
1.8 
2.8 
a Radioactivity was measured in a Phosphorimager. Data represent relative_ amounts of 
radioactivity in the two bands that result of PCR with primerset B (see figure 5.4 e), 
relative to the internal control (primerset D), which was set at 100%. Results from two 
different experiments are shown. 
Isolation of Kit protein 
To assess possible differences in the molecular mass of the SCF 'receptor protein 
between the FDC·PI(IL-3) and FDC-PI (SCF) cells, Kit was isolated after biotinylation 
of the cell surface proteins. Lysates from biotinylated cells were -immunoprecipitated \vith 
ACK-2, separated by SDS gel electrophoresis, and transferred to nitrocellulose. Staining 
of the blots showed two specific bands in both subtines (figure 5.5). Similar as 
previously reported in murine cells {Nocka ct aI., 1989] [Nocka et al.. 1990lfTan et al.. 19901, 
these bands represent proteins of approximately 125-135 kD and 160-165 kD.It is 
possible that these represent differentially glycosylated forms of the protein [Majumder et 
al.. 1988} [Nocka et al.. 1989]. In some of the experiments there was also a faint ~and visible 
that represented a protein of approximately 105-110 kD (figure 5.5 B), which is 
comparable to the unglycosylated form of Kit [Nocka et aI., 1989}. 
These results indicated that the sizes of Kit proteins in both sublines were similar. As 
we used equal numbers of FDC-P I (IL-3) and FDC-P I (SCF) cells at the start of each 
experiment, the amount of protein that was precipitated from the FDC-PI(SCF) cells 
appeared to exceed that of the FDC-PI(IL-3) cells. This is in agreement with the higher 
RNA expression in FDC-PI(SCF) than FDC-PI(IL-3) cells. 
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figure 5.5 
Analysis of Kit proteins on cells of the FDC·P1 sublines. 
A and B represent two independent experiments. In each experiment, equal numbers of 
cells from each subline were surface· labeled with NHS·blotin. Cell Iysates were 
immunoprecipitaled with anti·Kit antibody (lanes 1 and 3), separated by SDS·PAGE and 
blotted onto nitrocellulose membranes. Biotinylated proteins were detected using 
slreplavidin peroxidase and chemiluminescence. lmmunoprecipitation controls (lanes 2 
and 4) were treated the same, but no ACK·2 was added. 
Lanes 1 and 2 FDC·Pl(IL·3), lanes 3 and 4 FDC·Pl(SCF). Molecular weight markers 
(kD) are shown at the left. 
5,5 DISCUSSION 
Kit is expressed on the majority of the FDC·PI(IL-3) ceils, as detected by staining 
with the anti· Kit antibody ACK,2 (figure 5,2) [Jacobsen et at., 19951. However, as 
demonstraled in Ihis study, the ceils show no or very low binding of biolin-SCF. Taking 
into account the detection limit of this method, these results would indicate an expression 
of less than 50-100 receptors per cell [Dc long et aI., 1992] [Wognum ~tal., 1993) [Wognum et 
at., 1994J. The deficiency of receptors is in accordance with the inability of SCF to induce 
proliferation of FDC-PI(IL-3) ceils. In contrast, cells of the FDC-PI(SCF) subline do . 
respond to SCF. These cells express higher levels of Kit RNA (5-9x), protein, and anti-
Kit (=3x) binding sites on their surface than Ihe FDC-PI(IL-3)·ceils. However, biotin-
SCF binding resulted in a 40-fold higher signal in FDC-PI(SCF) as compared to FDC-
PI(IL-3) cells. This difference is much greater Ihan can be explainedby the difference in 
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Kit expression, which suggests that SCF binding sites are not equivalent to Kit protein. 
or that not all Kit molecules are able to bind SCF. 
To examine if impaired SCF binding was caused by a defective ligand binding site in 
FDC-PI(IL-3) cells, we used RT-P€R to examine the RNA expression o(the c-kit region 
that encodes for the extracellular part of the Kit protein containing this binding site 
(Blechman el al" 1993] (Lev 01 aI., 1993]. Additionally, to check whether the differences 
between Ihe FDC-PI sub lines might be caused by a 'physical inability of the Kit molecules 
to form receptor dimers, which is essential for high affinity binding of SCF and for signal 
transduction [Blume-Jensen et aI., 1991] [Lev et aL, 1992] [Blechman et aI., 1995]. we studied the 
expression of RNA that encodes for the part of the Kit protein that contains the putative 
dimerization s!te [Gokkel et aI., ,1992] [Blechman et ai., 1995]. Using primersets that include 
either the exons that encode for the second and third, or the exons that encode for the 
fourth and fifth immunoglobulin-like domains, we found PCR products of the expected 
sizes in both FDC-PI sublines. This demonstrated Ihat RNA for the binding site and 
RNA for the dimerization site were expressed in both sublines, although there was a 5-9-
fold lower expression in the FDC-PI(IL-3) cells than in the FDC-PI(SCF) cells. 
RT -PCR was also used to check the presence of the KitA isoform of the receptor. The 
Kit and KitA isofonns, which are conserved between human and mouse, ar~ coexpressed 
in normal as well as leukemic cells [Reith et aI., 19911 [Crosier et 301.,1993] (Piao et 301.,1994]: 
Although the biological role of KitA is still unclear, it is possible Ihat the insert of four 
extra amino acids immediately upstream of the transmembrane domain I~eilh et al.. 1991] 
changes the conformation of Kit and/or its affinity for SCF. Since expre~sion of Kit as 
I well as KitA was detected in both FDC-Pl sub lines, with no significant difference 
between the Kit:KitA ratios of the FDC-PI(SCF) and FDC-PI(IL-3) cells, KitA probably 
does not play an important role in the difference between the sub lines. 
To further examine the Kit protein itself, we used immunoprecipitation. Employing 
this method, simultaneous expression of human or mouse Kit proteins of. approximately 
120-130 and 145-165 kD has been reported.(Nocka el .1" 1989] (Blume-lensen et al" 1991] 
(Reith et ai., 1991], probably representing differentially glycosylated forms of the protein 
[Majumder et 301., 1988] [Nocka et al.. 19891. However, cross-linking studies using 125I-SCF 
have shown only a complex consisting of the labeled SCF linked to the large Kit protein 
on the cell surface [Pietsch et aI., 19921 [Turner et aI., 1992) [Broudy et al.. 1993]. Therefore, it 
could be possible that the smaller form of Kit is not present at the cell surface, like the 
125 kD mutant Kit in WfW mice (Nock. el ai., 1990], or that it is incapable of binding SCF. 
Since the latter possi~ility might provide the explanation for the differences between the 
FDC-PI(lL-3) and FDC-PI(SCF) cells,we examined the Kit proteins of the two, 
sub lines. Using immunoprecipitation with anti-Kit antibodies after labeling of the cell 
surface proteins with biotin, we found two different species of Kit protein, of 
approximately 125-135'and 160-165 kD on both sublines. The FDC-PI(SCF) cells 
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appeared to contain a larger amount of Kit protein than the FDC-PI(IL-3) cells, but the 
two forms of Kit protein seemed to be present at similar ratios in both sublines. Since 
only cell surface proteins are detectable using this method, this means that both forms of 
the Kit protein are expressed on the cell surface of both FDC-P I sublines. Whether or not 
the smaller form of the protein is capable of binding SCF remains to be established. 
Taken together, no qualitative differences in c-kit RNA and Kit protein expression 
were detected, suggesting that the differences between the FDC-PI(IL-3) and FDC-
PI (SCF) cells are caused by quantitative differences of Kit expression on the cell surface 
of the FDC-PI sublines. Since expression of c-kit RNA as well as cell surface Kit protein 
,vas higher in FDC-PI(SCF) than FDC-PI (IL-3) cells, it is possible that the number of 
SCF-binding Kit molecules on the cell surface of FDC-PI(IL-3) cells is below a certain 
thresh,?ld necessary for efficient dimerization. As a consequence, no high affinity SCF 
receptors are formed on the FDC-PI(IL-3) cells so that no binding of biotin-SCF to the 
FDC-PI(IL-3) cells is detectable: This would also explain the inability of soluble SCF to 
induce proliferation of these cells. High local concentrations of membrane-bound SCF 
may facilitate Kit dimerization more efficiently than soluble SCF, which might explain 
why membrane-bound SCF can stimulate proliferation of FDC-PI(IL-3) cells whereas 
soluble SCF cannot [Caruana et al.. 1993}. Additional information about the affinity for 
soluble ligand and the number of receptors per cell might be obtained by Scatchard 
analysis IScatchard. 1949} after binding of 125I-SCF, although it is difficult to obtain 
accurate meaStlrenients on cells that express very few receptors or receptors with a very 
low affinity. 
It will be of interest to further resolve the apparent discrepancy between Kit protein 
expression and ligand binding, especially since we have found similar differences 
between cell staining with biotin-SCF and anti-Kitantibodies on mouse (chapter 4 [De 
long et aI., 1996], [Visser et aI., 1993), and this study) and human EM cells [Wognum et al., 
t9961. The availability of theFDC-PI(IL-3) and FDC-PI (SCF) sublines may prove to be 
useful in this regard. For instance, the role of the high and low molecular weight forms of 
Kit in the ability of the FDC-P I cells to bind SCF can be examined by using digoxigenin-
labeledSCF (see also chapter 7) for immunoprecipitation of Kit on biotinylated cells. 
Detailed analysis of the two forms of Kit might also elucidate the influence of differential 
glycosylation on ligand binding. Apart from direct information on SCF binding, 
immunoprecipitation of Kit after chemical crosslin king of labeled SCF to the cells might 
give better .insight into the stoichiometry of SCF/Kit complexes. Moreover, such studies 
might provide information on the effects of interactions of Kit with other growth factor 
receptors, e.g. the EPO receptor [Wu et ai., t9951, or about other, as yet unidentified 
receptor components that are important for SCF receptor function, like the 200 kD protein 
that has been reported to associate with Kit [Linnekin et aI., ·1995]. 
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Above aB, .these d3:ta demonstrate that receptor expression data based on binding 
studies with anti-receptor antibodies have to be interpreted with caution, as antibody 
binding may not always predict the ability of the cells to bind and respond to the 
physiologically relevant ligand. 
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based on expression of CD34 and c-kit 
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6;1 ABSTRACT 
In this paper a novel approach is described to physically' separat~ erythroid 
progenitors from monocyte and granulocyte progenitors, based on the expression of 
CD34 and Kit. Using biotin-labeled human stem cell factor (SCF) and flow cytometry, 
Kit was detectable on 2-3% of the nucleated cells in rpestls monkey bone marrow. 
Combination of biotin-SCF with CD34 monoclonal antibodies showed that Kit was 
expressed on subsets of CD34 10w and CD34PoS cells. Our data clearly demonstrate that 
CD34POS cells are more heterogeneous with respect to Kit expression than observed in 
studies using Kit mAb. A small cluster, approximately 7% of the CD34poS cells, 
expressed CD34 at submaxiI.nallevels, and stained brightly with biotinylated SCF. This 
CD34poSj kithi fraction contained predominantly erythroid progenitors (BFU-E). The 
majority of the granulocytic and monocytic progenitors (CFU-GM) were CD34pOSj 
kitmed. S.ome BFU-E were also detected in the CD34Pos/ kitmed and CD34!ow/ kitfXls 
fractions at low frequency. In the latter subset, most erythroid colony forming units 
(CFU-E) were recovered. Using three-color flow cytometry, we analyzed ~xpression of 
Kit in relation to that of CD34 ,md the class II major histocompatibility antigen, RhLA-
DR. The most immature bone marrow cells that can be identified in vitro, i.e. CD34Pos/ 
RhLA-DRlow cells, were kitmed. The CD34POsj kithi and CD34pOSj kitneg subsets 
predominantly contained the more ~ature RhLA-DRbright celJs. Our results demonstrate 
that erythroid precursors express c-kit at much higher levels than monomyeloid 
pr{!cursors and pluripotent progenitors. The difference in expression levels of CD34 and 
c-kit can be exploited to isolate BFU-E populations that are virtually devoid of non-
erylhroid cells. 
6.2 INTRODUCTION 
The c-kit gene encodes a type I transmembrane glycoprotein and is a member of the 
tyrosine kiriase receptor family [Chabot et aL. 1988]. The Jigand of Kit exists in both 
transmembrane and sqluble forms and is variously known as stem cell factor (SCF), 
mast cell growth factor, Steel factor, and Kit ligand [Anderson et aI., 1990] [Huang et aI., 
19901 [Maclin el ai., 19901 [Zsebo etal" 1990al [Zsebo el al" 1990b]. Kit (CD 117) and its ligand 
are important for normal hemopoietic cell development in vivo as· demonstrated by the 
severity of hemopoietic defects in 'VAY mutant mice, ·which do not have functional c-
kit [Chubol et al.. 1988] [Geissler et aI., 1988], and in Steel mutant mice, which lack active 
SCF {Copelund et ai., 1990] [Flanagan and Leder. 1990} {Huang et aI., 1990] [Zseboet al.. 1990a]. 
The molecular cloning of human and rodent SCF has permitted detailed studies into 
the functional properties of this cytokine. The soluble form of SCF, which consists of 
the N-te~minal extracellular domain of the full-length transmembrane protein, is a poor 
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stimulator of hemopoietic cells in vitro on its own. However, in the presence of other 
hemopoietic growth factors (GFs), such as granulocyte-macrophage colony-stimulating 
factor (OM-CSF), interleukin-3 (IL-3) and erythropoietin (EPO), SCF enhances 
proliferation and differentiation of immature hemopoietic cells as well as monomyeloid 
and erythroid progenitors [Bernstein et al.. 1991] [Broxmeyer et al.. 1991aJ [Broxmeyer et ai., 
1991b] [Carow et al.. 1991] [De Vries et al.. 1991] [McNieee et al.. 1991a] [Metcalf and Nicola. 1991] 
. [Migl~accio e( al.. 1991] [Tsuji et aI., 1991] [Brandt ct al.. 1992]. [Heyworth et al.. 19921 [Migliaccio et 
al.. 1992] [Williams et al.. 199~J [Abboud et al.. 1994} [Steen et al.. 1994]. In addition. SCF affects 
the development of early lymphoid cells in the presence of IL-7, but is inactive at later 
stages ofT and B cell development [Martin et al.. 19901 [McNiece et nl., 1991b] [Katayama et al.. 
1993} [Morrissey ct. ai., 1994}. In vivo administration of SCF leads to u' dose-dependent 
expansion of both primitive and differentiated progenitor cells in the bone marrow 
(B.M) of mice, nonhuman primates or human patients .. As a result. mobilized 
progenitors appear in the peripheral blood. At the same time, there is an increase in the 
number of mature cells of multiple lineages [Molineux et aI., 1991] [Ulich et al., 199 i], [Bodine 
et al., 1992] [Hoffman et aI., 1993] [McNiecc ct aI., 1993} [Tong et aI., 1993] [Andrews et al.,. 1994]. 
The combined in vitro and in' vivo activities of SCF indicate that it acts on primitive 
progenitors as well as more differentiated lineage-committed cells. 
Studies with monoclonal antibodies (mAb) against Kit have provided information 
about the cellular distribution of c-kit on murine and human cells. In man Kit is 
expressed on a large fraction of BM cells that express CD34, an antigen specific for 
carly ~emopoietic cells, including stem cells, multipotent and lineage-committed 
progenitor cells [Civin et at., t9841. The CD34P'''1 kitPOS fraction includes cells that 
coexpress surface .proteins characteristic for differentiating progenitors, e.g., CD33. 
CD38, CD7l and HLA-DR, but also developmentally immature cells that lack or 
express only low levels of these antigens [Ashman et aI., 1991] [Papayannopoulou ct ai., 1991J 
{Broudy et ai., 1992] {Strobl et aI., 1992} [Gunji et aI., 1993] [Yamaguchi et aI., 1993J [Simmons et aI., 
t994J. In keeping with this, the CD34posi kitPOS subset contains committed monomyeloid 
and erythroid progenitors (CFU-OM and BFU-E, respectively) as well as cells that 
produce clonogenic progeny in long-term cultures in the presence of cytokines or 
stromal feeder cells [BriddeJl et aI., 1992] [Gunji et aI., 1993] [Simmons ct aI., ~994J. Such cells 
were undetectable or present at very low frequencies in the CD34POSj kitneg fraction. Kit 
has also been detected on small subsets of CD34POs BM cells that coexpress B- (CD 10, 
CD19) or T- (CD2, CD7) lymphoid-specific antigens, but the majority of Band T cell 
precursors appears to be kit neg [Ashman et al.,.199l} [Strobl et al.. 1992J [Simmons ct ai., 19?4]. 
BFU-E and CFU-E differ in their responsiveness to stimulation by SCF, or inhibition 
by SCF mAb [Papayannopoutou et at., t9911lBroudy et at., t9921, indicating a declining role of 
c-kit during late stages of erythroid differentiation. In line with this, a decreasing Kit 
expression during differentiation of granUlocytic, monocytic and erythroid cells was 
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shown by staining BM cells or cultured BFU-Eprogeny with t25I-labeled SCF [Metcalf 
and Nicola, 1991J [Broudy et aI., 1992]. However, the exact pattern of Kit expression during 
especially the early stages of differentiation -remains unclear. This may partially be due 
to-the differences in techniques and reagents used to detect and isolate Kit-expressing 
cells. The ability to distinguish ki'tneg, kit10w and kithi cells is influenced by the binding 
affinity of the Kit mAb .. In addition, some Kit mAb inhibit outgrowth of SCF 
responsive cells [Lerner et al.,-1991) [Broudy et aI., 1992] [Gunji et aI., 1993} [Liesveld et al.. 1995], 
which may impede functional characterization of purified kitPos subsets. Detection 
methods based on binding of the ligand itself provide more reliable information about 
the capacity of cells to bind and respond to a specific ligand than the use of receptor 
mAb. Biotin-labeled growth factors have been used extensively to study the expression 
of functional growth factor receptors on BM cells [Foxwell et a!., 1988] [Newman et al.. 19891 
[Taki et al.. 1989} [Peters and Norback. 1990] [Wognum et ai., 1990] [Pieri and Barritault, 1991] [De 
Jong et al., 1992} [Wognum et aI., 1992] [Wognum ct aI., 1993] [Wognum'ct al.. J994] {De Jong ct al.. 
1995] [Wognum et al.. 1995J. In the present study we have biotinylated recombinant human 
SCF and examined ~he distribution of functional receptors for SCF on rhesus monkey 
BM cells. With this method we show that erythroid progenitors can be distinguished 
and physically separated from immature multipotent cells and committed monocyte and 
granulocyte progenitors on the basis of CD34 and Kit expression. 
6.3 MATERIALS AND METHODS 
B!otinylation 
Recombinant human SCF (a gift of Dr. S. Gillis, Immunex, Seattle W A, USA) 
[Anderson et.al .. 1990] was biotinylated using biotin-N-hydroxy succinimide ester (NHS-
Biotin, Pierce, Rockford IL, USA) as described previously for other growth factors [Dc 
Jong et al.. 1992J [Wognum ct al., 19931 [Wognum ct al.. 1994] [Wognum ct ai., 1995J. Briefly, NHS-
Biotin dissolved in dimethyl sulfoxide (DMSO) was added to 10 ng aliquots of SCF in 
O. [ M carbonate-bicarbonate buffer pH 8.4 containing 0.02% (vol/vol) Tween-20, at 
molar Biotin:Protein (B:P) ratios of 10: I, 100: I or 300: I. A control sample was 
incubated with I?MSO without biotin. After 3h incubation at room temperature in the 
dark, biotin-SCF molecules were separated from the remaining free biotin molecules in 
the samples by size exclusion chromatography on a I ml Sephadex 0-,25 column 
(Pharmacia, Uppsala, Sweden), equilibrated in phosphate buffered saline, containing 
0.02% (wt/vol) Tween-20. To test the efficiency of the biotinylation, biotin-SCF was 
adsorbed onto streptavidin-agarose beads (Sigma, St. Louis MO, USA), and the amount 
of biological activity that remained in the supernatant was determined. Biotin-SCF was 
stored at -80"C in the presence of 0.02% (wt/vol) sodium a~ide. 
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Biological activity assay 
The biological activity of biotin-SCF was measured in a proliferation assay using 
cells from the human factor-dependent megakaryocyte cell line M07e [Avanzi et aI., 19881 
[Hendde et aI., 19911. Cells were grown in o:MEM supplemented with 10% (vol/vol) fetal 
calf serum, 0.05 mM j3-mercapto ethanol,S ng/ml human IL-3 and 10% (vol/vol) 
conditioned medium of the 5637 cell line. Cultures were maintained at 37'C in a 
humidified atmosphere of 10% C02 in air. To determine the biological activity of 
biotin-SCF, 5x104 cells per well of 96-well microtiter plates (Falcon 3072; Becton 
Dickinson Labware, Lincoln Park NJ, USA) were cultured in 200 III medium containing 
serial dilutions of growth factor. The cells were cultured for 40-48 hours, after which 
0.251lCi 3H-Thymidine was added to each well. The cells were harvested after 16-18 
hours of thymidine incorporation, and the radioactivity was measured in a liquid 
scintillation counter. At a B:P ratio of 10:1 SCF retained all of its biological activity, 
while the biotinylation efficiency was >99% as determined by adsorption onto 
, streptavidin-agarose beads, so this preparation was used for further experiments. 
Low density BM cell preparation 
BM aspirates from young adult rhesus monkeys (Macaca mulatta) from the TNO 
Primate Center, Rijswijk, The Netherlands, were collected in Hanks'. Hepes buffered 
salt solution (HH) with heparin and DNAse. The buffy coat fraction was collected after 
centrifuging the cells for 15 minutes at 2500 rpm at room temperature. Low density 
cells were obtained by centrifugation for 30 minutes at 2000 rpm at room temperature 
over a discontinuous bovine serum albumin (BSA) density gradient [Dicke et al.. 1970] 
consisting of 25%,23%,22%,21% and 17% (wt/vol)BSA in 0.2 M Tris-buffer I 
Phosphate buffer pH 7.2. Fractions were collected and washed in HH. Erythrocytes 
were lysed using 10 ruM potassium bicarbonate, 155 ruM ammonium chloride, pH 7.4, 
containing 0.1 mM EDT A. 
Immunocytochemlqal staining and flow cytometry 
Cells were stained overnight on ice with biotin-SCI" (I nM) in HH, containing 2% 
(vol/vol) fetal calf serum, 2% (vol/vol) rhesus monkey serum, 0.05% (wt/vol) sodium 
azide, and DNAse (0.5 mg/ml). Similar results were obtained by incubation for 2 h on 
ice. Specificity of binding of the biotin-SCF samples was determined by incubating the 
cells with biotin-SCF in the presence of either a lOO-fold molar excess of unbiotinylated 
SCF or the blocking Kit antibody SR-I (ascites I :200 dilution; kindly provided by Dr. 
V. Broudy, University of Washington, Seattle WA, U~A). The cells were incubated for 
30 minutes on ice with streptavidin-PhycoErythrin (Streptavidin-PE, I: 150 vol/vol; 
Molecular Probes, Eugene OR, USA). After each incubation the samples were washed 
in HH with fetal calf serum and azide. Fluorescence signals were amplified by 
incubating the cells for 30 minutes on ice with biotinylated PE mAb and Streptavidin-
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PE, as described earlier lWognum el aI., 1992]. During the last streptavidin-PE incubation, 
cells were double-stained with a CD34 IhAb (antibody 566, kindly' provided by Dr. T. 
Egeland, The National Hospital, Oslo, Norway) that .was labeled with Fluorescein 
IsoThioCyanate (FITC; Sigma) using standard procedures. For three color analysis, 
cells Were also incubated with a peridinin chlorophyll protein (PerCP) labeled antibody 
against the human Class II histocompatibility antigen HLA-DR (Becton Dickinson, 
Mountain View CA, USA) that cross-reacts with rhesus monkey RhLA-DR antigens. 
To study the expression of the transferrin receptor, double-staining experiments with 
biotin-SCF and a FITC-conjugated CD71 mAb (Becton Dickinson) were performed. 
Sorted cells with low CD34 expression were incubated with FIrC-Iabeled CD71 mAb 
as well. 
Samples were analyzed using a FACScan, or sorted using a FACS Vantage (Becton 
Dickinson, San Jose CA, USA). Cells were illuminated with the 488-nm line of an 
~rgon ion laser. Green FITC fluorescence was measured through a 530-nml 30-nm 
. bandpass filter. Orange PE fluorescence was measured through a 575-nml 26-nm or a 
585-nml 42-nm bandpass filter. Red PerCP fluorescence was measured through a 650-
nm longpass filter. Cells were analyzed in a light scatter window as indicated in figure 
6.2 C to include cells with intermediate to high forward light scatter (FLS) and low 'to 
intermediate perpendicular light scatter (PLS) properties, and to exclude granulocyte" 
dead cells and cellular debris. 
In vitro culture In semisolid medium 
Sorted, populations were assayed fdr their content of colony-forming units-
granulocytel macrophage (CFU-GM), colony-forming units-erythroid (CFU-E) and 
burst-forming units-erythroid (BFU-E) by in vitro colony formation in semisolid methyl 
cellulose culture medium. In 35 mm petri dishes (Becton-Dickinson), unsort~~ cells 
were plated at 50,000 per dish, sorted subsets were plated at 10,000 per dish (for cells 
from the light scatter window as shown.in figure 6.2 C) or at 500-1,000 per dish (for 
sub~ets of CD34jXls cells) in I ml methyl cellulose medium as described [Wognum et al., 
t994J. Methyl cellulose cultures included the following components: 0.8% (wl/vol) 
methyl cellulose in a-MEM (Gibco, Gaithersburg MD, USA); 5% (vol/vol) fetal calf 
serum (FCS), 1.5% (wtlvol) BSA, 10 ].Ig/nil insulin, 0.6 mg/ml human transferrin, 15 
].1M linoleic acid, 15 J.lM cholesterol, 0.1 mM p-mercaplo ethanol, 0.1 ].1M sodium 
selenite, 1 mg/ml nucleosides, 100 units/ml penicillin and 50 ].Ig/ml streptomycin. 
Recombinant rhesus mon~ey interleukin-3 (IL-3) was used at a final concentration of 30 
ng/ml, human recombinant granulocytel macrophage-colony stimulating factor (GM-
CSF; Behring, Germany) at 5 ng/ml, human SCF at 200 ng/ml, G-CSF at 100 ng/ml and 
human recombinant erythropoietin (EPO; Behring, Germany) at 4 VIm!. CFU-GM 
cultures were grown in the presence of IL-3, GM-CSF and SCF, with or without adding 
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G-CSF. BFU-E cultures were grown in the presence of EPO, SCF and 0.2 mM bovine 
hemin. CFU-E cultures were g{own in the presence of EPa and 0.14 ruM hemin. 
Cultures were maintained in a humidified atmosphere of 10% C02 in air. Colonies were 
counted at day 4 (CFU-E) and day II or 12 (CFU-GM and BFU-E). Data of duplicate 
dishes are expressed as average number of colonies per 1000 cells plated. Standard 
errors were obtained by taking the square root of the absolute number of colonies 
counted, assuming that crude colony counts are Poisson distributed [Blackett, 1974) 
[Iscove, 1977]. Incubation of the cells with biotin-SCF did not stimulate colony formation, 
since no difference in colony numbers was seen between cells that had, and cells that" 
had not been incubated with biotin-SCF. 
In vitro culture in liquid medium 
For liquid suspension cultures an automated single-cell dcposit unit (Becton 
Dickinson) was used to sort individual cells directly into separate wells of 96-well 
microtiter plates (Falcon 3072; Becton Dickinson Labware). In different experiments, 
either 1 or fooo cells were sorted into 200 !-ll culture medium per well. Cells were 
grown in a-MEM without GFs or supplemented with various cOI~~binations of IL-3 (30 
ng/ml), GM-CSF (5 ng/ml), SCF (200 ng/ml) and EPO (4 U/ml) (final concentrations). 
In cultures started with 1 cell per well, half of the culture medium was replaced every 
week. Cells werc,expanded before reaching con fluency by transfer to l"m} medium in 
24 well culture plates (Costar, Cambridge MA). Phenotypic analysis was performed by 
staining with antibodies against CD34, CD71, CDllb and HLA-DR, followed by 
FACScan analysis. In cultures started wit~ 1000 cells per well, separate culturcs were 
used for 3H-thymidine incorporation after 3, 5 or ,7 days of culture, and for phenotypic 
and morphological analysis of cells produced after 7 days of culture. 
6.4 RESULTS 
Blotln-SCF staining of M07e cells and rhesus monkey BM cells 
Cytochemical staining properties of biotin-SCF on M07e cells and on rhesus 
monkey BM cells were studied using flow cytometry. All cells df the SCF responsive 
cell line M07e and a fraction of the BM cells were stained brightly with biotin-SCF in 
combination with PE-conjugatcd streptavidin (figure 6,1 A and B). Because the number 
of kitPOS cells in unfractionated BM Was very low (2-3% of the nucleated cells, 
corresponding to 7% of the cells inside a light scatter window as indicated in figure 
6.2), Kit expression was also studied on cells inside a window based on high CD34 
expression (figure 6,1 C). Within the CD34PoS subset 30% of the cells were kitpos. The 
fluorescence signal of M07e as well as BM cells, incubated with biotin-SCF in the 
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presence of either unlabeled SCF or the blocking anti-Kit antibody SR-l [Broudy et at.. 
19921. was almost identical to that of control cells in~ubated without biotin-SCF. This 
indicated that binding of biotin-SCF to these cells was specific and due to binding to 
Kit. 
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figure 6.1 
Kil expression and specificity of biotin-KL staining on M07e and rhesus monkey BM cells. 
Cells were sequentially staineq with blolin-KL and streptavidin-PE. Rhesus monkey BM 
cells were double-stained with FITC-Iabeled CD34 mAb and analyzed inside a light 
scatter window as indicated in figure 6.2. 
(A) M07e cells; (8) rhesus monkey 8M cells (C) t:D34PoS rhesus monkey 8M cells. 
Histograms represent (from top' to bottom): cells, incubated wilh biotin-KL; in the 
presence of a 100-fold molar excess of unlabeled KL; in the presence of the SR-l anti-Kit 
antibody; control cells Incubated without biotin-KL. Markers were set on the basis of 
background fluorescence of unstained cells to indicate the percentages of kit pas cells 
and to show the specificity of the binding of biolin-K~ to the cells. 
Distribution of c-kit on rhesus monkey 8M cells 
Because of the low frequency of kitPos cells in unfractionated BM (figure 6.1). the 
relation between CD34 and Kit expression was studied O"n low density BM cells (flgur~ 
6.2). Kit expression was detectable on 15.2 ± 6.1 % (3 different experiments) of the low 
density BM cells inside the light scatter window as indicated in figure 6.2. Combination 
of biotin-SCF with CD34 mAb showed that 30-50% of these Kit positive cells were 
CD34 positive. The CD34JlOS cells were heterogeneous with respect to Kit expression. A 
small subset. containing 7% of the·CD34POs cells. expressed high levels of c-kit (region 
I in figure 6.2 A). CD34 expression on these CD34pos/ kithi cells was lower than on 
.another subset, that expressed Kit at intermediate levels (CD34poSj kipncd; region 2), 
which indicated that the latter population included the more immature cells. This kitmed 
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fraction contained more thim 60% of the CD34PoS cells. The remainder of CD34POs cells 
. had no detectable Kit expression (C~34posf kit neg; region 3). Finally, a subset of cells 
with low CD34 expression expressed c~kit in- a range from low to high. Most cells in 
this region, in particular those with high Kit expression, showed a small shift in 
fluorescence intensity after staining with the CD34 mAh, as compared to cells stained 
with isotype-control mAb. Therefore, this subset was designated CD34tow (CD341ow / 
kitPOS; region 4). 
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figure 6.2 
Expression of CD34 and Kit on rhesus monkey 8M cells, and light scatter properties and 
RhLA-DR expression of different subsets. 
Low density rhesus monkey 8M cells, stained with biotin-KL and streptavidln-PE and 
counter-stained wUh FITC-Iabeled CD34 mAb and PerCP-labeled HLA-DR mAb after 
amplification of the fluorescence signal, were analyzed by flow cytometry .. 
(A) Dot plot of Kit versus CD34 expression. The rectangular boxes indicate the windows 
used to sort cells on the basis of CD34 and Kit expression levels .. 
(8) Non-specific binding of biotin-KL was evaluated in the presence of a 100-fold molar. 
excess of unlabeled KL. The horizontal line is set on .the basis of background 
fluorescence of unstained cells to discriminate between brightly stained cells and cells 
with low or no Kit signal. 
(C) Perpendicular versus forward light scatter (PLS versus FLS) of low density cells, and 
of cells In the regions 1-4 as identified In A. 
Indicated Is the scatter window that was used in the sorting experiments, to include cells 
with intermediate to high FLS and low to intermediate PLS properties, and to exclude 
granulocytes, dead cells and cellular debris. 
(0) HhLA-DR fluorescence histograms of cells in the same regions as in C. 
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As shown in figure 6.2 C, CD34JXlS/ kithi and CD34POs/ kitmed cells (regions I and 2) 
displayed light scatter properties characteristic of immature, blast-like cells, i.e., 
intermediate to high forward light scatter and low perpendi_cular light scatter. CD34!oW j 
kitpos and CD34pOSj kitncg cells (regions 3 and 4) were more heterogeneous with respect 
to light scatter and also.contained cells with relatively high perpendicular light scatter. 
Additionally, small cells with low forward light scatter were found in the CD34Pos/ 
kitncg fraction (region 3). 
Analysis of.RhLA-DR expression on the different subsets (figure 6.2 D) indicated 
that most of the CD34JXlS/ kith; and CD34Pos/ kitncg cells (regions I and 3) were RhLA-
DR bright, whereas the CD34Pos/ kit mcd cluster (region 2) contained RhLA_DRbright and 
RhLA-DRduli cells at almost equal frequencies. The presence of RhLA-DRduli cells in 
region 2, in combination with the high CD34 expression of this subset, indicat~d that 
very 'irill11atu're cells express Kit at low to intermediate levels. RhLA-DR expression \vas 
also low on the CD34!oWj kithi cells, but these represent relatively mature cells, since 
CD34 levels on Ihese cells were very low. 
Colony forming potential of different fractions of rhesus monkey 8M. 
\Ve assayed the functional abilities of the subsets, discussed in the previous section, 
in standard colony assays in semisolid culture media: The results of two such 
experiments are shown in table 6.1. Most CF.V-OM were found in the CD34poSj kitmed 
fraction, which was 20-30x enriched in CFU-OM as compared to the low density cells. 
A much lower proportion of CFU-GM was recovered in the CD34POSj kitneg subset and 
less than I % of Ihe CFU-OM were found in the CD34POs/ kith; fraction. 
The CD34Pos/ kith; fraction contained at least 30-fold more BFU-E than CFU-OM. 
Asshown in lable 6.1, 200-400 in every 1000 CD34Pos/ kithi cells developed into a 
BFU-E colony, compared to 1-3 in every ·1000 low density cells, demonstrating an 
enrichment of 100- to 200-fold. Some BFU-E were detected in the CD34POs/ kitmed and 
the CD3410w / kitPOS fractions, but at 20- 10 50-fold lower frequencies than in the 
CD34POs/ kithi fraction. The erythroid origin of kith; cells was confirmed by double-
staining of cells with biotin-SCF and CD71 mAb, which showed that kith; cells 
expressed high levels of the transferrin receplor (fignre 6.3). 
The number of CFU-E colonies recovered after sorting was very low (table 6.1). 
Most of the CFU-E were present in the CD34 1ow/ kitPos fraction, suggesting that this 
fraction contained differentiating erythroid cells. In agreement with this, erythrobJasts 
were the predominant cell type identified in cytocentrifuge preparations from this 
fraction (not shown). Moreover, restaining of sorted CD34 low j kitPOS cells with CD71 
I1,lAb showed high CD71 expression on these cells (figure 6.4). However, on account of 
the low CFU-E recovery we cannot exclude the possibility that CFU-E were present in 
other subsets as well. 
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table 6.1 
Colony formation in vitro of different sorted fractions of low density rhesus monkey 8M celfs. 
CFU·GM BFU·E CFU·E 
sorted 
fracUon a % per 103 cells recovery b per 103 cells recovery b per 103 cells 
CD34PoS / kit hi 0.33% 14.5 ± 2.7 0.5% 419.3 ± 36.9 43.2% 48.8 ± 3,1 
CD34PoS / kit med 3.89% ' 181.5 ± 9.5 75.9% 21.0 ± 3,2 25.5% 0.0 ± 0.0 
CD34Pos/ kit neg 2.06% 16,0 ± 2.8 3.5% 0.0 ± 0,0 0.0% 0,0 ± 0.0 
CD341ow/ kitPOS 3.70% 0.0 ± 0,0 0.0% 18.0 ± 3,0 20.8% 133.3 ± 5,2 
low density. 100% 9,3 ± 0,2 100% 3,2 ± 0.3 100% 29.9 ± 0.5 
CD34PoS I kit hi 0.45% 0,0 ± 0.0 0,0% 188.0 ± 13.7 76.9% . 39,0 ± 11.3 
CD34PoS / kitmed 3,30% 101.5 ± 7,1 93.0% 3.5 ± 1.3 10.5% 0.0 ± 0.0 
CD34PoS / kit neg 2.65% 13,5 ± 2,6 9.9% 0.0 ± 0,0 0.0% 0,0 ± 0.0 
C034
'
?w/ kitPos 5.88% 0.0 ± 0.0 0.0% 0,5 ± 0,5 2.7% 13,0 ± 4,6 
scatter fraction 100% 3.6 ± 0.4 100% 1,1 ± 0.4 100% 2,6 ± 0,7 
a Cells inside a light scatter window as sho\vn in figure 6.2 C were sorted on the basis of 
CD34 and Kit expression in regions as shown in figure 6.2 A. 
f)esults of two independent sorting experiments (A and B) are shown. Data of duplica1e 
dishes are expressed as average number of colonies per 103 
cells plated, ± standard errors (the square root of the absolute number of colonies 
counted, see Malerials and Methods). 
b Recovery was calculated lelative to the unsorted low density fraction (experiment A), or 
relative to the fraction sorted inside p light scatter window 
as shown in figure 6.2C (experiment B). 
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Expression of CD71 and Kit on low density rhesus monkey BM cells. 
Cells were stained with biolln-KL, streptavidin-PE and FtTC-labeJed CD7i mAb. 
(A) Dot plot of Kit versus CD71 expression of cells inside the scatter window as indicated 
in figure 6.2 C. , 
(B) Non-specific binding of biolin-KL was evaluated in the presence of a 10Q-fold molar 
excess of unlabeled Kl. 
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FITe fluorescence intensity 
figure 6.4 
C07i expression on sorted C03410w I kitPOS rhesus monkey 8M cells . 
. Low density 8M cells, stained with biotin·KL, slreptavidin·PE and FITC·[abeled CD34 
mAb, were sorted In a window similar to region 4 In figure 6.2 A. Subsequently, half of 
the sample was incubated with buller only ([hin line), and the other hall with F[TC·[abe[ed 
CD71 mAb (thick line), and rean~[yzed. 
Growth factor responses In liquid culture 
To study the effect of different growth factors on the short term proliferation and 
differentiation of the various subsets, 1000 cells per well were sorted into liquid 
medium containing different (combinations of) cytokines. The highest proliferation was 
found in the wells with cells from the CD34Pos/ kitmed and CD34Pos/ kithi fractions, 
when cultured in the presence of SCF + IL-3 + OM-CSF. FACS analysis of the 
differcnt fractions after 7 days of culture showed mainly erythroid (CD7IPos/ 
CDllbneg/ RhLA-DR neg) cells in the CD34posi kit" fractions, and granulocytic 
(CD7}!ow/ CDllbP("/ RhLA-DRneg) and monocytic (CD71!ow/ CDllbP("/ RhLA-
DRPOS.) cells in the CD34Pos/ kit111ed fractions. Examples of CD71 and RhLA-DR 
expression on cultured erythroid cells and on cultured granulocyte and monocyte 
precursors are shown in figure 6.5 A and n, respectively. In agreement with these 
findings, cytospin preparations showed cells from the erythroid lineage in the CD3410w I 
kitPOs and CD34Pos/ kithi cell cuitures, and monomyeloid cells in the CD34POS/ kitmed 
and CD34POs/ kitneg cell cuitures (not shown). 
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figure 6.5 
Phenotypic analysis of cultured fractions of rhesus monkey 8M cells. 
Low densily 8M cells were slalned wilh blolin·KL, slreplavidin·PE and FITC-Iabeled 
CD34 mAb. 1000 cells per well were sorted on the basis of CD34 and Kit expression. as 
indicated by Ihe regions in figure 6.2 A. Sorted cells were cultured in medium in the 
presence of KL + IL-3 + GM-CSF. After 7 days of culture the cells were incubated with 
FITC·labeled CD71 mAb and PE-Iabeled HLA-DR mAb and analyzed by lIow cylomelry. 
Shown are cullures Ihal were slarted wilh CD34POS{ kithl (A) or CD34Pos{ kilmed (8) 
cells. 
To further characterize the long-term differentiation potential of the various 
fractions. individual cells were sorted directly into separate wells of 96-well microliter 
plates, and cultured in the presence of 11:-3, GM-CSF and SCF for a period of 4 weeks. 
No significant difference was seen between cultures with and without EPO (not shown). 
90% of the wells with CD34P(lS/ kilh! and 81% with CD34Pos/ kit med cells contained 
. proliferating cells, whereas only 33% of the CD34Pos/ kit neg cells showed proliferation 
(table 6,2). There was a large difference between the fraclions with respect to the 
amount of cells produced in the weBs and to the nature of these clones. In general. the 
kithi clones proliferated faster and were exhausted sooner than the kitmed clones, which 
kept on growing. up to 4 weeks after sorting. The number of cells in the kitneg clones 
stayed very low. Microscopic inspection of the wells showed erythroid cells in the kithi 
clones. and granulocytic and monocytic cells in the·kitmed and kit neg clones. About 25% 
of the wells with kith! cells (table 6,2) proliferaled sufficiently to perform a FACS 
phenotyping experiment, resulting in 46 erythroid (CD? I pDS) and I grauulocytic 
(RhLA-DRneg/ CDllbPoS) clone. Only 6 out of 192 wells with kitmed cells contained 
enough cells to be analyzed in this way, resulting in 4 granulocytic (RhLA-DRnegf 
COl IbpoS) and 2 monocytic (RhLA-DRpDS/ CDIlbPOS) clones. 
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table 6.2 
Proliferation of di,nerent subsets of CD34PoS low density rhesus monkey 8M cells. 
number of wells (from a total of 192) 
fraction proliferating a expanded b phenotype c 
2 
3 
E G 
CD34 POS! kit hi 173 130 46 
CD34 POS! kil med 155 51 0 4 
CD34 POS! kit neg 64 0 
a Cells were incubated with biotin·KL and CD34 mAb, and sorted one cell per well 
into liquid medium containing IL-3, GM-CSF and KL with or without EPO. 
Wells' in which proliferation occurred were counted. 
b Before reaching confluency, cI.ones ... mh extensive proliferation were expanded 
into 1 ml cultures. 
c Expanded clones that contaIned sufficient numbers of cells were stained with 
antibodies against CD71. CDll band HLA-DR. 
E: erythrOid (CD71 POS! CDllb neg! RhLA-DRPOS). 
G: granulocytic (CD71 low! CDll bPOs! RhLA-DRneg). 
M: monocytic (CD71 low ! CD11bPos! RhLA-DRPos). 
6.5 DISCUSSION 
M 
0 
2 
Kit expression on murine [Okada et al.. 1991] [Ikuta and Weissman. 1992] [Okada et al.. 1992] 
[Ogawaet al.. 1994] and human [Ashman et al.. 1991] [Lerner et al.. 1991] [Papayannopoulou et 411.. 
1991] [Briddcll et aL, 1992] [Broudy et aI., 1992} [Gunji et 411 .• 19931 [Simmons ct 411..1994] BM cells 
has been studied extensively, using Kit specific mAb. However, the exact expression 
patter~ of Kit during especially the early stages of hemopoietic cell differentiation is 
still not clear. Differences between published resuits may partially be explained by the 
use of different rnAb, because the 'ability to distinguish kit~i, kitmed, and kit low cells is 
influenced by the binding affinity of the Kit mAb. Moreover. as Kit mAb can inh'ibit 
outgrowth of kitPOS cells [Lerner et 411.. 1991] [Broudy et aL. 1992} [Gunji et 411., 1993] [Liesveld et 
al.. 19951. it is possible that the kitPOS cells do noi develop optimally in'culture if high-
affinity mAb are used for sorting. This would l~ad to a serious .underestimafion of the 
number of colony-forming cells in the kitPOS subset. Cell staining methods based on the 
ligand itself cause no such inhibition. In addition, such methods by definition provide 
more r~liable information about the capacity of th~ cells to bind and respond to a 
specific ligand than staining with rnAb against the receptor. In this study we have used 
biotinylated SCF to examine the expression of Kit ,on subsets of low density rhesus 
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monkey BM cel1s. Kit was detectable on 2-3% of the nucleated celis, similar to 
frequencies previously obtained for human BM, using Kit mAb {Ashman ct aI., 1991} 
[Lerner et aI., 1991}. Double-staining with biotin-SCF and CD34 mAb showed Kit 
expression on subsets of CD34POs as well as CD34toIV rhesus monkey BM cells. 
A small fraction of CD34poS cells with a high Kit expression was detected,. consisting 
almost exclusively of BFU-E. In line with this, CD34posi kithicells produced 
erythroblasts in liquid suspension cultures, and the kithi cells expressed high levels of 
the transferrin receptor. Some BFU-E were also found in the kit'ned population. This 
might reflect insufficient separation of this subset and the kithi cells, although the kithi 
cells are quite a distinct cluster. It is also possible that these kitmed cells represent a 
~eparate population, e.g. one tllat is more immature than the kithi BFU-E, since the kit hi 
cells express CD34 at a lower level than the kit mcd population. Heterogeneity within the 
-BFU-E population has also been observed by Simmons et a1. {Simmons et aI., 1994], who 
detected a small CD34Pos/ kitneg BFU-E fraction in sorting experiments using Kit mAb 
YBS.B8, Using another mAb, NU-c-kit, Gunji et al. [Gunji et at" 19931 separ~ted CD34PoS 
BM cells into kit hi , kit10w and kit neg sub~ets. In contrast to our results, these authors 
found the highest BFU-E frequencies in the kit low subset, whereas BFU-E frequencies 
in the kithi subset were very low [Gunji et aI., 19931. Unfortunately, no information was 
provided about the overall BFU-E recovery in the sorted fractions, so it cannot be ruled 
out that colony formation by kitN cells was underestimated. This might be in 
accordance with results reported by Broudy et al.. [Broudy et ai., 1992J, who showed that 
outgrowth of a small subset of human BFU-E is not inhibited by the Kit antibody SR-!' 
Such inhibition apparently does not occur with cells stained with biotinylated SCF, as 
demonstrated by the high recovery of BFU-E and CFU-GM after sorting (table 6.1). 
Most CFU-E were present in the CD34!ow/ kitPOs fraction. This poplliation was 
almost completely erythroid, as demonstrated by high CD71 expres~ion. These results 
indicate that BFU-E as well as CFU-E display Kit, which correlates well \vith the 
insufficient erythropoiesis and the occurrence of macrocytic anemia in \V I\V mutant 
mice, which do not have functional c-kit. Also· in accordance with these results, 
Papayannopoulou et al. [Papayannopoulou et aI., 1991] and Ashman et a!. {Ashman et aI., 1991) 
have shown that BM cells that had been isolated via either immune adherence to the 
SR-I antibody, or immune rosetting using the YBS.B8 antibody, were highly enriched 
for erythroid cells. Binding studies with. t2SJ-SCF on cultured BFU-E progeny showed 
th~t proerythroblasts labeled much more densely than erythroblasts {Broudy ct aI., 1992]. 
Although Kit is present on both BFU-E and CFU-E, SCF is necessary only for BFU-E 
outgrowth, but not for CFU-E and later erythroid cells lDai et at., 1991) [Broudy et at., t9921. 
Taken togethe~, the data suggest that Kit expression reaches its maximum at the BFU-E 
stage and gradually declines du(ing terminal erythroid differentiation. This pattern of 
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Kit expression appears similar to that of CD71 [Loken et aI., 1987] and the EPO receptor 
(Wickrerna et aI., 1992] [Wognurn et aI., 1992]. 
The CD34Pos/ kitneg fraction contained virtually no colony-forming cells. Although 
the presence of very immature cells in this fraction cannot be ruled out completely, 
most of the cells in this subset are more mature, as based on the relatively low CD34 
and high RhLA-DR expression, characteristic for activated and differentiating ceBs. 
These CD34Pos/ kit neg cells appear to represent primarily monocyte and granulocyte 
precursors. In addition, part of the CD34POS/ kitneg fraction has low forward and 
perpendicular light scatter properties, and probably consists of B-Iymphocyte precursor 
cells. In previous studies, Kit has been detected on only small subsets of CD34Pos/ 
CDIOPOS and CD34POS/ CDI9POS B-Iymphocyte precursors [Simmons et at., 19941. This is 
consistent with an involvement of SCF in early, but not later stages of B cell 
development [McNiece et aI., 1991a] [Nishikawa et aI., 1991] [Ogawa et aI., 1991] lUlich et aI., 1991]. 
Part of the CD34pos/ kitined cells showed high CD34 and low RhLA-DR expression, 
a phenotype that has previously been associated w.ith the most immature cells that can 
be identified in human BM [Brandt et aI., 1988} 1Sutherland et al.. 1991] [Briddell et aI., 1992}. 
Recently we have shown that the CD34pOSj DR dull rhesus monkey BM subset contains 
multipotential progenitors with high proliferative capacity [Wognum et al.. 1995}. 
Preliminary results from transplantation experiments indicate that the cells that can 
reconstitute lethally irradiated rhesus monkeys are also present in this subset 
(unpublished results). In accordance with the expression of Kit on immature rhesus 
monkey BM cells, murine bone marrow cells expressing Kit were enrich.ed for 
hemopoietic stern cells [Okada et aI., 1991] [Ikuta and Weissman, 1992] [Orlic et aI., 1993]. These 
results support the conclusion that Kit is already expressed at low to h1termediate levels 
at a very early stage of hemopoiesis. Further studies focusing on subsets of CD34pOSj 
kit med/ RhLA-DRdull rhesus monkey BM cells will be useful to establish the 
importance of individual hemopoietic growth factors during stem cell proliferation and 
differentiation, and to provide candidate stem cell fractions for transplantation studies. 
In summary, our data are consistent with a model in which immature, tnultipotent 
progenitors are CD34pos/ kitmed. Along the monomyeloid lineage, these cells 
differentiate into CD34Pos/ kitmed CFU-GM. Kit expression declines after the CFU-GM 
stage, and the cells lose CD34 expression. Along the erythroid lineage, CD34Pos/ kitmcd 
progenitors differentiate to kithi BPU-E, which gradually lose CD34 when they 
differentiate into CD341ow/ kithi CPU-E. This is followed by a graduardisappearance of 
Kit expression during terminal differentiation into mature red blood cells. The ability to 
distinguish the CD34Pos/ kithi popUlation provides a method to obtain highly enriched 
BFU-E populations that are devoid of non-erythroid cells. 
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CHAPTER 7 
Coexpresslon of Kit and the receptors for erythropoietin, 
interleukin-6 and granulocytel macrophage-colony stimulating 
factor on hemopoietic cells 
Marg O. de long, Yvonne Westerman, Gerard Wagemaker and Albertus W. Wognum 
Stem Cells (in press) 
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7.1 ABSTRACT 
The detection of functional growth factor (OF) receptors on subpopulations of 
hemopoietic cells may provide a further dissection of immature cell subsets. Since little 
information is available ab~ut coexpression 'of different GF receptors at the level of 
single hemopoietic cells, we studied the feasibility of simultaneous cell staining with a' 
combination of biotin- and digoxigenin-labeJed GFs forllow cytometric detection of 
functional receptors. Using thi~ me,thodology, coexpression of Kit and re~eptors for 
erythropoietin (EPO), interleukin-6 (IL-6), and granulocyte! macrophage colony-
stimulating factor (OM-CSF) on hemopoietic cells was studied by tripie-staining of 
rhesus monkey bone ,narrow (BM) cells with labeled OFs and antibodies against other 
cell surface markers. Most of the immature, CD34++ cells were Kit+ but did.not display 
detectable levels of EPO-receptors (EPO-R) or OM-CSF-R. Approximately 60% of 
these CD34++! Kit+ cells coexpressed the IL-6-R, demonstrating that immature cells 
are heterogeneous with respect to IL-6-R expression. Maturation of monomyeloid 
progenitors, as demonstrated by decreasing CD34 and increasing CD 11 b expression, is 
accompanied by a decline of Kit and an increase in GM-CSF-R expression, in such a 
way that Kit+! OM-CSF-R+ cells are hardly detectable. IL-6-R expression is 
maintained or even increased during ,monomyeloid differentiation. IL-6-R and GM-
CSF-R were not identified on most CD71 ++ cells, which indicated that these receptors 
are probably not expressed during erythroid differentiation. Together with previous 
resuits, our data show that both Kit and CD71 are upregulated with erythroid 
commitment of immature progenitors. Upon further differentiation, Kit+/ EPO-R- cells 
lose CD34 and acquire EPO-R. Maturing erythroid cells eventually lose CD71 and Kit 
expression but retain the EPO-R. In conclusion, this approach enables further 
characterization of the specificity of GFs for different bone marrow subpopulations. 
Apart from insight into the differentiation stages on which individual GFs may act, 
information about receptor coexpression may be used to identify individual cells that 
can respond to multiple GFs, and allows further characterization of the regulation, of 
lineage-specific differentiation. 
7.2 INTRODUCTION 
Syrvival, growth and differentiation of hemopoietic cells depend on binding of 
growth factors (GFs) to specific cell surface receptors. Studies with monoclonal 
antibodies (mAbs) against OF receptors (OF-R) or with labeled OF molecules have 
·enabled analysis of the distdbutionof OF-R on hemopoietic cells by means of 
multiparameter flow cytometry [Wognum et aL, 1996]. Such' approaches enable analysis of 
receptor expression in relation to the presence of other cell surface antigens. 
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To detect receptor-expressing cells, the use of labeled GFs is preferable to that of 
anti-receptor mAbs, because mAbs recognize only one epitope of a receptor, whereas 
high affinity GF-R for many of the GFs active in hemopoiesis are complexes of more 
than one subunit [Dukovich et aI., 1987] [Hayashida et aI., 1990] [Hibi et al.. 1990]. Moreover. 
some of these subunits can be shared by receptors-for different GFs [Kitamura et al.. 1991] 
[Tavernier et al.. 1991) [Kondo et at.. 1993] [Noguchi et al.. 19931 (Russell et aI., 19931. Therefore, 
deleclion of receplor-expressing cells based on binding of Ihe physiological ligand ilself 
is more indicative of the presence of functional receptors. than binding of antibodies. 
Previously we have used biotin-labeled GFs to study expression of one GF-R in 
relation to other parameters such as the presence of markers for early hemopoietic cells, 
in particular CD34 [Civin et al.. 19841 [Andrews et ai., 1989J, and markers that identify 
activated or differentiating cells, e.g. CDllb for mono~ytes and granulocytes, and 
CD71 for erythroid cells [Newman ct aI., 1982] (Loken et aL, 1987J. This approach has 
provided information on the expression of receptors for interleukin-3 (IL-3), IL-6, 
granulocyte! macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF), 
and erythropoietin (EPO) on normal hemopoietic cells, and allowed us to compare the 
receptor phenotype of immature normal ,?ells with that of their malignant counterparts 
in -patients with chronic myeloid leukemia (CML) [Wognum et aI., 1992J [Wognum et al., 
1993] [Wagnum ~t aI., 1994] [De Jong ct aI., 1995] [Wognum et ai., 1995J [De Jong et al.. 1996J. 
, The possibility to simultaneously detect two or more GF-R on the same cells could 
help explain functional and physiological interactions between these GFs on 
hemopoietic cells. This would also be helpful to further delineate differential expression 
of these GF-Rs during differentiation of stem cells into mature cells of distinct lineages. 
As an alternative to biotinylation, GFs can be labeled with the 391 D molecule 
digoxigenin (DIG) [Martin et al.. 1990J [Glcizes ct aI., 1994). which can be detected using 
anti-DIG antibodies. This approach has recently been used to identify binding and 
internalization of DIG-labeled basic fibroblast growth factor by target cells {Gleizes et al.. 
1994]_ In the present study we have examined the feasibility 10 directly study the 
coexpression of two GF:-R on hemopoietic cell subsets by staining rhesus monkey BM 
cells with combinations of biotin- and DIG-labeled GFs_ By combining these labeled 
OF molecules with mAbs against CD34, CDllb, ·and CD7I, we have examined 
receptor coexpression patterns during development of stem cel.'s to mature blood cells 
of myelomonocytic and erythroid lineages to demonstrate that such an approach is 
feasible and yields results that are consistent with existing functional data. For these 
studies, we used rheslls monkey BM cells, since, extensive data on sin'gle receptor 
staining were already available [Wognum et aI., 1993] [Wognul.ll et aI., 1994] [De Jong et aI., 
1995} [Wognum et a1.. 1995]. 
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7.3 MATERIALS AND METHODS 
Labeling of GFs with dlgoxlgenln or biotin 
Recombinant human SCF (a gift of Dr. S. Gillis, Immunex, Seattle WA, USA) 
[Anderson et aI., 1990) was labeled with digoxigenin (DIG) using Digoxigenin-3-0-
methylcarbonyl-e-aminocaproic acid-N -hydroxy-succinimide ester (NHS-DIG, 
Boehringer Mannheim, Mannheim, Germany) under similar conditions as described 
. previously for SCF labeling with NHS-Biotin [De long et al .. 1995J. Briefly, NHS-DIG 
dissolved in dimethyl sulfoxide (DMSO) was added to 5 [.lg aliquots of SCF in 0.05 M 
·phosphate buffered saline (PBS) pH 8.5 containing 0.02% (voJ/vol) Tween-20, at molar 
DlG:Protein (D:P)ratios of 10:1, 50:1 or 100:1. A control sample was incubated with 
DMSO without DIG (D:P 0). After 3 h incubation at room temperature in the dark, 
DIG-SCF molecules were separated from the remaining free DIG molecules in the 
samples by size exclusion chromatography on a I ml Sephadex G-25 column 
(Pharmacia, Uppsala, Sweden), equilibrated in PBS pH 7.4, containing 0.02% (wtlvol) 
Tween-20. 
Human glycosylated recombinant IL-6 (kindly provided by Ares-Serono, Geneva, 
Switzerland) and human recombinant GM-CSF (a gift from Genetics Institute, 
Cambridge MA, USA) were biotinylated using biotin-N-hydroxy-succinimide ester 
. (NHS-Biotin, Sigma, St. Louis MO, USA), under conditions similar to the NHS-DIG 
labeling of SCF and described previously [Wognum et at .. t993J (Wognum et at.. t994J. 
Human recombinant EPO (supplied by Behringwerke Aktiengesellschaft, Marburg, 
Germany) was biotinylated using biotin-aminocaproyl-hydrazide (Calbiochem, La Jolla 
CA, USA) as described previously IWognum et al .. t990J. 
Labeled GFs were stored at -80'C in the presence of 0.02% (wtlvol) sodium azide. 
eel/lines and biological activity assay 
Before adding sodium azide, the ability of the labeled GF preparations to stimulate 
cell proliferation was assayed using the appropriate OF dependent cell lines, as 
described lWognum et aI., 1993} [Wognum et ai., 1994} [De J~ng et ai., 1995], Briefly; the 
proliferative response of the human factor-dependent cell line M07e was used to 
determine the activity of SCF or GM-CSF [Brizzi et a!., 19901 [Hendrie ct ai., 19911. the 
human multi factor-responsive myeloid cell line TF-I was used for EPO [Kitamura ct ai., 
1989J, and the IL-6 dependent murine plasmacytoma cell line Tl165 for IL-6 [Lc et at.. 
1988J. Cells (1-5 x 104 per well of 96-wells flat bottom microtiter plates) were cultured 
in 200 ftl culture medium containing serial dilutions of GF. After 48 hours, 0.25 [.lCi 
3H-Thymidine was added to each well. The cells were harvested after 16-18 hours of 
thymidine incorporation, and the radioactivity was measured in a liquid scintillation 
counter. Alternatively, to determine the viable cell content of each well, a commercial 
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proliferation kit (CellTiter 96 Aqueous non-radioactive cell proliferation assay, 
Promega, Madison WI, USA) was used, based on the colorimetric assay described by 
Mosmann [Mosmann, 1983]. Therefore, the cells were cultured for 3 days'. after which a 
mixture of 3-( 4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-( 4-
sulphophenyl)-2H-tetrazolium (MTS) and phenazine methosulphate (PMS) was added 
'to the weBs according to the manufacturer's instructions. After 4·18 hours the quantity 
of formazan, formed by conversion of MTS by dehydrogenase enzymes in 
metabolically active cells, was measured as the amoullt of 450 nm absorbance in"a Bio-
Rad model 450 microplate reader (Bio-Rad,Hercules CA, USA). 
Low density 8M cell preparation 
Young adult rhesus monkeys (Macaca mulatta) from the TNO Primate Center, 
Rijswijk, The Netherlands, were used as BM donors. BM was collected by piercing the 
head of the humeral shaft with a pediatric spinal needle, or by extrusion of the cells in a 
tissue press from the cleansed bones of a monkey that was sacrificed for collection of 
BM for various experiments and transplantation purposes [Van Bekkum and De Vries, 1967}. 
All animal e;<periments were performed in accordance with national ethical regulations. 
BM was collected in Hanks' Hepes buffered salt solution (HH) with heparin and DNAse 
(0.5 mg/ml). A buffy coat fraction was obtained by centrifuging the cells for 15 min at 
2500 rpm at room temperature. To enrich for progenitor cells, buffy coat cells were 
subjected to centrifugation for 30 min at 2000 rpm at room temperature over a 
discontinuous bovine seru'm albumin (BSA) density gradient {Dicke et at, 1970] consisting 
of 25%,23%,22%,21 % and 17% (wtlvol) BSA in 0.2 M Tris-buffer I Phosphate buffer 
pH 7.2. Fractions were collected and washed in HH. Erythrocytes were lysed using 10 
mM potassium bicarbonate, ISS mM ammonium chloride, pH 7 A, containing 0.1 ruM 
EDTA. 
Immunocrtochemlcal staInIng 
Cells were incubated overnight on ice with DIG-SCF and either biotin-EPO, biotin-
IL-6 or biotin-GM-CSF in HH, containing2% (vol/vol) FCS, 0.05% (wtlvol) sodium 
azide, and DNAse (0.5 mg/ml). Specificity of binding of the labeled GF samples was 
determined by incubating the cells in the presence of a lOa-fold molar exces~ of 
unlabeled GF. After each incubation the samples were washed in HH with FCS and 
azide. The cells were stained for 30 min on ice with mouse anti-DIG antibodies 
(Boehringer Mannheim), foHowed by a mixture of Fluorescein IsoThioCyahate- or 
PhycoErythrin-labeled goat anti-mouse antibodies (GAM-FITC, Dako NS, Glostrup, 
Denmark; GAM-PE, Sigma, St. Louis MO, USA) and PhycoErythrin- or TriColor-
labeled streptavidin (Streptavidin-PE, Molecular Probes, Eugene OR, USA; 
streptavidin-TriColor, Caltag, San Francisco CA, USA). Indirect staining of the DIG-
SCF gave better fluorescence signals than direct staining methods using FITC-Iabeled 
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sheep anti-DIG antibodies (Boehringer Mannheim). Attempts to amplify th~ FITC-
labeled sheep anti-DIG signal using FITC-labeled rabbit anti-sheep antibodies (Nordic 
Immunological Laboratories B.V., Tilburg,. The Netherlands) resulted in high 
background. Fluorescence signals of biotin-GF labeled cells were amplified by 
incubating the cells for 30 min on ice with biotinylated anti-streptavidin antibodies and 
fluorescently tagged streptavidin, as described earlier [De Jong et aI., 1992]. For three color 
analysis, cells were stained in a final incubation step with fluorescently tagged 
antibodies against CD34, CD71, or CD 11 b. This was done by resuspending the cells in 
50 !II HH with FCS and azide eontaining 4% (vol/vol) normal rhesus senun and 10% 
(vol/vol) normal mouse serum. After 15 min incubation on ice, 50 J.11 of the respective 
antibodies diluted in HH with FeS and azide was added, and the cells were incubated 
for another 30 min. We used an anti-CD34 antibody (antibody 566, kindly provided by 
Dr. T. Egeland, Institute of Transplantatio~ Immunology, Rikshospitalet, Oslo, 
Norway) that was labeled with FITC (Sigma) using standard procedures. CD71-FITC 
and CD 11 b-PE mAbs were from Becton Dickinson (Mountain View CA, USA): 
To distinguish between living and dead cells, in,some of the experiments propidium 
iodide (PI, final eoncentration 0.6 flg/ml; Molecular Probes) was added prior to analysis 
to samples that were stained with FITC aud PE, or Hoechst 33258 (H58, final 
concentration I Ilg/ml; Molecular Probes) was .added to samples that were also stained 
with TriColor. 
Flow cytometry 
Samples were analyzed using a FACScan or a FACS Vantage flow cytometer 
(Becton Dickinson, San Jose CA, USA). Cells were illuminated with the 488-nm line of 
an argon ion laser (Coherent Innova 90, Palo Alto CA, USA). Green FITC fluorescence 
w~s measured through a 530-l1ml 30-nm bandpass fiiter, orange PE fluorescence 
through a 575-nm/26-nm or a 585-nml 42-nm bandpass filter, and red TriColor or PI . 
fluoresct;:nce was measured through a 620-nm or a 650-nm longpass filter. H58 
fluorescence was measured through a KV408 cut-off filter using UV light (351/364 nm) 
from the second argon ion laser (Spectra Physics. Series 2000, Mountain View CA. 
USA) of the FACS Vantage. Data of 10,000-20,000 cells per sample were stored in list 
mode using Lysys software (Becton Dickinson) on a HP340 computer. Data were 
analyzed using Spyro data analysis software developed by R.R. Jonker (TNO Delft, The 
'Netherlands) on an Apple Macintosh computer. Viable H58- or PI-negative cells were 
analyzed in a light scatter window as indicated in figure 6.3 A to include cells with 
intermediate to high forward Iiglit scatter (FLS) and low to intermediate perpendicular 
light scatter (PLS) properties, and to exclude granulocytes, dead cells and cellular 
. debris. 
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Statistics 
Results are given as means ± standard deviation if appropriate. Standard deviations 
were calculated on the assumption of a normal distribution. 
7.4 RESULTS 
Bl%gical activity and cell staining 
SCF was labeled with DIG at molar DIG:Protein (D:P) ratios of 10: I. 50: I or 100: I. 
The ability of these DIG-SCF preparations to stimulate cen proliferation was assayed 
using the human factor-dependent megakaryocyte cell line M07e [Bd"i et al.. 1990J 
[Hendde et al.. 1991J. which expresses 35.000-120.000 high' affinity cell surface SCF 
receptors per cell [Budel et al.. 19931 [Turner et al.. 19951. As shown in figure 7.1. SCF 
retained all of its biological activity at a D:P ratio of 10: I. At D:P 50. approximately 
67% of the biological activity of SCF remained. whereas at D:P 100 most of the 
biological activity was lost. All three preparations of DIG-SCF bound to M07e cells. as 
was examined by flow cytometry (figure 7.2). Binding of DIG·SCF was specific. since 
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figure 7,1 
Biological activity of DIG-SCF on M07e cells. 
DIG·SCF was prepared at different DIG:Protein (D:P) ratios, A control sample (D:P 0) 
was mock-labeled without adding DIG. M07e cells were incubated with seriaJ dilutions of 
DIG-SCF for 3 days in 96-well microtiter plates, after which a mixture of MTS and PMS 
was added to the wells (see Malerials and Methods). The amount of 450 nm absorbance 
of each well was measured, indicating the amount of metabolically active cells. Open 
circles ,represent mock-labeled control SCF; triangles, squares, and closed circles 
represent DIG·SCF at D:P 10, 50, and 100, respectively. Each data point represents the 
mean value of 3 different wells. Standard deviations are indicated. Dotted horizontal line 
indicates 50% maximal stimulation of the cells. 
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the fluorescence signal of cells incubated with DIG-SCF in the presence of an excess of 
unlabeled SCF was almost identical to that of control cells incubated without DIG-SCF 
(figure 7.2). Despite the partial loss of biological activity, the DIG-SCF sample 
prepared at aD:P ratio of 50 yielded a stronger fluorescence signal than the other 
samples. This preparation was used in further experiments. 
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figure 7.2 
Fluorescence histogram of Kit expression on M07e cells. 
M07e cells were sequentially stained with DIG-SCF, anti-DIG mouse antibodies and PE-
conjugated anti-mouse goat antibodies (thick solid lines). Control cells were incubated in the 
presence of a 100-fold molar excess of unlabeled SCF (broken lines), or stained only with 
anli-DIG mouse antibodies and PE-conjugated anli-mouse goat antibodies without DIG-SCF 
(thin solid lines). . 
(A) DIG-SCF labeled at a DlG:Protein (D:P) ratio of 10:1, 
(8) DIG-SCF labeled at a D:P ratio of 50:1, 
(e) DlG-SCF labeled at a D:P ratio of 100:1. 
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Correlation of Kit expressIon and EPO-, IL-5-, and GM-CSF-R expression on 8M cells 
The availability of DIG-SCF enabled us to examine coexpression of Kit and 
receptors for other growth factors, using biotinylated preparations of these growth 
factors. Ce.Jl surface expression of Kit on low density rhesus Iponkey EM cells was 
studied in relation to the expression of EPO-, IL-6- and GM-CSF-R, respectively, using 
DIG-labeled SCF in combination with biotinylated preparations of each of these GFs_ In 
figure 7.3, the results of one of five separate experiments are shown. Staining with the 
labeled GFs was specific, as demonstrated by incubation with DIG-SCF and biotin-GF 
in the presence of a IOO-fold molar excess of the relevant GF. 
iflJiJ ~g $CJ
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o 1000 
forward 
light scatter 
EPO-R IL-6-R GM-CSF-R 
figure 7.3 
Ught scatter properties and GF-R expression of low density rhesus monkey 8M cells. 
(A) Perpendicular. versus forward light scatter. The scatter window that Includes cells with 
low to high forward and low to intermediate perpendicular light sea tier properties was 
used to exclude granulocytes, dead cells, and cellular debris. 
(B, C, D) Coexpresslon of Kit and receptors for EPO, IL-S, or GM-CSF, respectively. 
Cells were stained with DIG-SCF combined with biotinylated EPO, IL-S, or GM-CSF. The 
windows used to analyze the subsets coexpressing the different GF-R are Indicated. 
(E, F, G) Control cells were Incubated In the presence of a 100-fold molar exceSs of lhe 
appropriate unlabeled GF. 
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Combination of DIG-labeled SCF with biotinylated EPO (figure 7,3 B) showed that 
more than half of the Kit+ rhesus monkey BM cells also expressed the EPO-R, This 
Kit+! EPO-R + fraction contained approximately II % of the low density cells (table 
7,1) and included cells with high as well as cells with low or intermediate Kit 
expression. A subset of EPO-R+ cells did not express Kit at detectable levels. This 
population represented approximately 6% of the BM cells and appeared to be 
contiguous to the Kitlow! EPO-R + subset. A separate cluster of Kit+ cells did not 
express the EPO-R, and contained'" 9% of the low density BM cells. Most of these 
cells showed intermediate Kit expression. 
Staining with DIG-SCF and biotin-IL-6 (figure 7,3 C) indicated that most cells with 
high Kit expression were IL-6-R-, whereas most cells with high IL-6-R expression did . 
. not express Kit. The Kit+!IL-6-R- subset coillained approximately 10% of the low 
density BM cells, the ~it-! IL-6-R + fraction represented z 22% of the cells (table 7,1). 
A small population, containing approximately 7% of the cells, expressed both receptors, 
but mostly at intermediate levels. 
table 7.1 
Distribution of low density rhesus monkey 8M cells over different fractions, based on expression 
of growth factor receptors. 
fraction a %b 
Kit+! EPO·R- 8.5 ± 1.9 
2 Kit+! EPO·R+ 10.6 .± 5.3 
3 Kit-! EPO-R+ . 5.5 ± 2.5 
4 Kit-! EPO-R- 49.8 ± 4.8 
Kit+!IL-6-R- 10.2 ± 1.3 
2 Kit+!IL-6-R+ 6.8 ± 0.4 
3 Kit-!IL-6'R+ 22.2 ± 0.6 
4 Ktt-IIL-6-R- 38.7 ± 0.8 
Kit+! GM·CSF·R- 18.4. ± 4.7 
2 Kit+! GM·CSF·R+ NDc 
3 Kit-! GM·CSF·R+ 11.3 ± 1.3 
4 Kit-! GM-CSF·R- 41.7 ± 3.9 
a Cells were stained with DIG·SCF and biotinylated EPO, IL-6, or GM·CSF. 
b Data represent the distribution of low density 8M cells over the receptor-expressing 
regions as IndIcated in figure 7.3 8-D (mean ± SO of 5 separate samples), ,analyzed 
inside a light scatter window as shown In figure 7.3 A. Note that percentages do not add 
up to 100% $ince events outside the 4 receplor-expresslon windows were left out of the 
analysis. 
C ND = not detectable. 
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Similar to the distribution of Kit and the IL-6-R, analysis of Kit and GM-CSF-R 
expression (figure 7.3 D) showed a subset of Kit+ I GM-CSF-R - cells, which cOmprised 
approximately I I % of the cells, as well as a cluster of Kit-I GM-CSF-R + cells, which 
represented approximately 6% of the low density cells (table 7.1). Different from Kit 
and the IL-6-R, very few, if any, cells expressing both Kit and GM-CSF'R were found. 
Phenotypic characterization 01 8M subsets based"on expression 01 Kit and EPO-R 
To examine the nature of the differenf subsets of GF-R expressing cells, phenotypic 
analysis of low density rhesus monkey BM cells was performed after triple-staining 
with labeled GFs and mAbs against different cell surface markers (figures 7.4, 7.S, 7.6 
and table 7.2). Consistent with previous findings [Wognurn et at., 1992]' very few rhesus 
monkey BM ~ells that expressed CD34 at high levels, characteristic for immature 
hemopoietic cells, were EPO-R+ (figure 7.4 A and table 7,2). Most of the 
2 
3 
4 
A CD34 6 CD71 C CD11b 
=.,------,-'--, 
all cells 
+ -Kit tEPO-R 
Kit+; EPO-R+ 
- + Kit t EPO-R 
-. -
Kit tEPO-R 
flUorescence Intensity 
fjgure 7.4 
Expression of CD34, CD71, and CD11b on different fractions of low density rhesus 
monkey 8M cells, based on expression of Kit and the EPO-A. 
Cells were stained with labeled GFs and (A) anti·CD34, (6) anti·CD71, or (C) anti·CDll b 
mAbs, and analyzed inside a.light scatter window as shown in figure 7.3 A, in the regions 
that are indicated in figure 7.3 B. From top to bottom are shown: all cells; (1) Kit+/EPO-
R-- cells; (2) Kit+tEPO-R+ cells; (3) Kit-tEPO-R+ cells; (4) Kit-/EPO-R- cells. Dotted 
histograms in the upper panels show background fluorescence of control cells. Vertical 
broken lines indicate the threshold values that were used to discriminate between cells 
with low or no fluorescence Signal and brightly stained cells. Results are representative 
for 3 Independently performed experiments. 
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table 7.2 
Distribution of low density rhesus monkey BM cells over different fractions, based on expression 
of growth factor receptors and other cell surface markers. 
2 
3 
4 
2 
3 
4 
2 
3 
4 
CD34+t CD71 +t CDllb+ 
fraction a %b %b %b 
Kit+/ EPO-R- 8.7 (56.0) 2.5 (14.6) 0.2 (1.9) 
Kit+/ EPO-R+ 0.7 (4.2) 13.2 (78.9) 0.1 (1.0) 
Kit-/ EPO-R+ 0.2 (104) 0.3 (1.5) 004 (3.2) 
Kil-/ EPO-R- 2.5 (16.2) 004 (2.3) 6.0 (46.3) 
Kil+/IL-6-W 2.8 (20.7) 704 (58.9) 0.0 (0.2) 
Kit+/IL-6·R+ 404 (3304) .1.8 (14.1) 0.8 (4.7) 
Kit-/IL-6-R+ 2.5 (18.8) 0.2 (104) 12.5 (75.2) 
Kit-IIL-6-R- 1.2 (9.3) 05 (3. 7) 0.2 (1.3) 
Kit+/ GM-CSF-R- 4.1 (53.3) 8.1 (66.7) 0.0 (0.6) 
Kil+/ GM-CSF-R+ NDc NDc NDc 
Kit-/ GM-CSF-R + 004 (5.0) 0.1 (0.7) '6.3 (37.3) 
Kin GM-CSF-R- 1.2 (16.5) 004 (304) 2.0 (11.8) 
a Cells were stained with labeled growth factors and anli-CD34, anti-CD71 or anti-CD11b 
mAbs. Data represent results of 1 experiment, which was representative of 3 
independenlly performed experiments_ Cells weTe analyzed Inside a light scatter window 
as shown in figure 7.3 A. in the receptor-expressing regions as indicated in figure 7.3 S-
D. 
b Data represent the percentages of BM cells that were (ound in the receptor-expression 
windows and expressed CD34, C071, or CD11 b, respectively. Between brackets are the 
same data, relative to the total number of cells expr.essing these markers (normalized to 
100%; note that percentages do not add up to 100% since events outside the 4 receptor-
expression windows were left out of the analysis). For example, 8.7% of the 8M cells 
were CD34++/ Kit+/ EPO-R-, which means that 56.0% of all CD34++ cells were found 
inside the Kit+/ EPO-R- region. 
c NO = not detectable: 
CD34++ cells were' Kit+/ EPO-R- (figure 7.4 A). The majority of the Kit+/ EPO-R+ 
cells showed low CD34 expression, demonstrating that these cells were more 
differentiated than the CD34++/Kit+/ EPO-R- cells. The average level of CD34 
expression on the Kit-/ EPO-R + cells was even lower, indicating that these cells were 
more mature than the Kit+/ EPO-R+ cells. Consistent with earlier results,' showing Kit+ 
as well as Kit- cells within the CD34++ subset of rhesus monkey BM [De Jong et at. 
t995), some CD34 ++ cells Were also found in the Kit-/ EPO-R- subset. 
Almost all erythroid cells, identified by high CD7l expression (Newman et aI., t982) 
ILoken et al.. t987), were Kit+ (figure 7.4 B) (De long et al.. 1995), and most of these (z 
80%) expressed the EPO-R (taBle 7.2). These CD71 ++ cells comprised one third'of the 
cells in the Kit+ / EPO-R- fraction and the majority of cells in the Kit+/ EPO-R + . 
fraction. Most of the Kit-/ EPO-R+ cells were CD7l-. These CD71-/ Kit-/ EPO-R+ 
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cells displayed the low forward and perpendicular light scatter pattern that is 
characteristic of normoblasts (not shown), which are known to have lost CD71 
expression (Loken et aI., 1987J, The combined data are consistent with a model in which 
Kit expression on erythroid progenitors precedes expressi'on of the transferrin receptor 
and the EPO-R. The data also demonstrate that during terminal erythroid maturation the 
EPO·R is retained until a later differentiation stage than both Kit and the transferrin· 
receptor. 
Analysis of expression of CD 11 b, which is a marker for differentiating precursors of 
the granulocyte and monocyte lineages, showed that mos't of these cells were KH- and 
EPO-R - (figure 7.4 C and table 7.2). This is consistent with the absence of the EPO-R 
on myelomonocytic cells and the disappearance of Kit during later stages of myeloid 
differentiation (see below). 
Phenotypic characterization of 8M subsets based on expression of Kit and IL·6·R 
In parallel with the examination of Kit and EPO·R expression on he~nopoietic 
subsets. we also studied coexpression of Kit with the IL-6-R and GM-CSF-R.· 
respectively. The immature rhesus monkey BM cells were heterogeneous with respect 
to IL~6-R expression. since high CD34 expression was found on Kit+/ 1L-6-R+ as well 
as Kit+/ IL-6-R- cells (figure 7.5 A and table 7.2). Average CD34 expression was 
higher on Kit+/ 1L-6-R+ than on Kit+/ IL-6-R- cells. suggesting that on average the 
Kit+/ IL-6-R + cells were more immature than the Kit+/ 1L-6-R- cells. 
Of the approximately 20--25% CD34 ++ cells that did not express Kit. approximately 
two thirds were 1L-6-R+ (figure 7.5 A and table 7.2). which suggests that there are also 
immature cells that express the IL-6-R but not Kit. Almost all CD Ilb+ cells were also 
found in the Kit-/ IL-6-R+ subset (figure 7.5 C). which is consistent with the 
expression of IL.6:R during differentiation of monocytes and granulocytes [Wognum et 
31..19931. Therefore. Ihe CD34++/ Kit-/ IL-6-R+ cells rnaY.represent differentiating 
myelomonocytic progenitors that have lost Kit expression. The CDllb- cells in the 
Kit-/ 1L-6-R + population probably represent mature T-cells. which have been shown to 
express IL-6-R at high levels [Taga eI al.. 198711Coulie et 31..19891 [Wognum et al.. 19931. 
Most of the Kit+ cells with low CD34 expression. which include erythroid 9010ny-
. forming cells (CFU-E) and (pro)erythroblasts [De long;t al.. 19951. were found in the IL-
6-R- fraction (figure 7.5 A). In agreement with this. IL-6-R were not expressed on the 
majority of the Kit+/CD71++ erythroid cells (figure 7.5 Band table 7.2). However, 
the presence of approximately 14% of the CD71 ++ cells in the Kit+/ 1L-6-R+ fraction 
indicated that the 1L-6-R may be present on a subset of erythroid cells. 
In conclusion, these results are consistent with a model in which Kit and IL~6·R are 
coexpressed on a subset of progenitors which includes the most immature cells 
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identified by high CD34 levels. During maturation of erythroid cells Kit expression 
increases and IL~6~R e~pression decreases. In contrast, myeloid differentiation is 
accompanied by a decrease in Kit expression and an increase in IL~6-R expression. 
A CD34 B CD71 C CD11b 
+ -KitIlL-6-R 
fluorescence intensity 
figure 7.5 
Expression of C034, CD71, and CD11b on different fracllons of low density rhesus 
monkey 8M cells, based on expression of Kit and the IL·6·R. 
. Cells were incubated with DIG·SCF combined with biolinylated IL·6 and the same 
antibodies as in figure 7.4. Cells were analyzed inside a light scatter window as shown In 
figure 7.3 A, in the regions that are indicated in figure 7.3 C. 
(1) Kit+JIL·6·R- cells; (2) Kit+JIL·6·R+ cells; (3) KiI-JIL·6·R+ cells; (4) KiI-JIL·6·R- cells. 
Phenotypic characterization of 8M subsets based on expression of Kit and GM-CSF·R 
As shown in figure 7,3, Kit+ and GM-CSF-R + rhesus monkey BM populations 
showed. little overlap. Kit+J GM-CSF-R- populations included primitive cells with 
highest CD34 expression and erythroid cells with high CD?I expression (figure 7.6 A 
and B). The Kit-I GM-CSF-R+ population, on the other hand, contained most of the 
CDllb+ cells (figure 7.6 C and table 7,2), which is consistent with the expression of 
GM-CSF-R on monocytic ·and granUlocytic cells [Walker·and Burg~ss, 1985] [Wognum ct ai., 
1994]. As shown in figure 7.6 C, this GM-CSF-R+ popUlation covered a broad range of 
COl tb expression, which indicates that GM-CSF-R are expressed from immature 
(CDllb 1ow ) to mature (CD Ilbbrigh') monomyeloid cells. Additionally, some CD Ilb+/ 
Kit-cells that d,id not express detectable amounts of the GM-CSF-R were identified 
(figure 7.6 C), which may represent a subset of NK cells or their precursors. These 
combined results are consistent with a model in which immature Kit+J COl tb- cells 
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lose Kit expression (and acquire GM-CSF-R) during monomyeloid differentiation and 
deVelop into CDllb+ cells that express hi~h levels ofGM-CSF-R. 
·A CD34 B CD?t C CDttb 
t 'Kitl GM-CSF-R- :j ~, I :J ~, :J.6,: , 
"j' All I "j A II I "' !-M"'~ A~~.I_ • ''!,b • 0(\ , • .-..... ,..,.".. - + 3 Kit I GM-CSF-R 
,~, .I. ~j4!, ,~,.l. ~V» ,J, .I. 
fluorescence intensity 
figure 7,6 
Expression of CD34, CD71, and CD11b on different fractions of low density rhesus 
monkey 8M cells, based on expression of Kit and the GM-CSF-R. 
Cells were Incubated with DIG-SCF combined with biotinylated GM-CSF and the same 
antibodies as in figure 7.4. Cells were analyzed Inside a light scatter window as shown in 
figure 7.3 At in the regions that are Indicated in figure 7.3 D. 
(1) Kit+/GM-CSF-R- cells; (3) Kit+/GM-CSF-R+ cells; (4) Kit-/GM-CSF-R- cells (note 
that the Kit+/GM-CSF-R+ fraction (2) contained too iew cells for analysis). 
DISCUSSION 
In this paper we show that DIG-SCF and biotinylate~ GFs can be used to study 
coexpression of Kit and other GF-R on 1.1emopoietic cells. As expected from previous 
studies using biotin [De long et ai., 1995), SCF could be labeled efficiently with DIG, with 
retention of most of its ability to stimulate cell proliferation. By combining DIG-SCF 
~vith biotinylated GFs and mAbs against differentiation markers, we were able to 
examine. coexpression of Kit and receptors for EPO, IL-6, and GM-CSF on rhesus 
monkey BM cells at different stages of differentiation of various blood cell lineages. 
This allowed a better definition of the subpopulation structure of the immature 
hemopoietic cell compartment. A schematic representation of changes in GF-R 
expression during erythroid and monomyeloid differentiation is shown in figure 7.7. 
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stem cell progenitors precursors mature blood cells 
l I ~ 
-
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VKit++ Kit + il EPO-R+ EPO·R++ 
.. - IL-6-R? 
Kit+~ __ • __ 
* f 
neutrophilic \ f ~ ~ granulocytes 
K;t+~ Kit+· GM·CSF·R++ 
IL·6·R+ . IL·6·R++ lL·6·R ++ 
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• 
~ It monocytes --
II EPO-R 
Kit+· GM·CSF·R +++ 
• IL-6-R IL·6·R ++ [L·6·R +++ 
GM·CSF·R++ 
* GM-CSF-R 
figure 7.7 
Schematic representation of erythroid and monomyeloid differentiation, displaying 
receptor expression for SCF, EPO, IL·6, and GM·CSF. 
The majority orthe immature, CD34++ rhesus m~H1key BM cells were Kit+. This is· 
in agreement with previous studies using anti-Kit antibodies on human cells [Ashman et 
aI., 1991] [Papayannopoulou et aI., 1991] (Briddell et al.. 1992] [Gunji et aI., 1993] [Simmons et aI., 
1994) and biolin-SCF on rhesus monkey BM cells [Dc long et al .. 1995)_ In Ihese reports, 
using antibodies against CD34, CD33, CD38, and HLA.DR, Kit expression was 
demonstrated on the ,most immature subsets of CD34 +t cells that can be detected in 
vitro (Brandt et ai., 1988] [Sutherland et ai., 1989] [Terstappen et aI., 1991], which probably 
contain pluripotent hemopoietic stem cells relevant to hemopoietic reconstitution 
[Wagemaker et nl.. 1995]. In line with this, cells with long-term repopulating ability were 
also found in the Kit+ fraction of murine BM [Ogawa et al.. ·1991] [Okada et aI., 1991J [Orlic ct 
aI., 1993J [De long etaL, 1996). 
GM-CSF-R were absent from or expressed at a very low level on immature cells. 
This is in agreement with previous studies using purified CD34 + rhesus monkey BM 
cells, showing no GM-CSF-R on erythroid and myeloid progenitors with light scatter 
characteristics that were similar to those we used for analysis [Wognum et ai., 1994]. 
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Similar findings were recently reported by McKinstry et a!., who found little or no 
binding of radiolabeled GM-CSF to purified mouse EM subsets enriched for 
hemopoietic stem cells [McKinstry et al.. 1997]. Taken together. these results suggest that 
GM-CSF-R are not expressed on hemopoietic stem cells, or only at' extremely low 
levels. 
Within the population of CD34++ 1 Kit+ immature rhesus monkey EM cells, IL-6-R + 
as well as IL-6-R- cells were found, consistent with the previously demonstrated 
heterogeneity of immature hemopoietic cells with respect to IL~6~R expression [Wognum 
et aI., 19931. The average CD34 expression of the CD34 ++1 Kit+ 1 IL-6-R- cells is lower 
than that of the CD34++1 Kit+1 IL-6-R + cells, which might indicate that the IL-6-R+ 
cells are .more immature. Previo~s three-color immunofltlorescence experiments 
showed that n..~6~R are expressed on a large subset of very immature rhesus monkey or 
human cells with high CD34 and low HLA-DR and CD38 expression [\Vagemaker et al., 
1995] [Wognum ct al.. 1996). In situ autoradiographic studies and reverse transcriptase 
. polymerase chain reaction (RT-PCR) also showed binding of IL'6 and expression of 
mRNA for IL-6-R and its partner gp130 on highly enriched fractions of murine EM 
stem cells and progenitor cells [McKinstry et al.. 1997][49, 50]. However, as some cells 
with a very high CD34 expression are also present in the Kit+1 IL-6-R- subset (figure 
7.5), it is possible that the most immature cells lack the IL-6-R. This is supported by the 
finding that the majority of the long-term culture-initiating cells (LTC-IC) and mixed 
colony-forming cells have been found in the CD34 +1 IL-6-R - fractions of human EM 
and cord blood JTajima ct al.. 1996J. This population did. however, express gp130 and 
could respond to IL-6 in the presence of soluble IL-6-R ITajima et aI., t9961. 
Maturation of progenitors into monomyeloid cells is accompanied by a loss of Kit 
expression prior to acquisition of the CDllb antigen (figures 7.4-7.6). The decline of 
Kit expression occurs after the progenitor cell stage, since cells that form in vitro 
colonies (CFU-GM) were previously shown to be CD34++1 Kit+ (De long ct aI., t995]. 
Expression of the IL-6-R increases during monomyeloid differentiation, as most 
CDllb+ cells were IL-6-R +, and high levels of IL-6-R expression have been identified 
on monocytes. macrophages, and granulocytes. and on the precursors of these cell 
(figure 7.5) [Bauer ct aI., 1989] [Munck Peterscn et al., 1990J [Wognum et aI., J993J [Tajima et al., 
J996] [McKinstry cl ai., 1997J. As GM-CSF-R were present, on the majority of the CDllb+ 
ce/ls but not on most of the immature, CD34++ cells (figure 7.6), expression of GM-
CSF-R also increased during differentiation into mature granulocytes and monocytes. 
Similar results have been derived from binding studies using t25I-GM-CSF or biotin-
OM-CSF on cell lines and murine and rhesus monkey BM cells [Heyworth et al.. 1991] 
[Wognum et aI., 1994J [McKinstry et al.. 1997]. A small cluster of CDllb+ cells was found in 
the Kit-I GM-CSF-R- fraction, and may represent natural killer (NK) ce/ls (Werfel el aI., 
199tJ. CDII b- cells with the scatter pattern of lymphocytes were found in the subsets 
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that were Kit-, EPO-R- and GM-CSF-R-. A fraction of these cells expressed the,li.-6' 
R (figure 7,5), as is in agreement with the presence of IL-6-R on T lymphocytes and 
absence on resting B lymphocytes [Taga et aL, 1987] [Coulie et al., 1989] [Wognum et aI., 1993]. 
Differentiation into CD7I ++ erythroid' cells is accompanied by a gradual loss of 
CD34 expression of the immature CD34++ I Kit+ cells during the transition of erythroid 
, burst-forming units (BFU-E), which are CD34 + and express very high Kit levels, to 
CFU-E, which have been found in the CD3410wI Kit+ fraction IDe long el ai., 19951. 
Simultaneously, EPO-R, which is not detectable on most CD34++ cells, is upregulated 
during erythroid differentiation, reaching maximal levels on CD71 ++1 Kit+1 EPO-R+ 
CFU-E and pro-erythroblasts [Bwudy et aI., 199tl [Wognum,el al .. 19921. Expressibn of EPO-
R on a subset of rhesus monkey BM cells that did not express Kit or CD71, and showed 
the light scatter pattern characteristic of TlOrmoblasts, indicates that the EPO-R is 
retained on maturing erythroid cells even after the loss of the transferrin receptor and 
Kit. The expression of IL-6-R on erythroid cells is less clear. Most of the CD71 ++ 
rhesus monkey BM cells were IL-6-R-, which demonstrated that the IL-6-R is not 
expressed on the majority of the erythroid cells. Moreover, most erythroid colony-
forming cells have been'found in the CD34+1 IL-6-R- fraction of human BM and cord 
blood [Tajima et al .. t9961. A small snbset of CD71 ++ cells was identified in the Kit+ I li.-
6-R + fraction, which may indicate that some erythroid cells expressed the IL-6-R. This 
would be in line with the reported erythropoietic effect of IL-6, as demonstrated by an 
increase in BM normoblasts induced by in vivo administration of IL-6 in rats [Ulich et al., 
1991J .. Alternatively, these cells might also represent activated non-erythroid cell s that 
are Kit+/ IL-6-R+, as CD71 is also upreguJated on activated cells of other lineages 
[Larrick and Cresswell, 1979] [Newman et aI., 19821. 
In conclusion, GFs that are labeled with DIG provide a useful extension of the 
existing cell staining methods to detect receptor expressing cells by flow cytometry. It 
is relatively easy to construct biotin- or DIG-labeled OFs, which retain the ability to 
bind to receptor expressing cells. By combining different labeled OFs with rnAbs 
against cell surface markers, it is possible to distinguish small subpopulations of bone 
marrow cells which coexpress various high affinity GF-R simultaneously. This 
approach is particularly useful to study changes in receptor expression patterns during 
differentiation of immature hemopoietic cells, and to explain the stimulatory and 
inhibitory interactions of hemopoietic GFs on phenotypically defined hemopoietic cells. 
However, it is more di~ficult to exclude a direct action on a given cell type, because the 
detection limit of the method is approximately 50-100 receptor molecules per cell [De 
long et a!.. 1992] [Wognum et aI., 19931 [Wognum et aI., 19941, whereas expression of only a few 
receptors can be sufficient for a biological response [Wognum et ~I., 1994] {Wognum et aL, 
1995] [Wognu~ et ai., 1996]. It is likely that neither radioactive labeling nor fluorochromes 
will yield even lower detection levels, which means that detection of such very low 
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receptor levels 'can as yet only be achieved by sensitive RT-PCR methods at the single 
ceilleve!. 
Keeping these limitations in mind, simultaneous cell staining with DIG-GF and 
biotin-GF can be used to identify individual cells responding to multiple GFs. Since two 
GF-R can engage in physical interactions when coexpressed on the same ceil, as has 
recently been demonstrated for Kit and EPO-R on transfected murine cell lines [Wu et ai., 
1995l, the abilily to detect the binding of different GFs to the same target cell can be 
used to examine whether similar interactions can take place on primary hemopoietic 
ceBs. Moreover, it provides an alternative approach to examine sharing of receptor 
subunits betwe~n different GF-R on rare hemopoietic ceBs, which are difficult to isolate 
in sufficient numbers to perform competition experiments using radioactively labeled 
GFs. A combination of various labeled GFs with a panel of cell ~urface markers will 
allow further characterization of stem cells and progenitor cell subsets on the basis of 
GF-R expression. 
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8.1 ABSTRACT 
The production of peripheral blood cells is regulated by hemopoietic growth factors 
(GFs) which promote the survival of stem cells and stimulate the proliferation and 
maturation of progenitors as well as effector functions of mature blood cell subsets. The 
actions of hemopoietic GFs are determined by the cellular distributi.on of receptors for 
these GFs within the hemopoietic tissues and by the functional program t~at receptor-
expressing cells can execute after GF stimulation. Identification of stem cells and their 
progeny and delineation of the GF receptor (GF-R) phenotype of these cells will 
estaqlish target cell range and functions of individual GFs in hemopoiesis. Cells with 
specific OF-R can be detected and isolated by flow cytometric methods, e.g., by 
staining with biotinylated ligand and fluorescently-tagged streptavidin, and classified 
on the 'basis of expression of the CD34 antigen and other markers that disti'nguish 
immature progenitors from more differentiated cells. Using_ this approach, distinct 
expression patterns have been identified for the receptors for interleukin-3 (IL-3), IL-6, 
granulocyte/ macrophage colony-stimulating factor (GM-CSF) and stem cell factor 
(SCF) on subsets of CD34 + and CD34- cells in bone marrow (BM). Expression of the 
IL-3 receptor (IL-3-R), IL-6-R and GM-CSF-R appears to be very low on the most 
immature subsets of CD34+ cells, but incr~ases progr~ssively during successive stages 
of, in particular, myelomonocytic differentiation. In contrast, the receptor for SCF, Le.,· 
Kit, is highly expressed on very immature CD34 bright/HLA-DRdult cells, which include 
stem cells. Kit levels decline during myelomonocytic and B-Iymphoid differentiation of 
CD34 + cells whereas t~ey increase to maximal levels during early stages of 
erythropoiesis. The heterogeneity in receptor expression, together with other 
immunophenotypic characteristics, aJIows for the identification of distinct progenitor 
cell subsets and differentiation stages within the CD34+ cell compartment. By selecting 
appropriate phenotypic criteria it will be possible to further dissect the stem cell 
compartment and eventually establish the, possibly heterogene-ous. hemopoietic GF-R . 
phenotype of pluripotent stem cells. 
8.2 INTRODUCTION 
The continuous production of peripheral blood cells is maintained by a co-ordinated 
process of self renewal, proliferation and differentiation of a small pool of hemopoietic 
cells in the bone marrow (BM) and other hemopoietic organs. Immature hemopoietic 
cells comprise only ..... 1 % of nucleated BM cells and are identified by expression of the 
CD34 cell surface antigen [Civin ct al., 1984}. The CD34+ population is heterogeneous 
and contains all cells that are needed for stable, long-term multiJineage hemopoiesis and 
those that are required for short-term production of functional blood cells of individual 
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lineages [Strauss et al.. 1986J [Berenson et al.. 1988] [Andrews et al .. 1992}. Immature, 
multi potent progenitors and more differentiated lineage-committed precursors within 
the CD34 + population can be distinguished on the basis of a variety of phenotypic and 
functional. parameters. These include DNA content, fluorescent dye uptake, and 
differential.e~pression of cell-surface antigens th~t are associated with activation status 
or lineage commitment. Examples of these antigens are HLA-DR, CD38, and Thy-I, 
which are differentially expressed on immature and more differentiated CD34+ cells, 
CD?I, which is highly expressed on activated and erythroid cells, CD33, which is most 
strongly expressed on myelomonocytic cells, and CD19, which is present on B-
lymphocyte progenitors [Loken et al.. 1987bJ [Loken et al.. 1987a] [Andrews et al.. 1989] 
[Sutherland et aI., 1989J [Terslappen et al., 1991J [Craig et aL. 1993J. 
Receptors for hemopoietic OFs provide additional, but less commonly used markers 
to distinguish CD34 + subpopulations, because they can be differentially expressed on 
immature progenitors and on differentiating cells of specific lineages. The ability of 
individual GFs to mediate stem cell survival and promote the outgrowth of specific 
lineages is determined by the expression of receptors for these GFs on different 
hemopoietic subsets and by the intrinsic developmental program receptor-expressing 
cells can execute after being stimulated. By analysis of GF-R expression, on CD34+ 
cells it is possible to identify the differentiation stages and lineages on which individual 
GFs can act and to further define the possible functions of individual OFs in regulating 
hemopoiesis at the level of single hemopoietic cells. Analysis of the co-expression of 
GF-R and changes in receptor expression in response to hemopoietic OF stimulation is 
important to clarify the complex patterns of redundancy, cooperation and antagon ism 
between different GFs that act on hemopoietic cells 
The purpose of this review is to discuss the cellular distribution of GF-R on 
hemopoietic cells, with emphasis on the receptors for IL-3, IL-6, OM-CSF, and stem· 
cell factor (SCF) on subsets of CD34 + cells. 
8.3 DETECTION OF RECEPTORS ON HEMOPOIETIC CELLS 
methodological aspects 
A variety of techniques has been used, in different studies, to detect GF-R 
expression on hemopoietic and mature blood cell populations (table 8.1). Quantitative 
binding studies with radiolabeled OFs have provided insight into binding kinetics, 
affinity and number of receptors on cell lines, leukemic blasts and mature blood ·cells 
[Budcl et aI., 1989] [Park ct al.. 1989] [Broudy et ai., 1992b]. This approach has also enabled 
analysis of receptor structure and interactions between different GFs, such as 
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competitive binding to shared receptor subunits and· modulation of receptor levels 
[Lopez et al.. 19891 [Elbaz et ai" 19911 [Lopez et aL, 1991J {Dudel et aL, 19931. 
table B.l 
Methods for detection of receptor expression on hemopoietic cells. 
Method 
1. Radiolabeled ligand binding 
2. In situ autoradiography with 
radiolabeled ligand 
3. RT·PCR 
4. Flow cytomelry (anti-receptor 
antibodies or labeled ligand) 
major applications 
Quantitative analysis of ligand/receptor 
interactions in homogeneous cell populations 
(cell lines, purified cells). Information on receptor 
structure and on Interactions between different 
ligands (competition. receptor modulation). 
Analysis of receptor distribution on 
morphologically recognizable cells. 
Detection of receptbr gene expression in small 
numbers of purified cells, 
Ana.lysis of receptor distribution within 
heterogeneous cell populations; comparison with 
. other immuno-phenotypic characteristics: 
isolation of cells on the basis of receptor 
expression. 
Quantitative binding with radiolabeled ligand requires large cell numbers and can 
only be used indirectly to m~asure receptor expression on rare cells, e.g., by correcting 
receptor numbers on unfractionated hemopoietic cells for those measured on a cell 
fraction from which CD34+ cells have been depleted ITesta et at" 1993J. Such studies 
have demonstrated that receptors for JL-3, IL-6, GM-CSF and erythropoietin (EPO) are 
expressed on CD34 + cells and that expression levels are rapidly modulated in r~sponse 
to OF stimulation. However, this approach does not provide insight into the expression 
of these· receptors on different subsets and differentiation stages within the CD34 + 
population or enable comparison with morphology or other phenotypic characteristics. 
In situ autoradiography with radiolabeled ligands is useful to examine receptor 
distribution in populations of morphologically recognizable hemopoietic precursors and 
mature blood cells [Sawada ct ~I., 1988) [Broudy et ~I., 1992b],·but is less suitable for analysis 
of CD34 + subsets, which show little morphological heterogeneity. 
Analysis of receptor mRNA expression by RT-PCR methods can provide 
information on receptor expression on small numbers of purified hemopoietic cells. 
This approach is. very sensitive and can even be used on single cells. However, stringent 
purification of target cells is required to get reliable results. In addition, the expression 
of receptor mRNA is not necessarily predictive of the presence of functional receptor 
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proteins. Discrepanci'es between mRNA and protein expression levels can occur as' a 
result of variations in gene transcription rates, RNA processing and stability, and 
mRNA translation efficiency. 
Flow cytometric methods that ,employ receptor-specific monoclonal antibodies or 
fluorescently tagged GF molecules as probes provide direct information on receptor 
protein expression and are suitable to detect receptor-expressing cells within 
heterogeneous populations. These approaches also require few cells and allow 
simultaneous analysis of other phenotypic characteristics such as expression of CD34 
and other cell-surface antigens. In addition, it is possible to isolate hemopoietic cells on 
the basis of their receptor phenotype for functional characterization. 
To obtain relevant information on the ability of cells to respond to a certain GF it is 
important th~t receptors are detected that are capable to bind cognate ligands at 
physiological concentrations. Most functional, high-affinity receptor complexes consist 
of homodimers [Lev et al., 1992J [Blechman et aL, 1995] {Blechman and Varden, 1995J, 
heterodimers [Hayashida et aL, 19901 [Itoh et ai., 1990] [Kitamura et aI., 1991], or larger 
complexes [Ward et aI., 1994] [Paonessa et aI., 1995] of individual receptor chains. Anti-
r~ceptor antibodies usually recognize individual receptor subunits and do not 
distinguish between cells that express functional receptors and cells that only express 
individual subunits or non ligand-binding isoforms. Hence, varia~ions between the 
ligand binding ability of different target cell populations, caused by differential 
expression: of individual subunits or isoforms, can remain unnoticed in binding 
experiments with antibodies. 
Flow cytometric detection of hemopoietic GF-R expression using labeled GF 
molc'cules has been used with a variety of ligand! receptor systems, e.g., IL-2, IL-3, ll...-
6, GM-CSF, G-CSF, SCF and EPO [Shimada et ,\., 19921 [Wagnum et ,1,,1992J [Wagnum et ,\., 
1993] [Wognum et aL, 1994]'[De long et aI., 1995a] [De long et aI., 1995b] [Wognum et aI., 1995J. 
Most often the GFs are covalently modified with biotin and used in combination with 
fluor<?chrome-conjugated streptavidin, but other approaches, e.g., direct conjugation of 
GFs with f1uorochromes or use of digoxigenin~conjugated GFs. in combination with 
fluorescently c.onjugated antibodies have been used as well [Glcizes et aI., (994). 
Specificity of staining is usually assessed by competition with-excess unlabeled ligand 
or anti-receptor antibody. The high detection sensitivity allows analysis of low receptor 
levels. For example, IL-6-Rs have been detected on CDS+ T-Iymphocytes, which 
express fewer than 100 high-affinity I~-6-Rs per cell [Taga et aI., 19871 [Munck Petersen et 
aI., 1990) (Wognum et aI., 1993]. Similarly, GM-CSF receptors have been identifie;d on 
myelomonocytic cell lines, such as HL60, which express 50-150 GM-CSF receptors per 
cell [Oasso/;l et al., 1986] [Park et aI., 1989] [Wognum et aI., 1994). 
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Receptor expressIon on Immature hemopoletlo cells 
Information on the receptor phenotype of rhesns monkey BM and on gradual 
changes in the expression levels during differentiation has been obtained by isolation 
and culture of receptor-expressing BM cells and by comparing receptor distribution 
with the expression of CD34 and RhLA-DR using multiparameter flow cytometry. The 
composition of different subsets of hemopoietic cells in rhesus monkey BM, identified 
by CD34 and RhLA-DR expression, is presented in table 8.2. Examples of the 
expression of receptors for GM-CSF, IL-3, IL-6 and SCF in relation to CD34 and DR 
expression on mononuclear BM celJs and on purified CD34+ cells are shown in figure 
8.1 and 8.2, respectively. 
The CD34bright population can arbitrarily be divided into DRbright and DR dull cells 
which, respectively, represent -0.5% and 0.1-0.2% of mononuclear BM cells. The 
small DRduli population contains committed progenitor cells and more primitive, 
multipatent cells that display high proliferative capacity, self renewal, and the ability to 
generate clonogenic cells for extended periods in hemopoietic GF- or stromal cell-
table 8.2 
Phenotype of rhesus monkey bone marrow cells idenlified on the basis of CD34 and RhLA-DR 
expression. 
region 1 Fraction 
CD34 '/DRbright 
2 CD34 '/DRdull 
3 
4 CD34 dull/DRdull 
5 CD34 brighl/DRbrighl 
6 CD34bright/DRdull 
As shown in figure 8.1 A. 
5.0·18.8 
9.0·37.4 
0.8-2.7 
1.5-3.0 
0.3·0.8 
0.1·0.2 
Phenotype3 
(immature and) mature a-lymphocytes; 
(monocyte p'recursors; activated T-
lymphocytes) 
resting T·lymphocytes; erythroblasts 
Pre-B-Iymphocytes; 
monocyte and granulocyte precursors; 
(e",throid progenitors: CFU-E and late BFU-
E) 
erythroblasts; (granulocyte precursors) 
committed progenitors and precursor cells 
of all major lineages 
commiUed and immature progenitors; 
(repopulating stem cells) 
2 Frequency relative to mononuclear bone marrow cells; range of 4 separate bone marrow 
samples. 
3 Phenotype of major cell types detected in the respective subsets. Between brackets: 
minor cell types, making up < 5% of the cells In each speCific region. 
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RhLA-DR: + 
figure 8.1 
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biotinylated growth factor + streptavidin-PE 
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++ 
+ 
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++ 
Hemopoietic growth factor receptor distribution on different subsets of rhesus monkey 
bone marrow cells; 
Low density bone marrow cells were stained first with biotinylated growth factors and 
then with phycoerythrin-conjugated streptavidin. Cells were counterstained with anti-
CD34-FITC and anli-HLA-DR-PerCP and analyzed by three-color flow cytometry. 
A. Relation between CD34 and RhLA-DR expression for cells gated in a light scatter 
window to exclude mature granulocytes, red blood cells, debris and aggregates from the 
analysis. The rectangular boxes indicate the electronic windows set to analyze the 
cellular composition (table 8.2) and receptor expression profile (8) of the different 
subpopulations that could be Identified. 
B. GM-CSF-R, IL-3-R, IL-6-R and Kit expression In the six distinct cell populations 
identified on the basis of CD34 and DR expression, as Indicated In A. Solid lines: cells 
stained with the respective blolinylated growth faclors. Dotted Ilnes: negalive controls, 
i.e., cells stained with biotinylated growth factor in the presence of 100-fofd excess 
unlabeled growth factor. 
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supported in vitro cultures [Brandt et aI., 1988} [Sutherland et ai., 19891 [Leary et aI., 19921 
[Wognum et aL, 1995]. It is assumed that the populations identified by such in vitro growth 
behavior contain the cells responsible for rapid hemopoietic reconstitution as well as 
those that sustain long-term multilineage hemopoiesis in vivo. Although formal proof 
of this hypothesis will require transplantation studies with allogeneic or genetically 
marked cells, results of syngeneic transplantation experiments with limited numbers of 
flow sorted autologous BM cells in rhesus monkeys indicate that rapid and stable 
multilin~age regeneration is mediated by CD34 brightl DRdull cells, but not by 
CD34 bright! DRbright .cells [Neelis et al; manuscript in preparation]. 
As shown in figure 8.2, Kit as well as the receptors for IL-3 and IL-6 can be 
detected on CD34 brightl DRdul! cells, which indicates that these receptors are present on 
immature hemopoietic cells. In contrast, the GM-CSF-R is barely detectablC in this 
subset, which may indicate that GM-CSF-R expression on immature cells is· much 
lower than that of the other receptors or that it is not expressed on ·most DR dull cells. 
Distribution of the receptors for GM-CSF, IL-3, and IL-6In the myelomonocytlc and 
erythroid lineages 
Differentiation of immature, CD34bright! DRduli cells is accompanied .by increased 
receptor expressioil. This is particularly evident for the GM-CSF receptor (figure 8.2). 
The highest levels of receptor expression for IL-3, IL-6, andGM-CSF are found on 
cells with low CD34 and high DR expression, which consist of immature precursors for 
neutrophils, basophils and monocytes (figure 8.1) [Wognum et al., 1994] [Wognum et al., 
1995]. Upon further differentiation, maturing neutrophils and monocytes continue to 
express the IL-6 and GM-CSF receptors, but lose the IL-3-R, at least in rhesus 
monkeys. Results from radiolabeled IL-3 binding experiments on purified monocytes 
suggest that the IL-3-R remains expressed at low levels on mature human monocytes 
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Hemopoietic growth factor distribution on purified CD34+ cells. 
CD34 + rhesus monkey bone marrow cells were affinity-purified using anti-CD34-coated 
immunomagnetic beads (Egeland and Gaudernack, 1994]. The Isolated cells were 
stained for growth factor receptor, CD34 and RhLA-DR expression and analyzed by flow 
cytometry. 
A. Relation between CD34 and RhLA-DR expression of the isolated CD34 + bone marrow 
cells. The rectangular boxes Identify the three subpopulations which could be identified 
and that were examined for light scatter (B) and receptor expression patterns (C). Note 
that regions 1, 2 and 3 have similar CD34 and DR expression as those in regions 3, 5 
and 6 in figure 8.1 and represent comparable cell populations. 
B. Light scatter of the cells identified In the three different regions shown in A. Cells with 
very low forward and right angle light scatter typical for lymphoid cells were found in 
region 1; region 2 contained cells with relatively high forward and diffuse right-angle light 
·scatter; whereas most cells in region 3 displayed Intermediate forward and low right-
angle light scatter. . 
C. Diiferential GM-CSF-R, IL-3-R. IL-S-R and Kit expression on each of the 3 CD34+ eel.1 
subsets identified in A. Broken lines represent control cells (stained In the presence of 
100-fold excess· unlabeled ligand). 
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[Elliott et aI., 1989} [Bude! et aI., 1990] [Elliott et aI., 1992]. It is possible that such results are 
caused by contamination of monocyte preparations with other cells, e.g.,- basophils, as 
we.have never found evidence for the presence of IL-3-Rs on monocytes in binding 
studies,with biotinylated IL-3 {Van Gils et ai., 19951 [Wognum et aI., 19951. Maturing basophil 
precursors, which are present in significant quantities in BM and blood of rhesus 
monkeys during the course of in vivo JL-3 treatment, maintain the IL-3-R at high levels 
and the GM-CSF receptor at low levels, but lose the IL-6-R [Van Gils et at., 1995]. The IL-
3, IL-6, and GM-CSF receptors are thus predominantly expressed on differentiating and 
mature cells of the myelomonocytic series, but show distinct distribution patterns on 
precursors and mature cells of individual lineages. 
It has been known for some years that early stages of erythropoiesis are regulated by 
other GFs than EPO [Wagemaker et al.. 1979] [Iscove et aI., 1982]. It is now clear that SCF is 
the major physiologic regulator of early erythroid development (see below). IL-3 and 
GM-CSF have also been implicated a~ stimulators of early erythropoiesis [Goodman et aI., 
t985] [Sieff ct at., t9851. Receptors for these cytokines are npt detectable on erythroid 
colony-forming cells or on cells that express erythroid antigens, such as CD7! [Wognum 
et al., 19941 [Wognum et at., t9951. This may indicate that IL-3 and GM-CSF require very 
low receptor levels to stimulate erythroid progenitors directly or that they act indirectly. 
e.g., via stimulation of OF production by accessory cells. IL-6-Rs can be identified on a 
small subset of CD71 bright BM cells that also express Kit (de Jong et ai, submitted). 
This suggests that IL-6 activities in erythropoiesis may be exerted through direct 
stimulation of erythroid cells [Ulich ~t ai., 19911. 
Kit expression on myelomonocytlc and erythroid cells 
Variable results have been reported for Kit distribution on cells of different lineages 
and differentiation stages [Ashman et aI., 1991] IPapayannopoulou et aI., 1991] [Broudy et aI., 
1992a] [Strobl et aI., 1992] [Gtmji et aI., 1993] [Reisbach et al., 1993] [Simmons et a!.. 1994]. These 
differences may be caused, in part, by differences between the target cell populations, 
variations in the binding affi~ity of anti-Kit antibodies used in different studies, and by 
the ability of some anti-Kit antibodies to inhibit proliferation of Kit+ cells, which may 
result in underestimating the clonogenic cell content of sorted Kit+ subsets. 
Nevertheless, the conclusion from most antibody studies is that Kit is predominantly 
associated with immature and erythroid cells, and less with differentiating-cells of 
monomyeloid and lymphoid lineages. Our results with biotinylated SCF are consistent 
with this view and indicate that most myelomonocytic proge~itors, i.e., granulocyte! 
macrophage colony forming units (CFU-GM), are present in the population of the -30-
"50% of CD34 bright cells that express Kit at intermediate levels similar to the levels 
found on more immature, CD34 brightIDRduil cells. Kit gradually disappears during 
granulocyte and monocyte differentiation in parallel with the loss of CD34 [De Jong et aI., 
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1995bl. A fraction (10·25%) of immature erythroid ce}}s, i.e., erythroid burst forming 
units (BFU·E), express Kit at similar levels as CFU·GM, but most BFU·E can be 
isolated in a distinct population that expresses Kit at very high levels and contains few, 
if any, non·erythroid progenitors [De long el al" 1995bl. Direct analysis of Kit and EPa 
receptor co-expression on BM cells. by combining biotinylated EPO with digoxigenin-
labeled SCF shows that Kit expression gradually declines after the CFU·E and pro· 
erythroblast stages, but is det~ctable until the nonnoblast stage [De Jong et al., in press]. 
Receptor expression on B-/ymphold cells 
Distinct receptor expression patterns have also been observed for the B·lymphocyte 
series. IL-3-Rs are expressed at various stages of B-lymphocyte differentiation (figure 
8.1). These include CD34 dull pre·B·lymphocytes, which express DR, CD 10 and CDI9, 
and CD34- immature B-Iymphocytes, ,vhieh express IgM and low levels of CD20 
(figure 8.3) [Salo el at" t9931 [Wognum el aI., 19951. CD20brighl mature B-cells are receptor-
negative (figure 8.3). The presence of IL-3-Rs on the B-celilineage is consistent with 
the reported activities of this cytokine in regulating B-lymphopoiesis in vitro and in 
vivo [Palacios ct ai" 1984J [Tadmori et al.. 1989] [Wonnann et a1., 1989] [Cockayne et al., 1994}. 
IL-6-Rs and GM-CSF-Rs have not been identified'on B~cell precursors or on mature 
B-Iymphocytes [Coulie et a!., 1989} [Wognunl et al., 1993]. However, ll..-6 has been shown to 
be essential for the developmel}t and continued growth of B cell neoplasms and to be 
involved in the differentiation of normal B-cells into Ig-secreting plasma c~lIs [Hirano et 
al., 19861 [Kawano et at., 19881 [Hilb"l el al., 1995J. This suggests that lL-6-R may become 
expressed aner B-cell activation. SCF is active at early stages of B,lymphopoiesis, but 
not at later stages and this is reflected by expression of Kit on only a small fraction of 
CD34+f CDI9+ BM cells, as determined in binding studies with anti-Kit antibodies 
[Simmons ct-al., 1994J. 
Receptor expre~sion on stem cells 
CD34 brighlfDRduil BM cells constitute a small cell population that is heterogeneous 
and stlII a factor IOL 103 remote from a pure stem cell population. The presence of IL-
3, IL-6 and SCF receptor expressing cells in the CD34 brighlf DRdull subset (figure 8.2) 
indicates that these receptors are expressed ·on immature celis, but does not provide 
definitive evidence for expression on pluripotent stem cells. 
Kit is dete~table on the majority of immature CD34 brighlf DRdull cells in human and 
rhesus monkey BM (figure 8.2) and on CD34 brighl f CD38- human BM cells, which 
represent a comparable immature cell population [Briddell ot al.. 1992J. For this reason, it 
is likely that Kit is expressed on pluripotent stem cells. Direct evidence for the presence 
of Kit on repopulating stem cells comes from transplantation studies in mice, as limited 
numbers of sorted Kit+ BM cells can reconstitute short-term and lo~g-term 
multilineage hemopoiesis in recipient mice, whereas much higher numbers of Kit- <:elis 
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cannot [lkuta and Weissman, 1992] [Okada et aL, .1992] {Odic et aL, 1993] (chapter 4). Similar 
transplantation studies with sorted ce1ls are not possible for the IL-3 and IL-6 receptors 
since expression levels on immature cells are much lo\ver than that of Kit and 
insuffic.ient for reliable separation of receptor-positive and receptor-negative cells. 
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figure 8.3 
The IL-3 receptor is expressed at low levels on CD20dull/lgM+ immature B-cells but not 
on CD20bright mature B-cells. 
,Parallel bone marrow samples were stained for IL-3-R exp·ression, using biotinylated IL-3 
and slreptavidin-PE, counterstained with anti-CD20-FITC and anti-lgM-FITC, 
respectively, and analyzed by two-color flow cytomelry. Note that CD20dull cells (A) and 
a fraction of IgM+ cells (C) show specifiC staining with biotinylated IL-3, whereas. specific 
staining is not detectable on CD20bright cells (8), 
Information on the importance of these cytokinel receptor pairs for early stages of 
hemopoiesis has been obtained from receptor mRNA expression studies and from 
studies with mice in which GF- or GF-R-genes were inactivated by homologous 
recombination_ A highly selected fraction of immature hemopoietic cells, prepared by 
elimination of dividing cells by 5-Fluoro-Uracil treatment, has been shown to express 
RNA for Kit and for both chains of the IL-6:R, but to be negative for the Ct chain of the 
GM-CSF-R and the shared P chain of the IL-3-R, IL-5-R and GM-CSF-R [Bemrdi et aI., 
1995J_ These data confirm the flow cytometry data that show that Kit and the IL-6-R are 
expressed on very immature cells, whereas the GM-CSF-R becomes expressed at later 
stages_ These resuits also suggest that the IL-3-R, although detectable on CD34bright/ 
DR dull cells, may not be exp~essed on the most primitive cells within this population. 
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In agreement with receptor expression data, gene knockout mice that lack functional 
IL-6 or the gp130 sig-nal transducing subunit have reduced numbers of immature 
hemopoietic cells [Kishimoto et nl., 19951 [Kopf et nl., 1995]. Thus it appears that IL-6 is 
important for early hemopoiesis in vivo, although it remains to be established to what 
extent the activities of IL-6 on stem cells and immature progenitors can be taken over 
by other cytokines that utilize gp130 for signal transduction, e.g., IL-ll, oncostatin-M 
or Leukemia Inhibitory Factor. 
In contrast to IL-6 deficient mice, hemopoiesis is relatively normal in homozygous 
mutant mice that either lack functional OM·CSF or the shared p chain of the IL·3, IL-5 
and GM-CSF receptors [Drnnoff and Mulligan. 1994] [Nishinakamura et aI.. 1995]. This 
confirms that GM-CSF is nonessential for early hemopoiesis, at least unc;ier normal 
steady-state conditions. Appraisal of the role of IL-3 in early hemopoiesis in vivo will 
require inactivati<?n of the genes for IL-3 itself, for the IL-3-R 0: chain, or the genes for 
both the shared and unique IL-3-R P chains that are co-expressed in murine cells [Hara 
nnd i\-Hyajima, 1992], as miCe that lack only the gene for the unique IL-3-R P chain art:;: 
normal [Nishinnkamura ct al.. 19951. 
In summary (see-table 8.3); the combined data indicate that Kit is expres~ed on stem 
cells and remains expressed at detectable levels after lineage commitment and during 
early stages of differentiation after which Kit levels diverge upon further maturation of 
erythroid, B-Iymphoid, and myelomonocytic lineages. In addition to myelomonocytic 
cells and mature T -lymphocytes, the IL-6-R appears to be expressed on stem cells, but 
. at low levels. The expression of the IL-3-Rand OM-CSF-R on stem cells is uncertain. 
The IL-3;.R becomes detectable at earlier differentiation stages than the OM-CSF-R, as 
the IL-3-R can be detected 011 CD34brighli DRdutt celis, whereas the OM-CSF-R is 
barely detectable on these cells. Whether or not the iL-3-R expressing CD34brighli 
DR dull cells include stem cells or consist of progenitors committed to myelomonocytic 
or B-Iymphoid differentiation remains to be established. 
Receptor expression on malignant cells 
Comparison of the receptor phenotype of normal hemopoietic cells with that of 
leukemia ceHs may help to identify the cells that initiate and maintain the malignant 
clone and may provide informati_on on the OF regulation of leukemic cells. IL-3 and 
GM-C~F receptors as well as Kit have been identified on acute myeloid leukemia 
(AML) blasts by equilibrium binding of radiolabeled GFs IBudet el aI., t98911Broudy el aI., 
1992b] [Pietsch et nl., 1992}. However, the average number of receptors did not correlate 
with the ability of AML cells to respond to these OFs as measured in short term assays 
that measure 3H-tbymidine incorporation or colony formation. Results of 
multiparameter FACS studies with anti-receptor antibodies [Ashman et al.. 1988] [BUhring et 
aI., 199tl [Reuss·Borsl el aI., H94], or with biotinylated ligand (figure 8.4) have indicated 
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heterogeneity within AML populations with respect to the expression of Kit and CD34. 
This heterogeneity can explain the discrepancies between OF responses and average 
receptor levels, as only specific subsets of AML cells may have the ability to grow in 
vitro and the receptor phenotype of these subsets may not correspond with that of the 
AML population as a whole. 
table 8.3 
Overview of receptor expression on hemopoietic cells and mature blood cell subsets. 
receptor ce"type expression level 
GM·CSF-R c?mmilled progenitors 550 
myelomonocytic precursors 102·4x103 
monocytes _4x103 
neutrophilic granulocytes 5x10 2·1x103 
basophilic granulocytes _10 2 
IL-3-R immature progenitors 550 
committed progenitors _10 2 
myelomonocytlc precursors 102·5x103 
B-Iymphocyte precursors 102'5x102 
basophilic granulocytes 1x103-2x103 a 
IL-6-R stem cell~limmalure progenitors 550 
Kit 
progenitors 50-102 
myelomonocytic precursors 102-103 
monocytes 103 
neutrophilic granulocytes -5x102 
CD4 + T-Iymphocytes -4x10 2 
CD8 + T -lymphocytes -1x102 
stem cellslimmature progenitors _103 
myelomonocytic progenitors (CFU·GM) _103 
myeJomonocytic precursors <102-103 
erythroid progenitors (BFU-E) 103-6x103 b 
erythroId precursors 102-6x103 b 
Receptor numbers are estimated on the basis of the sensitivity of the flow cytornetric 
receptor detection method (-50 receptors per cell), the relative fluorescence intensity of 
different subsets and by comparison with receptor numbers on purified cell populations 
obtained In equilibrium binding experiments with radlolabeled growth factors. Only cell 
subsets on which receptors have been Identified are indicated. 
a High-affinity sites; basophils also express 15,000-30,000 low affinity IL-3-R; (see (Van 
Gils et aI., 1995)) 
b Kit expression gradually inbreased during BFU-E differentiation and declines after the 
CFU·E/ pro'erythroblast stage. 
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figure 8.4 
Heterogeneity of CD34 and Kit expression on AML cells. Bone marrow cells from four 
patients with AML were stained for Kit expression (using biotinylated SCF and 
slreplavidin·PE) and for CD34 expression (using anli·CD34·FITC) and .analyzed on Ihe 
FACS. The quadrants indicate the limits of CD34 and Kit expression based on the 
fluorescence 'of specificity controls (cells stained with biotinylaled SCF in the presence of 
excess unlabeled SCF and cells stained with a FITC-Iabeled isotype control antibody). 
Note that each AML sample is heterogeneous with respect to Kit and CD34 expression 
and that the four AML cases show non-identical cellular distribution ollhese antigens. 
Evidence for functional heterogeneity of AML cells has been obtained in cell culture 
and SCID mouse transplantation studies with purified AML subsets [Lapidot et a!., 1994] 
. [Terpstra ct ai., 1996]. The results indicate that only specJfic subsets can initiate leukemia 
in scm mice and Ihat in vivo leukemogenic ability of different subsets does not 
correlate with the ability for short-term growth in vitro [Lapidot et ai., 1994] [Terpstra et ai., 
19961. In one study, only CD34+/ CD38- AML cells could develop in transplanted 
scm mice. This suggests that Ihe immunophenotype of leukemia-initiating AML'cells 
is identical to that of the most immature hemopoietic cells that can be identified in 
normal BM [Lapidotet 01., 1994J, HOlVever, in another AML case, scm repopulating cells 
were present in CD34+ and CD34- subsets [Terpstra et aI., 1996]. This indicates 
differences between the phenotypes of leukemic stem cells from different AML cases 
and heterogeneity within the leukemic stem cell pool of individual cases. The apparent 
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lack of a common phenotype of AML stem cells probably reflects the diversity of target 
cells and target" genes for leukemic transformation in AML and this will complicate the 
analysis of the GF-R phenotype and GF regulation of the AML subsets with in vivo 
leukemogenic ability. 
Chronic myeloid leukemia (CML) is a more homogeneous disease than AML as it is 
caused by a specific chromosomal translocation between the abl proto-oncogene and 
the ber locus on chromosomes 9 and 22, respectively. in a pluripotent stem cell or early, 
multipotent progenitor [Fialkow et al., 1977] [De Klein et aI., 1982] [Groffen et aI., 1984]. The 
,leukemic stem cell in CML is believed to phenotypically resemble; its normal 
counterparts and to express high levels of CD34. As yet, little is known about the 
hemopoietic GF-R phenotype of immature CML subsets. Because Kit is expressed on 
normal stem cells and is involved in regulating early stages of normal hemopoiesis it is 
of interest to examin~ the role of the Kit and its ligand in the growth of early CML 
cells. It is unknown whether bcdabl expression can alter Kit expression and SCF 
responsiveness in CML cells. Neverthele'ss, immature CML cells show impaired 
outgrowth when cultured on SCF deficient stromal cells [Agarwal et aI., 1995], and this 
reduced SCF responsiveness may be related to reduced Kit expression levels on 
immature, CD34,bright/ CD38- CML cells [Wognum ct ai., 1995]. Alterations in receptor 
gene expression as a result of p210bcr/abl action may also be involved in the increased 
expression of the IL-2R a chain and of the EPa receptor on immature CML cells, 
which are usually not detectable on most normal CD34 + cells {Visani et al.. 1987} [Wognum 
et<lI.,1992}. 
Further comparison of GF-R expression on normal hemopoietic cells and those of 
cells at comparable stages of leukemic cell differentiation will improve our knowledge 
of the phenotype and GF regulation of leukemic cell survival and proliferation. In 
addition to a better understanding of th'c· pathophysiology of leukemia this information 
will be relevant to the design of improved therapeutic strategies aimed at selective 
elimination of leukemic stem cells. 
8.4 ConclUding remarks 
The heterogeneous composition of the CD34 + cell compartment with respect to 
immunophenotype and receptor expressi~n profile allows distinction between 
progenitor cells of individual lineages and at different stages of differentiation. By 
selecting .appropriate immunophenotypic crheria and by combining in vitro stem cell 
assays with analysis of the repopulating ability of purified cells, e.g. by transplantation 
into SCID mice or lethally irradiated rhesus monkeys, it will be possible to further 
dissect the stem cell compartment and eventually focus on the pluripote'nt stem ceiL It 
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remains to be seen if a single phenotype and receptor profile can be associated with the 
pluripotent stem cell or that the stem cell constitutes a heterogeneous population itself. 
Heterogeneity in the relative expression levels of GF-R on stem cells, either as a result 
of stochastic processes or induced by external stimuli, can confer flexibility on the 
responsiveness of stem cells to different hemopoietic stimuli. This ensures that 
sufficient stem cells are recn,lited in response to any given set of stimuli to meet blood 
cell demands, while suffici~nt stem cells remain unresponsive and quiescent. Such a 
mechanism would be crucial to prevent depletiOJl of .the stem cell pool during 
emergency hemopoiesis. 
The details and significance of these mechanisms in regulating the balance between 
quiescence and activation, self renewal and lineage commitment of pluripotent stem 
cells are still far from clear. Elucidation of receptor (co-)expressioll on the pluripotent 
stem cell and its immediate progeny and of changes in the expression levels of different 
GF-R on these immature cells in response to GFs and inhibitors will be pivotal to a 
better understanding of stem cell regulation. In this respect it will also be important to 
further delineate the expression of the STK -lfFIt31FIk-2 receptor tyrosine kinase [Smail 
et ai., 1994) and the TPO receptor, Mpl [DebiJi et aI., 1995} , on stem cells and on progenitors 
and to examine the modulating effects of soluble GF-R subunits, which may act either 
as co-stimulators or inhibitors of cell'growth (for a recent review see [Heaney and Golde, 
1996]) Finally, studies into the GF regulation of stem cells and immature progenitors 
will be important to select suitable target cell populations and transduction conditions 
for gene marking and gene therapy of stem cells and for the rational use of GFs to 
support hemopoietic recovery in myelosuppressed patients. 
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9.1 Purpose and methodology 
Growth factors (GFs) play an important role in the maintenance of viability and the 
stimulation of proliferation and differentiation of hemopoietic cells. Despite the 
increasing insight into GF actions in vivo and in various culture systems, little is known 
about the specific target cells for each individual GF and the mechanisms by which 
GFs, individually and in cooperation with each other, stimulate hemopoiesis. The 
interaction of a OF with its target cell is inediated by cell membrane receptors specific 
for the particular OF. Therefore, analysis of OF-receptor (OF·R) expression on 
hemopoietic stem' cells (HSC) and of changes in receptor expression during 
differentiation of blood cell lineages provides a direct means to assess the target,cell 
range and thus the possible spectrum of biological activities of OFs within the 
hemopoietic system. 
To obtain relevant information on the1ability of cells to respond to a certain OF, it is 
important that cells are de!ected that express the functional receptors that are able -to 
bind OFs. In this thesis, the development and application of methodology to examine 
cell surface receptor protein expression on hemopoietic cells is described.-The principal 
method used in this' study is based on sequential staining of cells with biotinylated GF 
moleCUles and f1uorescently labeled (strept)avidin, followed by analysis of receptor-
expressing cells using flow cytometry. This allows simultaneous detection of receptors 
and other cell surface markers, and is suitable to examin.e receptor expression on subsets 
of heterogeneous cell populations such as bone marrow (BM). Moreover, this approach 
can ,be used to isolate viable hemopoietic cells on the basis of their receptor expression 
for functional characterization. 
The feasibility of preparing and using biotinylated GFs to',study GF-R expression 
was examined using interleukin-2 (IL-2). IL-3, IL·6, granulocyte! macrophage colony-
stimulating factor (OM-CSF), and stem cell factor (SCF) (chapter 2). As GF-R 
expression on immature hemopoietic cells can be \~ery low, we applied methodology to 
increase the fluorescence signals, of cells stained with biotinylated GFs and 
fluorescently labeled (strept)avidin. Fluorescence amplification by incubation with 
alternate layers of biotinylated anti-(strept)avidin antibodies and fluorescently labeled 
(strept)avidin resulted in a detection sensitivity lower than 100 molecules per ceH,.as 
estimated from a cell line with known receptor numbers (chapter 2). However, these 
results were obtained using homogeneous cell suspensions; cells with low receptor 
numbers may remain undetected in heterogeneous cell suspensions, such as BM, 
especially when these cells are present at low frequencies. 
Using 1L-2 as a model system for hemopoietic OFs, different meth~ds and reagents 
to labe~ GFs with biotin were compared, and the most sllttable biotin derivatives were 
selected (chapter 3). These experiments showed that high oiotinylation efficiency, 
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retention of biological activity, and specific staining of receptor-expressing cells can be 
achieved by GF labeling with N-hydroxy-succinimide (NHS) biotin, potentially with an 
extended spacer arm. Other biotinylation reagents, such as p-Diazobenzoyl Biocytin 
Precursor (DBB) or photoactivatible biotin, performed less well on IL-2. Optimal 
biotinylation conditions are dependent on the type of GF, which determines the 
possibilities for modification of amino acid or sugar residues, and the biotin-to-protein 
(B:P) ratio that yields the highest degree of conjugation and maximal retention of 
biological activity. With NtiS-biotin we achieved good results on IL-2 as well as all 
other GFs that were labeled in this study (e.g. chapter 2), and was used in the 
experiments described in this thesis. 
9.2 Kit expression studies on murine cells 
To characterize hemopoietic celI.s that express the SCF-R, Kit, murine BM cells were 
stained either with biotinyJated SCF or with anti-Kit antibodies, after which Kit+ and 
Kic cells were sorted llsing flow cytometry (cliapter 4). In vitro and in vivo analysis of 
these cells showed that Kit is expressed on immature cells at various differentiation 
stages. The Kit+ BM fraction contai,ns HSC with long- as well as cells with short-term 
repopulating ability, cells that form colonies in spleen and cells that form colonies in 
culture (CFU-S and CFU-C (CFU-GM + BFU-E), respectively), and morphologically 
recognizable immature myeloid and erythroid cells. In contrast, in the Kit- BM subsets, 
very few CFU-C and CFU-S are found, and hardly any long-term repopulating cells .. 
Compared to unfractionated BM, the biotin-SCF+ mouse BM subset is 40- to 70-fold 
enriched for clonogenic cells (chapter 4). Since the Kit+ subset comprises 1-2% of the 
nucleated BM cells, higher enrichment values than 50- to I DO-fold cannot be expected 
using Kit expression as a single sorting parameter, and additional markers are needed 
for further enrichment of immature cells. Negative selection against expression of 
various lineage markers, which is used by some groups in combination with positive 
selection for Kit expression [Okada et a!., 1991), does not result in further enrichment for 
clonogenic cells, as these markers. are not expressed on Kit+ cells. A possible candidate 
for further enrichment of Kit+ fractions for immature cells is Rhl23 retention, as we 
have shown that Kit,+ cells are heterogeneous with respect to Rh 123 retentio~ [Visser et 
aI., 1993], and it is known that the Rhl23dull fraction contains the HSC, whereas more 
differentiated progenitors are found in the Rh123 brigl"lt population (Ploemacher and Brons, 
t9881. A disadvantage of Rhl23 is that it is technically difficult to achieve sufficient 
fluorescence compensation between the Rhl23 and the Kit-PhycoErythrin (PE) 
fluorescence signals on the flow cytometer; and two separate sorts are required to purify 
Kit+t Rhl23dult cells. In this respect the use of other fluorochromes, such as the vital 
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DNA stain Hoechst 33342, may be of interest to separate primitive progenitors frotn 
more mature cells within the Kit+ population [Baines and Visser, 1983] {Goodell et aI., 1996]. 
\Vithin the Kit+ fraction, differences were found between the cells that bound biotin-
SCF and the cells that reacted with anti-Kit antibodies (ACK-2). A higher percentage of 
BM cells could be stained with ACK-2 than with biotin-SCF (chapter 4). Selection of 
Kit+ cells after incubation with biotin-SCF yielded fractions with 2- to 3-fold higher 
frequencies of cionogenic cells than obtained after staining with ACK-2. An effect of 
cell staining with biotin-SCF or ACK-2 on colony formation or repopulating capacity 
was not found, which excludes the possibility that some progenitors were inactivated or 
stimulated by these reagents. It is possible that these differences reflect a different target 
cell specificity of biotin-SCF and ACK-2, as the biotin-SCF+ and ACK-2+ fractions 
display different morphology, light scatter, and Rhodamine 123 (Rh 123) retention 
properties [Visser et ai., 1993]; 
\Ve have attempted to elucidate the molecular basis for the differential cell staining 
with biotin-SCF and anti-Kit, using sublines of the IL-3 dependent murine cell line 
FDC-PI (chapter 5). Although ACK-2 binds to parental FDC-PI cells, which 
demonstrates Kit protein expression, no or very low fluorescence signals were found 
after incubation of these cells with biotin-SCF, and SCF did not induce detcctable 
proliferation of the cells. In contrast, after adaptation of FDC-PI cells to grow in 
medium supplemented with SCF, a subline was selected that showed specific staining 
with ACK-2 as well as biotin-SCF. These results indicate that ACK-2 binding (and thus 
Kit+) cells may b~ heterogeneous with respect to ligand binding capacity. Amplification 
of various regions of c-kit RNA, using the reverse transcriptase polymerase chain 
reaction (RT -PCR), did not provide an indication of structural alterations in domains 
known to be involved in ligand binding or receptor dimerization on the subline that 
showed Kit expression without binding SCF. Isolation. of Kit molecules llsing 
immunoprecipitation also did not reveal evidence for qualitative differen~es in 
expression of the Kit proteins on the cell surface between the FDC"PI subline that binds 
SCF and the subline that does not. Although these results do not exclude the possible 
occurrence of structural differences that are not detectable with the approaches llsed, 
our RT-PCR and immunoprecipitation results suggest"that only quantitative differences 
exist between the FDC-P 1 sublines. As the differences in Kit expression are too small to 
explain the large differences in biotin-SCF binding between the sublines, it was 
postulated that this discrepancy may be caused by the requirement for a minimum 
number of Kit monomers to enable efficient dimerization of Kit molecules to form high 
affinity SCF-R. 
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9.3 Kit expression studies on rhesus monkey cells 
To examine expression of the SCF-R on hemopoietic cells from primate origin, we 
double-stained rhesus monkey BM cells with biotin-SCF and an antibody against 
CD34, a marker that.is specific for immature cells [Civin et aI., 1984] [Krause et aI., 1994]. 
Although recent murine transplantation studies suggest that some HSC in this species 
may be CD34- [Osawa el al" 1996J. results of autologous and allogeneic transplantation 
studies with purified simian ~D34+ cells [Berenson et aI., 1988] [Wielenga, 1990] and 
evidence from transplantations with purified CD34+ cells in human patients [Berenson et 
aI., 1991J [Kawashima el .1., 1996J [Yab~ el .1., 1996J have demonstrated that all the necessary 
cells for short-term reconstitution and long-term multilineage hemopoiesis can be found 
within the CD34 + population. 
The in vitro colony-forming potential of CD34 + rhesus monkey BM cells expressing 
Kit at high, intermediate, or low (undetectabJe) levels was analyzed (ehapter 6). These 
experiments showed, that the majority of the granulocyte! macrophage colony-fonning 
units (CFU-OM) reside in a fraction of CD34 +! Kitmed cells (figure 9.1). This subset 
also contains the cells with highestCD34 expression and low levels of the class II 
histocompatibility antigen RhLA-DR (the rhesus monkey equivalent of HLA-DR), a 
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figure 9.1 
Changes In CD34 and Kit expression during erythrOid (black arrows) and monomyeloid 
(white arrows) differentiation of rhesus monkey 8M cells. 
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phenotype that is associated with the most primitive cells that can be detected in vitro, 
e.g. in long-term BM cultures, and that has recently been shown to. contain the cells 
needed for rapid hemopoietic reconstitution in irradiated rhesus monkeys [Neelis et al., 
manuscript in preparation]. Similar to our results in mice, these data strongly suggest 
that Kit is expressed, although at low levels, on repopulating HSC in primates. 
Additional studies, e.g. transplantation with allogeneic or genetically marked rhesus 
monkey BM cells will be needed to definitively establish whether all cells requited for 
rapid reconstitution as well as stable long-term hemopoiesis express Kit. 
During monomyeloid differentiation the immature, CD34 +/ ~itmed rhesus monkey 
BM cells gradually lose both Kit and CD34 (figure 9,1). During erythroid 
differentiation, Kit expression is initially upregulated. Some erythroid burst-forming 
units (BFU-E) express Kit at a relatively low level, but most BFU-E are found in a 
distinct population that expresses very high Kit levels and contains few, if any, non-
·erythroid progenitors. Upon further differentiation into erythroid colony-forming units 
(CFU-E), CD34 expression declines, and Kit is gradually lost from the cell surface. 
In contrast to our results on rhesus monkey EM, most BFU-E in human BlvI were 
found in the ·Kit1ow.subset, whereas few BFU-E were Kithi [Gunji et aL, 1993] [Simmons et 
aI., 1994]. This might reflect a difference between Kit expression on human and rhesus. 
monkey erythroid cells. In several double-staining experiments with biotin-SCF and 
anti-CD34, we have found that c.lusters of CD34v and Kitvexpressing subsets in human 
BM were less distinct than in rhesus mo.nkey BM. This sugge.sts that Kit distribution on 
human progenitors may indeed be different from that on rhesus monkey progenitors. 
Another possible explanation for the observed differences is the methodology us.ed to 
detect Kit expression. All studies of Kit expression on human cell.s have been 
performed with anti-Kit antibodies, which may show different target cell specificity to 
I . 
primate BM subsets than biotin-SCF, sin~i1ar to what we reported for murine BM 
(chapter 4). Indeed we found that a larger fraction of human BM cells binds anti-Kit 
antibodies than biotin-SCF [Wognum et aI., 1996], although the reason for these differences 
is still unresolved. Cell staining with anti-Kit antibodies can cause inhibition of 
outgrowth of Kit+ cells, which results in underestimation of colony formation by the 
Kit+ cells after staining with anti-Kit [Lerner et aI., 1991] [Broudy et aI., 1992] {Gunji et al., 
19931 [Liesveld et al.. 1995]. Neutralization of Kit+ cells does not occur after binding of 
biotin-SCF (chapter 4 and chapter 6). Comparison of in vitro clonogenic ability of the 
different Kit-expressing subsets of human and rhesus monkeY,BM after staining with 
biotin-SCF and with anti-Kit is needed to elucidate these differences, and establish the 
Kit expression profile for human celis". 
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9.4 Changes in coexpression of GF-R during differentiation 
To define the functional interaGtions of different GFs on hemopoietic cells it is of 
interest to examine the patterns of coexpression of these receptors on BM subsets. For 
simultaneous examination of the expression of receptors for two different GFs on the 
basis of ligaTld binding, we developed a method that combin'es cell staining witli 
biotinylated GFs and digoxigenin- (DIG-) labeled GFs (chapter 7). Using this method 
togethet with antibodies against other cell surface markers, patterns of coexpression of 
receptors for SCF and either erythropoietin (EPO), IL-6, or granulocyte/ macrophage 
colony stimulating factor (GM-CSF) on immature progenitors and on differentiating 
erythroid and myelomonocytic precurso~s in rhesus monkey BM were analyzed. 
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figure 9.2. 
Changes in coexpressibn patlerns of Kit and the receptors for EPO, IL-6, and GM-CSF. 
respectively, during differenllallon of monomyeloid (while arrows) and erythrOid cells 
(black arrows). 
Simultaneous expression of Kit and EPO-R was not found on the CD34+ ceils 
(chapter 7). The abSe!lCe of EPO-R from HSC is in agreement with the notion that 
early stages of erythropoiesis are regulated by other GFs than EPO [Iscove, 1977] 
[Wagemaker et al.. 1977J [Wagemakeret aI., 1979J. \Vith erythroid commitment of immature 
progenitors, Kit is upregulated, and the cells then acquire EPO-R (figure 9.2). After the 
erythroid colony-forming unit (CFU-E) an.d pro-erythroblast stages, Kit expression 
gradually declines, but remains detectable up to the normoblast stage, EPO-R 
expression is retained on maturing erythroid cells even after these cells lose CD?1 and 
Kit. These results indicate that SCF is a more important regulator of early erythroid 
development than EPO, which plays a role on more mature erythroid cells. The 
coexpression of Kit and the EPO~R may be crucial for the balance between proliferation 
and differentiation of erythroid cells, as it has recently been shown that tyrosine 
phosphorylation of the EPO-R by Kit is essential for EPO-induced proliferation but not 
for differentiation of erythroid precursors- [Wu et aI., 1997}. Thus, the loss of Kit late in 
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erythroid development may result in the cessation of EPO-induced mitogenesis and 
promote the final maturation of ~rythroblasts. 
Part of the CD34+/ Kit+ cells coexpress the IL-6-R (chapter 7), and IL-6-R can be 
detected on CD34brighl/ DRdu·1t cells (chapter 8). As the hetero~eneous CD34 brighl/ 
DR dult BM subset is still a factor I OL I 03 remote from a pure stem cell population, we 
do not know whether IL-6-R are expressed on HSC. Transplantation studies with sorted 
cells, similar to those described for Kit (chapter 4), are not possible for IL-6-R, because 
the expression level of this receptor on immature cells is not sufficiently high for a 
reliable separation of receptor-positive and receptor-negative cells. RNA for the IL-6-R 
as well as RNA for the gpl30 signal transduction subunit have been detected in the 
human immature hemopoietic cell fraction [Berardi et ai., 19951. In addition, gene 
knockout mice that lack functional IL-6 or gpl30 have reduced numbers of immature 
hemopoietic cells [Kishimoto et aL, 1995J [Kopfet al., 1995J. Thus it appears that IL-6-R are 
expressed at HSC, although at low levels. However, it is also possible that the majority 
of the HSC express only the gpl30 subunit and not the IL-6-R itself, implying that the 
cells cannot be stimulated by IL-6 alone, but only by a combination of IL-6 and soluble 
IL-6-R. In agreement with this, most of the' long-term culture-initiating cells (LTC-IC) 
have been found in the CD34+ /IL-6-R- ftactions of human BM and cord blood [Tajima 
et aI., t996J. 
During granulocyte and monocyte differentiation, Kit graduaUy disappears, whereas 
IL-6-R are upregulated (figure 9.2). Maturing monocytes and neutro~hilic granulocytes 
express IL-6-R. basophils do not [Wognum el al.. 1993J [Van Gils el al .. 1995J. During 
erythroid differentiation, IL-6-R expression is lost on the majority of the cells, although 
a small subset 9f erythroid cells may remain IL-6-R +, as IL-6-R can be identified on a 
small subset of CD71 +/ Kit+ BM cells (chapter 7). 
Coexpression of Kit and GM-CSF-R was not found on CD34+ cells (chapter 7), and 
no GM-CSF-R were detectable on CD34brighl/ DRduli cells (chapter 8). This implies 
that the GM-CSF-R is not expressed on HSC, or that its expression Jevel is below the 
detection limit of 50-100 receptors per cell. GM-CSF-R are also absent from the 
erythroid lineage, suggesting that the erythroid-burst promoting activity previously 
attributed to GM-CSF [Melcalf el al .. 1980J might be mediated by indirect mechanisms. 
During monomyeloid differentiation, GM-CSF-R expression levels are upregulated 
(figure 2). RNA for the murine GM-CSF-R p subunit was found in a subset that 
contains committed progenitor cells, but not in the subset that includes HSC [Visser et al., 
1993J, which supports the lack of GM-CSF-R on HSC. Moreover, RNA for the shared 
IL-3/ IL-5/ GM-CSF-R P subunit or the GM-CSF-R a subunit was not found in a highly 
enriched immature hemopoietic cell fraction of human BM [Berardi et aI., 19951. Further 
evidence that GM-CSF is dispensable for early stages of hemopoiesis is provided by 
reports of relatively normal hemopoiesis in homozygous mutant mice that either lack 
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functional GM-CSF or the shared IL-3/ !L-S/ GM-CSF-R P subunit [Dranorrand Muttigan, 
1994} {Nishinakamura et al.. 1995}. 
These studies have shown that it is possible to examine receptor coexpression on 
cells in different hemopoietic subsets,. including immature CD34+ cells. Due to 
technical limitations we have not been able to directly examine receptor coexpression 
on the most primitive, CD34 +/ RhLA-DR dult cells. The availability of novel 
fluorochromes that can be combined in multi-color flow cytometry, as well as the 
development of advanced multi-laser flow cytometers now enable further examination 
of receptor coexpression patte"rns on different BM subsets by ;::::: 4-color flow cytometry, 
e.g. after staining of rhesus monkey BM with biotin- and DIG-labeled GFs and with 
antibodies against CD34 and RIlLA-DR. 
9,5 Possibilities and limitations of staining with labeled GFs 
Many high affinity GF-R consist of complexes of sev~ral subunits, some of which 
are shared with receptors for other GFs (see chapter.I). Anti-receptor antibodies 
usually recognize individual receptor chains, and are very useful to detect differences in 
expression of receptor subunits between cell types, and to examine the r~lationship 
between structure and function of receptor subunits. If only antibodies against one of 
the subunits are used, differences between cells that express functional receptors and 
. cells that only express non ligand-binding receptor isoforms can remain unnoticed in . 
binding experiments. Therefore. to detect cells that are able to bind GFs, staining with 
labeled hemopoietic GF molecules is preferable to staining with anti-receptor 
antibodies. 
The high detection sensitivity of the biotin-GF method allows analysis of cells with 
low receptor levels. \Ve have estimated on the basis of studies with cell lines and blood 
cell subsets, of which receptor numbers are known from equilibrium binding studies, 
that the detection sensitiVity of our method is in the range of 50-100 molecules per cell. 
However, cells with less than 50 receptors may still be OF responsive [Bude! et aI., 1989]. 
As it is likely that radioa<;tive labeling will not yield even lower detection levels, and 
notwithstanding the possibility that novel fluorochromes with superior fluorescence 
properties or improved fluorescence amplification methods may be developed in the 
near fulure, it will be necessary to adopt other methods to detect such very low receptor 
levels. An example of a very sensitive method to examine receptor expression at the 
RNA level is RT-PCR. To use this method in the study of GF-R expression on rare 
cells, high demands must be made on the stringency of the purification of the cells, to 
exclude signals from cOiltaminating cells. 
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E~pr~ssion of receptors that are internalized upon binding of GFs can be 
demonstrated indirectly, using GF-toxins or biotinylated GFs in combination with 
streptavidin-toxin conjug'ates. Internalizati~I1 of the toxins results in elimination of GF-
R-expressing cells, including those \~ith very low receptor expression, and this can be 
detected by functional characterization of the surviving cells [Siegall et a1., 1990] [Kreitman 
,et aL, 1992] [Chan,et ai" 1995] [CiJan·et ai., 1996] [Rozemuller et aI., 1996]. Although in principle 
this technique only requires internalization of 1 toxin molecule, the actual number of 
cell surface receptors required for effective killing is not known. Recent results indicate, 
that CFU-GM are not eliminated by incubation with GM-CSF-toxin [Terpstra et aL, in 
press]. Although these data suggest that GM-CSF-R expression on CFU-GM is lower 
than on AML blasts, it is thus n?t yet resolved whether these cells are GM-CSF-R-, or 
express receptor numbers that are t~o low for the cells to be sensitive to the toxin. 
GF~R expressIon does not necessarily predIct GF responsiveness 
The assumption that the presence of GF-R on a cell predicts whether that cell can 
respond to GF stimulation may not always be correct. It is possible that cells that are 
recept~r-neg~tive do respond to GF stimulation, if a complex between the OF and a 
. soluble receptor subunit can bind to a second receptor subunit on the cell. This has been. 
demonstrated for hemopoietic cells that express gp130, but are IL-6-R negative, which 
can be activated by a complex of IL-6 and soluble IL-6-R [Taga et aI., 1989] [Mullberg et aI., 
1992] [Sui et aI., 1996] [Tajima et aI., 19961. On the other hand, -when antagonizing soluble 
receptor subunits are present that neutralize OFs, GF-R positive cells might not be 
stimulated by these GFs. E.g., the soluble human GM-CSF-R a. subunit can antagonize 
th" activity of GM-CSF by competing for GF binding with the high affinity 
transmembrane GM-CSF-R complex [Brown et aI., 1995]. 
It is also possible that cells that are able to bind GFs do not respond to GF 
stimulation, due to a lack of (parts of) molecules that are essential for signal 
transduction but not for ligand binding, slich as certain receptor. subunits. That 
truncation or alteration of the intracellular domain of a receptor subunit can cause 
profound effects on signal transduction and biological responses without altering ligand 
binding characteristics, has been shown for the G-CSF-R in neutropenic patients [Dong 
ct al.. t993] [Dong et al.. 1994] and for the JL-21IL-41IL-7-R y subunit in patients with X-
chromosome-linked severe combined immunodeficiency (SeID) {Noguchi et ai., 1993]. 
Cells that respond to OF stimulation can be identified by detection of signal 
transduction events, which may include changes in "the intracellular calcium 
concentration, and the activation of specific kin.ase pathways. These can be identified by 
intracellular staining of cells with antibodies that recognize phosphorylated epitopes on 
specific signaling intermediates. Activation of a limited number of receptor molecules 
can lead to the recruitment and activation of a cascade of signaling molecules and thus 
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to amplification of the signal. Therefore, if it becomes possible to· detect signal 
transduction in small populations, of phenotypically defined hemopoietic cells, this 
approach may be useful to detect receptor levels that are too low for direct detection by 
flow cytometry. In addition to providing a neW approach to examine the GF-R 
phenotype and GF responsiveness of HSC and immature progenitors, analysis of signal 
transduction events may be useful to obtain essential information about the GF 
regulation of HSC survival, proliferation, and differentiation, and' on functional 
interactions between GF-R on the level of individual HSC. 
9.6 Assessment of GF-R expression on hemopoietic precursors: 
possible implications and applicability 
Elucidation of GF-R expression on immature hemopoietic cells is particularly useful 
for understanding the GF regulation of HSC and progenitors. This knowledge is 
important to select suitable target cells and transduction conditions for gene marking 
and gene therapy. In addition, the feasibility of GF stimulation for in vitro amplification 
of HSC for transplantation purposes depends on the expression of GF-R on the target 
cells and the type of biological response induced by these GFs. By analogy, the choice 
of GFs to support hemopoietic recovery in myelosuppressed patients might be a 
function of GF-R expression on various types of hemopoietic progenitors. Moreover, 
knowledge of receptor expression on malignai~t cells as compared to their normal 
counterparts may enable the development of strategies_ to selectively eliminate 
malignant $tem cells. 
\Vith exception of Kit, ~t is still not established which GF-R arc already expressed on 
HSC or which are expressed as a result of activation of quiescent ste:m cells. Analysis of 
the distribution of other receptors on immature hemopoietic cells than those examined 
in this thesis, such as F1tJ, also referred to as F1k -2 or STK -I [Smail et 01 .. 19941, and Mpl, 
the receptor for thrombopoietin (TPQ) [Vigon et ai., 1992], might supplement information 
about the GF requirement of HSC. 
The non-proliferating state of HSC might either he a passive process involving 
absence of positive signals or an active process involving suppressive negative 
regulators [Moore, 1991}. Therefore, analysis of receptors for inhibitory GFs, such as 
transforming growth factor P (TGFP), macrophage inflammatory protein 10: (MIPlo:), 
tumor necrosis factor a . (TNFa), or interferon, wiH also be important for a better 
understanding of the regulation of immature hemopoietic cells [Klimpcl cl aI., 1982] 
IPloemacheret ai., 19931 [R.!Jslen el ul., 1994J [Van Runsl ci al., 1996). 
Analysis of GF-R expression on HSC using labeled GFs is seriously limited by the 
expression of low receptor numbers oil these cells, and by the lack of suitable 
phenotypic markers for the immature cell compartment. To distinguish quiescent from 
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activated stem cells within immature cell compartment, cell cycle parameters such as 
DNA content or expression of cyclins and other essential proteins involved in cell cycle 
regulation might be examined, provided that these approaches can be used in a 
multiparameter setting in combination with analysis of cell surface antigen and GF-R 
expression. 
The GF-R phenotype of pluripotent stem cells may not be uniform. GF-R 
heterogeneity may form the basis of different possible outcomes of OF stimulation: 
quiescence, self renewal, 1ineage commitment and apoptosis. Changes in relative 
expression levels of different OF-R on HSC, in combination with the relative levels of 
different OPs in the microenvironment, may determine which fraction of HSC will be 
activated and become committed to sp~cific differentiation pathways or remain 
quiescent. Heterogeneity in OF-R expression also provides a possible safeguard against 
depletion of HSC pool or differentiation into only a limited set of blood cells at the 
expense of other lineages, because it can be expected that a heterogeneous stern cell 
popUlation shows differential responses to different activating stimuli. 
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1 Bloedcelvormlng 
Bloedcellen vervullen een aantal belangrijke functies, waaronder 02 en C02-
transport (rode bloedcellen of erythrocyten), bloedstolling (bloedplaatjes), specifieke 
immuniteit en produktie van antilichamen (lymphocyten), en aspecifieke afweer tegen 
ziekteverwekkers (monocyten/ macrofagen en granulocyten). De meeste bloedceHen 
hebben een beper~te levensduur, varierend van enkele uren'tot enkele maanden. Va or 
het vervangen van deze cellen heeft een gemiddelde volwassene een dageHjkse 
aanmaak van 2 x 10 t 1 rode en 1,5 x 10 1 t witte bloedcellen nodig. Deze produktie-
capaciteit kan onder bepaalde omstandigheden (bijvoorbeeld een lage zuurstofspanning) 
of door oorzaken als bloedverlies, weefselbeschadiging of infecties, zeker lO~maal 
verhoogd worden. Het proces van bloedcelvorming,hemopoi~se, vindt in volwassen 
zoogdieren voornamelijk plaats in het beenmerg (BM). In de foetale hemopoiese spelen 
lever en milt een beJangrijke rol; in volwassen muizen vindt ook bloedcelvorming 
plaats in de milt. 
Aile bloedcellen zijn afstammelingen van een klein aantal pluripotente 
hemopoietische stamcellen (HSC). De meeste HSCzijn in rust; slechts een klein deel 
ervan is actief. Deze populatie is verantwoordelijk voar de vorming van dochtercellen, 
die na verscheidene celdelingen hun mogelijkheid tot multipotente differentiatie 
verliezen en de karakteristieke fenotypische en functionele eigenschappel'i van de' 
verschillende bloedcellijnen verkrijgen (figuur 1). Deze voorlopercellen ontwikkelen 
zich verder tot rijpe bloedcellen die in de bloedsornloop terecht komen. 
Groeifaktoren spelen een belangrijke rol in het stimuleren van overleving, deling en 
uitrijping van hemopoietische cellen. Hoewel er steeds meer bekend wordt over de 
werking van groeifaktoren in viv,o en in allerlei in vitro kweeksystemen, is er nog 
relatief weinig kennis over de manieren- waarop groeifaktoren, aileen en sarnen met 
andere, de bloedcelvorming stimuleren. Stamcellen zijn zo zeldzaam, dat het vrijwel 
niet ~ogelijk is om deze in' grote hoeveelheden te isoleren voor in vitro studies. 
Bovendien is het moeilijk om in dergelijke studies onderscheid te mal\en tussen de 
direkte effekten van een groeifaktor op een voorlopercel en de werking op diens 
nakomelingen. Ook is het onmogelijk om indirekte effekten op de celgroei waarbij 
andere groeifaktoren betrokken zijn uit te sluiten. Daarom is in het hier beschreven 
onderzoek gekoz~n voor een meer direkte benadering om te bestuderen op welke cellen 
van het hemopoietische systeem bepaalde gtoeifaktoren invloed kunnen uitoefenen. 
Deze aanpak is gebaseerd op het feit dat een groeifaktor reageert met een eel door 
binding aan celopperv)akte-receptoren die specifiek zijn voor deze groeifaktor. Door 
gebruik te maken van deze specifieke binding is een methode ontwikkeld om te 
analyseren of de betreffende' receptoren tot express~e komen op hemopoietische 
voorlopercellen. Deze methode is toegepast bij het bestuderen van de veranderingen in 
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receptor-expressie tijdens de uitrijping van stam- en voorlopercellen tot vol was sen 
bloedcellen. 
flguu, f 
Schematische voorstelling van hemopoietlsche stamceldifferentiatie. 
1 
t 
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2 Doel en methodologie 
Veel receptoren met hoge affiniteit voor" een groeifaktor bestaan uit complexen van 
verschillende eiwit-molekulen. Sommige van die receptor-ketens maken deel uit van de 
receptoren van verschillende groeifaktoren (zie hoofdstuk 1). Antilichamen tegeil 
receptoren herkennen meestal individuele receptor-onderdelen en kunnen worden 
toegepast am verschillen in expressie hiervan te ontdekken, en om de relatie tussen 
struktuur en functie van de receptor-ketens te bestuderen. In bindings-experimenten 
waarin aileen antilichamen tegen, een van de receptor-onderdelen wC!rden gebruikt, 
worden soms verschillen niet ontdekt fussen cellen die functionele (= groeifaktor 
bindende) receptoren tot expressie brengen, en cellen die slechts delen van receptoren 
op het celoppervlak hebben. Voor de detectie van cellen die daadwerkelijk in staat zijn 
om groeifaktoren te binden verdient het dus de voorkeur groeifaktor-molekulen te 
gebruiken in plaats van anti-receptor antilichamen. 
Voor het aantonen van celoppervlakte-receptoren is in de hier l?eschreven ~tudies 
gebruik gemaakt van groeifaktoren wa~raan bfotine-molekulen gekoppeld zijn. Deze 
kunnen in een flowcytometer worden aangytoond na binding van (strept)avidine-
molekulen met daaraan gekoppelde fluorescerende moh!kulen (figuur 2). Door de 
kleuring met groeifaktoren te combineren met antilichamen tegen andere molekulen op 
het celoppervlak is het mogelijk am receptor-expressie op ceHen in heterogene 
populaties, zoals BM, te bestuderen. De cellen ondervinden geen schade van de 
kleuring, zodat deze aanpak ook. gebruikt kan worden om, voor functionele studies, 
levende hemopoietische cellen t~ isoleren op basis van receptor-expressie. 
De uitvoerbaarheid van het maken en gebruiken van gebiotinyleerde groeifaktoren 
om receptor-expressie te bestuderen is onderzocht voor verschillende groeifaktoren: 
. . . 
interleukine-2 (IL-2), IL-3, IL-6, granulocytl macrofaag kolonie-stimulercnde faktor 
("colony-stimulating factor", oftewel GM-CSF) en stamcelfaktor (SCF) (hoofdstuk 2). 
Op het celoppervlak van vrocge hemopoietische cellen zijn soms zeer weinig receptoren 
aanwezig. Daarom' werdell methodes ontwikkeld om de fluorescentie-signaten te 
versterken van cellen die met gebiotinyleerde groeifaktoren en' fluorescerende 
(strept)avidine-molekulen ge~leurd viaren. Na versterking van het signaal door 
incubatie met afwisselende lagen van gebiotinyleerde nntilichamen tegen (strept)avidine 
en f1uorescerende (strept)avidine-mo!ekulen (figuur 2), was het mogeJijk cellen met 
minder dan 100 receptoren per cel te detecteren (hoofdstuk2). 
Met IL-2 als modelsysteem voor hernopoictische groeifaktoren werden verschiHende 
methodes en reagentia om biotine-molekulen aan groeifaktoren te koppelen vergeleken, 
en de meest geschikte biotinepreparaten uitgezocht (hoofdstuk 3). Uit deze 
experimenten bleek dat groeifaktor-koppeling aan N-hydroxy-succinimide (NHS) 
biotine zeer docltreffend was vpar de mate waarin IL-2 gebiotinyleerd werd, het behoud 
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van biologische activiteit van d~ groeifaktor en de specifieke kleuring van cell en met 
receptoren op het celoppervlak. Andere biotinepreparaten, zoals p-Diabenzoyl 
Biocytine Precursor (DBB), of biotine die met behulp van Hcht activeerbaar is, gaven 
minder goede resultaten. 
3 Kit expressie op cellen van de muis 
flguur 2 
Schematlsche voorstelling van 
celk/euring met gebiotinyleerde 
groeifaktoren (1) en fluorescerende 
(slrepl)avidinemolekulen (2), en 
versterking met gebiotinyleerde anti-
(slrepl)avidlne antilichamen (3) en 
een tweede laag van fluorescerende 
(slrepl)avidinemolekulen (4). 
Om te bepalen op welke hemopoietische ceJlen de SCF receptor (Kit) tot expressie 
komt werden BM cellen van de mnis gekleurd met gebiotinyJeerd SCF of met 
antilichamen tegen Kit. waarna Kit+ en Kit- cellen werden gesortecrd met behulp van 
flowcytometrie (hoofdstuk 4). Vit celkweek- en transplantatie-~xperimenten met deze 
cellen bleck dat Kit tot expressie kornt op hemopoietische voorlopercellen in 
verschill~nde stadia van ont\vikkeling. Onder de Kit+ BM cellen bevinden zich HSC die 
in staat zijn tot stabiele lange termijn repopulatie van getransplanteerde 1l1uizen, en 
voorlopercellen die aIleen gedurende een korte periode na transplantatie nieuwe 
bloedcellen kunn~n VOfillen. Bovendien bevinden zich in de Kit+ fractic cellen die 
kolonies knnnen vormen in de milt van getransplanteerde muizen ("colony forming 
units in spl.een", oftewel CFiJ~S). cell en die kolonies vamlen vormen in kweeksystemen 
("colony forming units in culture", CPU-C), en morfologisch herkenbare vroege 
myeloYde en erythroYde ceHen. In de Kit- BM populaties daarentegen werden vrijwel 
aileen rijpere cellen aangetroffen. 
Binnen de' Kit+ BM populatie werden verschillen gevonden tus'sen de ceHen die 
bioline'SCP binden en de cellen die mel het anli-Kit anlilichaam ACK-2 reageren. Hel 
percenlage BM cellen dal kan worden gekleurd met bioline-SCP is kleiner dan mel 
ACK-2 (hoofdstuk 4). In de bioline-SCP+ fracties is de frequentie van 
koJonievo~mende celJen echter 2- tot 3-maal zo hoag als in de ACK-:2+ fracties. Dit 
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verschil wordt niet veroorzaakt door stimulatie of inactivering van voorlopercellen door 
biotine-SCF of ACK-2, aangezien er geen effect van celkleuring met deze reagenlia op 
kolonievonning of repopulatie werd waargenomen. Het is mogelijk dot de celpopulaties 
waaraan biotine-SCF bindt en die waaraan ACK-2 bindt niet identiek zijn, te meer daar 
de biotine-SCF+ en ACK-2+ fraeties ook verschillen vertonen in morfologie, 
lichtverstrooiing en Rhodamine 123 kleuring. 
De molekulaire basis voor de verschillende celkleuring met biotine-SCF en ACK-2 
werd verder onderzocht met behulp van sUblijnen van de IL-3 afhankelijke 
muizencellijn FOC-PI (hoofdsluk 5). Hoewel ACK-2 bindt aan de oorspronkelijke 
FDC-PI cellen, die dus Kit tot expressie brengen, binden deze cellen weinig of geen 
biotine-SCF. Bovendien veroorzaakt SCF geen detecteerbare deling van deze cellen. 
Echter, na gewenning van FDC-PI cellen aan het groeien in medium met SCF, ontstaat 
een sublijn die specifiek kleurt met zowel ACK-2 als biotine-SCF. Deze resultaten 
IVijzen erop dat ACK-2 bindende (en dus Kit+) cellen heterogeen kunnen zijn IVat 
betreft hun mogelijkheid om SCF te binden. We hebben echter met diverse technieken 
geen kwalitatieve verschillen in de stmktuur van de Kit-molekulen kunnen aantonen op 
het celoppervlak van de FDC-PI sublijnen. Hoewel dit niet uitsluit dat er verschillen 
kunnen zijn in struktuur, die niet aantoonba~r zijn met de gebruikte methodes, 
suggereren deze resultaten dat de versehiHen tussen de FDC-P I sublijnen van 
kwantitatieve aard zijn. De verschillen in Kit expressie zijn echter te klein am het grate 
verschil in biotine-SCF binding tussen de sUblijnen te verklaren. We veronderstellen 
daaram dat oak een verschil in affiniteit van Kit voor SCF een ral speelt. Mogelijk is er 
cen minimum aantal Kit monomeren nodig am efficiente dimerisatie van Kit molekulen 
mogelijk te maken, zodat receptoren met een hoge affiniteit voar SCF gevormd kunnen 
worden. Cellen met lagere rec"eptor-aantallen kunnen weI ACK-2 binden, maar vormen 
geen hoag-affiene receptoren die SCF kunnen binden. 
4 Kit expressie op beenmerg cellen van de rhesusaap 
Voor het bestuderen van expressie van de SCF receptdr op vroege hemopoietische 
cellen, en veranderingen tijdens de uitrijping van verschillende typep voorlopercellen, 
werden BM cellen van de rhesusaap dubbelgekleurd met biotine-SCF en een 
antilichaam" tegen CD34. CD34 is een merker die specifiek is" voar vroeg"e 
bloedvormende celIen. In vitro kolonievorming werd onderzocht van CD34 + cellen die 
Kit sterk, middelmalig of zIVak tot expressie brachten (hoofdslnk 6). Deze 
experimenten tonen aan dat de meerderheid van de cellen die granulocytl macrofaag 
kolonies vormen (de zogenaamde CPU-OM) zich bevinden in een fractie van CD34 + 
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cellen met middelniatige Kit expressie (figuur 3), Tijdens de verdere differentiatie 
verl,;ezen deze cellen geleidelijk zowel Kit als CD34 van het celoppervlak, 
Tijdens de erythroide differentiatie wordt Kit expressie aanvankelijk hoger. 
Sommige vroege erythroide cellen (de "erythroid burst forming units", BFU-E) brengen 
Kit tot expressie op een relatief laag niveau, maar de meeste BFU-E worden gevonden 
in een aparte populatie met een zeer hoge Kit expressie (figuur 3), Tijdensde verdere 
differentiatie tot Jatere eythroi'de- kolonievormers C'erythroid colony forming units", 
CFU-E) neemt de CD34 expressie af en verdwijnt Kit geleidelijk van het celoppervlak, 
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flguur 3 
Veranderingen in expressie van Kit en CD34 tijdens de differenliatie van 8M cellen van 
een rhesusaap-tol erythrolqe (zwarte pljlen) en monomyelofde cellen (witte pijlen) .. 
, 5 Veranderingen in receptor co·expressle tijdens de differentiatie 
Om de functionele interacties van verschillende groeifaktoren op hemopoietische 
cellen te bepalen, is het nuttig om de co-expressie patronen van deze receptoren op BM 
te bestuderen,' Hiertoe werd een methode ontwikkeld waarill celkleuring met 
gebiotinyleerde groeifaktoren gccombineerd \~ordt met andere groeifaktoren, waaraan 
digoxigenine (DIG) molekulen gekoppeld zijn (hoofdstuk 7), Met behulp van deze 
methode samen met antilichamen tegen andere celoppervlakte-merkers werd co-
expressie van receptoren voor SCF en respectievelijk erythropoietine (EPO), IL·6, en 
GM·CSF op cellen In BM van rhesusapen geanalyseerd, De resultaten van deze 
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experimenten z.ijn samengevat in figuur 4, waarin de co-expressie patronen van deze 
receptoren op vroege v<?orlopers en op differentierende erythro)·de en myelo"ide 
voor)opercellen getoond worden. De expressie van de receptoren voor IL-3, IL-6, GM-
CSF, en SCF op verschillende BM cellen is besproken in hoofds!uk 8. 
101 102 10 3 104 100 101 102 103 104 
EPO-R IL-6-R GM-CSF-R 
flguur4 
Veranderingen in co·expressie patronen van Kit en de receptoren voor iespeclievelljk 
EPO, IL·6 en GM·CSF tljdens de differentiatie'van monomyeloide (witte piilen) en 
erythroide cellen (zwarte pijlen). 
6 Conclusies en suggesties voor verder onderzoek 
Onderzoek van receptor-expressie op vroege hemopoietische ceHen is nodig om de 
regulatie van HSC en voorlopercellen door groeifaktoren te begrijpen. Deze kennis is 
belangrijk voor specifieke therapeutische toepassingen van groeifaktoren, zoals de ex 
vivo e~pansie van stam- en voarlopercellen voar transp.iantatie-doeleinden en 
gentherapie. Keimis hierover kan oak gebruikt worden bij de keuze van groeifaktoren 
die taegediend worden om de hemopoiese te stimuleren van patienten van wie de 
bloedcelvorming is onderdrukt, bljvoorbeeld als gevolg van chemotherapie of 
bestraling. Daarnaast kan kennis van receptor-expressie op leukemie-celIen, vergeleken 
met hun normale tegenhangers, inzicht geven in de abnormale groeiregulatie van 
maligne hemopoietische cellen en een bijdrage leveren aan het ontwikkelen van 
methodes om deze cellen selectief Ie elirnineren. 
Met uitzondering van Kit is nog niet bekend welke groeifaktor-receptoren tot 
expressie komen op HSC en welke tot expressie g~b~acht worden na activeren van. 
rustende stamcellen. Analyse van andere receptoren dan die onderzocht zijn in dit 
proefschrift, zoals bijvoorbeeld Flt3! Flk-2 en de TPO receptor, c-Mpl, kan informatie 
toevoegen over de groeifaktoren die nodig zijn voor HSC. Ook onderzoek van 
receptoren van negatieve regulatoren kan in dit opzicht belangrijk zijn, aangezien 
216 
Marg de Jong Samenvatting 
dergeJijke remmende "groei"faktoren belangrijke funkties kunnen hebben in het in mst-
toestand hauden van stamcellen. 
Analyse van receptor-expressie op HSC wordt bemoeilijkt door het lage receptor-
aantal dat deze cellen tot expressie brerigen. en de afwezigheid van·bmikbare merkcrs 
am stamcellen van andere primitieve vooriopercellen te onderscheiden. Om rustende en 
geactiveerde stamcellen van elkaar te onderscheiden kan wellicht gebruik gemaakt 
worden van celcyclus parameters zoals DNA gehalte. of expressie van cyclines en 
andere eiwitten die essentieeI zijn voor de regulatie van de celcyclus. 
Dit onderzoek heeft niet geleid tot identifieatie van het reeeptor-fenotype van 
repopulerende stameellen, Het is mogeliJk, dat dit fenotype niet voor aile HSC hetzelfde 
is. Heterogeniteit in receptor-expressie zou de basis kunnen vormen van verschillende 
effekten van groeifaktor stimulatie. zoals vorming van dochtercellen die identiek zijn 
aan de oorspronkelijke stameel, differentiatie tot rijpere eelien, eeldood door apoptose, 
of juist rust. Veranderiilgen in het relaticve expressie-niveau van verschillende 
receptoren op stamceHen kunnen. samen met de beschikbaarheid van verschillende 
groeifaktoren, bepalen welk deel van de HSC geaetiye,erd wordt en \Yelk deel inrust 
blijft. Heterogeniteit van receptor-expressie kan ook dienen als beveiliging tegen 
uitputting van de stamcelvoorraad als gevolg van een sterke of Jangdurige stimulus, of 
tegen differentiatie van stamcellen tot slechts een type bloedcellen ten koste van andere 
typen. aangezicn het waarschijnljjk is dat cen heterogene stamcelpopulatie op 
verschillende manieren zal reageren op verschillende stimuli. 
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mochten we met de werkbesprekingen meedraaien en kregen we af en toe een flesje 
IL-2 toegeschoven. 
Na de verhuizing naar de afdeling" Hematologie van de Erasmus Universiteit 
Rotterdam ging ik zelf bij "de \Vagemakers" horen. Daar kwam ik, samen met Hannie 
Busking-van der Lelij, terecht op een projekt van mijn co,-promotor Bert \Vognum. Bij 
de lange termijn repopulatie experimenten kreeg ik veel huJp van Trui Visser en vooral 
oek van Dorinde Kieboom-~luimes. Met de eindeloze hoeveelheden in situ glaasjes 
hieJp Wati Dimjati. Oak Astrid Borsboom Iiet zich af en toe inschakelen. Toen we de 
kleuringen op rhesus beenmerg gingen loslaten reisden wc aanvankelijk na~r Hilco 
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Wiersema op TNO, later kon ik op de EUR ook terecht bij Manuel van Teeffelen en 
Karen Neelis. Yvonne Westerman was altijd bereid me met'raad en daad bij te staan in 
allerlei, al dan niet radioactieve, molekulair-biologische avonturen. Veel praktische tips 
kregen wc hierbij ook van Saskia Buchwaldt, Marti Bierhuizen cn \ViI Loenen. Het bij 
de experimenten benodigde gJaswerk was altijd schoon dankzij lneke van de Kraats. En 
eell sccrctariaat zander lneke de Poorter is niet denkbaar, haar hulp was zeer welkom bij 
aile formaliteiten die bij het opsturen van het manuscript kamen kijken. Mirjam 
Bosman en Karola van Raoyen hielpen de resultaten van de experimenten in dia's om te 
zetten, en voor de onmisbare last-minute hulp bij de foto.'s en de ornslag voor dit boekje 
ben ik Karola vee I dank verschuldigd. En dat mijn mede-promovcndae Monique 
Verstegen en Simone Hartong bereid zijn als paranimf op te treden vind ik heel erg 
leuk. 
Tot slot wil ik mijn vrienden en (schoon)familie bedanken voer ,hUll steun tijdens de 
helc promotie-periode. Eigenlijk zou ik dit boekje \villen opdragen aan j~l1lie allemaal, 
mamma'en pappa, Omita, Groot, Net en Kees, Eric .en Margot, Mariet en Bart en Tim 
en Koen, Kees en HaUllet en Merel! Maar nog het meeste aan Robbert, mijn prins-op-
het-witte-paard, aan wie ik vast kan verklappen dat ik volgende week "jail ga zeggen. 
En dan kornt na de huwelijksreis weer tijd voer de sociale contacten! 
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